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ABSTRTACT 
Since 1996, the U.S. swine industry has seen disease outbreaks characterized by 
reproductive failure at early gestation and/or neurologic disorders in sows and young pigs, 
which are commonly referred to as "Porcine reproductive and neurologic syndrome 
(PRNS)". A previously unrecognized small enveloped RNA virus of approximately 50 nm in 
size was repeatedly isolated from field cases of PRNS and tentatively named "Virus X". The 
disease and/or lesions of PRNS were reproduced in pregnant sows and young CDCD pigs 
experimentally infected with Virus X and the virus was re-isolated from those pigs, fulfilling 
Koch's postulates. Both polyclonal and monoclonal antibodies specific for Virus X were 
produced. The polyclonal antibody did not cross react with any known viral pathogens for 
swine except for ruminant pestiviruses (i.e., bovine viral diarrhea virus and border disease 
virus) on immunofluorescence test and Western immunoblotting. Polyclonal antibodies 
raised against the ruminant pestiviruses cross-reacted with Virus X to a degree. However, 
Virus X could not be recognized by pan-BVD virus monoclonal antibodies. Sequence and 
peptide analysis of Virus X for 5' UTR and NS3 regions indicated that the virus is 
phylogenetically separate from any known pestiviruses. Furthermore, Virus X could be 
differentiated from the ruminant pestiviruses by laboratory procedures employing the 
monoclonal antibody (15A2-3E9) produced in this study. In conclusion, a previously 
unrecognized swine pestivirus is responsible for the newly identified disease. 
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GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation begins with an abstract and is followed by a review of the literature. 
Three papers are presented on the experimental work that was done. The doctoral 
candidate is the first author for all three papers. The dissertation concludes with a general 
discussion, a list of references cited in the literature review and acknowledgements. 
Literature Review: Response of cells to RNA virus infection 
1. Introduction 
Viruses can be divided into several categories based on their genomic type and 
structure: a) RNA and DNA genome, b) single- and double-stranded, c) positive and 
negative sense; and d) segmented and non-segmented (64). The viruses also can be 
divided into 2 groups based on the presence and absence of envelope, which determines 
their attachment and stability in the environment (64). Genomic and envelope structure of a 
virus influences its infection, replication and stability. 
During viral replication several events take place. The first step is attachment of the 
virus to the cell surface that is mediated by a ligand present on the surface of the virus and 
receptors on the plasma membrane of the cells. Sometimes this process is called uptake or 
penetration of the virus and two main mechanisms are known: receptor-mediated 
endocytosis and fusion. Uncoating then takes place and the viral genome is available for 
transcription, translation, and replication of the viral nucleic acids. The last event of the viral 
replication cycle inside the cell is assembly of the virion and release of complete viral 
particles (i.e., progeny) either through budding from the cellular membrane, or by exocytosis. 
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Transcription of some RNA viruses is a unique process since it requires RNA-
dependent RNA polymerase that is encoded by the viruses. Complementary RNA made 
during the replication normally serves as a template for making viral RNA. For negative-
sense RNA viruses, the complementary strand is mRNA and is either subgenomic or full-
length RNA. Translation takes place in order to make early and late viral proteins that have 
an effect on the viral life cycle and cell life as well. Early proteins are present only in infected 
cells and are defined as non-structural proteins (polymerases, proteases and other 
enzymes). Viral proteins that are translated later (late proteins) are called structural proteins 
as they are mostly incorporated into virus particle. Most of the time viral RNA of positive 
polarity binds directly to the ribosome and the translation process begins without any further 
transcriptional steps. Some positive-sense RNA viruses like picornaviruses or flaviviruses 
have polycestronic RNA that has one open-reading frame and serves as a template for 
transcription. This protein is later cleaved by enzymes made by the virus (303;315). 
The most common and oldest way to observe viral replication in the host is to look 
for changes in the cell structure, the so-called cytopathic effect of viruses on the cells (88). 
Normally there are several categories of changes that happen to the cell during replication 
of various viruses: 1) cell rounding and detachment, 2) syncycia formation, 3) presence of 
inclusion bodies, and 4) cell lysis. Classification of viruses according to 3 of these categories 
was proposed by Enders et. al (88). One causes cellular lysis, another induces inclusion 
bodies and cell degeneration, and the third forms multinucleated cells or syncytia. Another 
form of cell degeneration is necrosis during virus infection due to physical damage or toxic 
effect. Some cells die of apoptosis during development of hormonal signaling in response to 
DNA damage (fragmentation). In some instances, the virus and cell live together in 
symbiosis, and in other cases the virus will not destroy cells during the replicaton process. 
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Most often, however, productive viral infections lead to cell death and lysis. Details of cell 
response to viral infection are described later in this chapter. 
2. Virus entry into cells and cellular receptors 
The first step for viral replication is entry into cells where the virus uses the cellular 
machinery to promote its own replication. Virus entry can be divided into two stages: 1) 
binding to cell receptors and 2) penetration of plasma membrane. Viruses use several 
different cell-surface molecules as their receptors such as protein molecules, lg-related 
proteins of integrins, and carbohydrates or glycolipids for attachment to the cells 
(20; 144;222). There are two major pathways of entry into cells: 1) fusion between the viral 
envelope and the cell plasma membrane and 2) receptor-mediated endocytosis. Enveloped 
viruses generally gain entry to the cell cytoplasm by fusion of the lipid envelope with the 
membrane or endosomal membrane. Many viruses even within the same family or genus 
use different receptors for cell attachment. 
There are two mechanisms by which enveloped viruses enter into cells: 1) via 
clathridin-coated pits in absortive endocytosis (5;246) 2) through endosomal acidification 
(216) as demonstrated in Figure 1 (324). These mechanisms change the properties of many 
enveloped viruses and allow them to react with the cell lipid membrane directly 
(146;298;336;337) by fusion of the envelope with the endosomal membrane and injection of 
nucleocapsid directly into the cytoplasm. Influenza virus is the best studied enveloped virus 
that enters cells by endocytoses via clathridin-coated pits where it uses hemaglutinin (HA) 
as the ligand that binds to sialic acid on the cell membrane (149;335). The acidic pH 
environment of the endosomal lumen causes some conformational changes in HA protein 
and promotes virus fusion with the membrane (47). Low pH leads the trimer HA to form a 
loop called a coiled-coil structure and this structure fuses with the membrane and RNA is 
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injected into the cytoplasm. Fusion peptide and transmebrane domains of HA2 are localized 
in the same lipid bilayer. 
Figure 1. Virus attachment and entry into the cell. 
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Legend: 1- Attachment of the virus to the cell membrane; 2- Foramtion of endocytotic pit and 
fusion with membrane; 3 - Viral particle in cytoplasm. Adapted from A. T. Young (348) 
For example, viruses of the family Picornavirida, which includes poxviruses, ECHO 
virus typel, and ECHO virus type 7, belonging to the genus Enterovirus, have cell receptors 
like lg-like protein (PVR) and integrin VLA-2 (21). As another example, rhinoviruses have 
LDL receptors (127). Some viruses belong to a different family but share the same 
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receptors. For example, Coxsakie virus B3 is another enterovirus that shares a receptor 
nucleolin with adenovirus type 2 (205); and human immunodeficiency virus (HIV) is a 
retrovirus that shares the CD4 receptors with human herpesvirus (206). 
For many viruses, receptors may simply serve as attachment molecules to the cells 
and as transport vehicles after entering the cell. For poliovirus, the receptors dock and 
destabilize the virions. Poliovirus has four different viral proteins such as VP1, VP2, VP3 
and VP4, and one of them (VP1) has a deep pocket canyon that interacts with cell surface 
receptors. During entry, the viral particle of poliovirus goes through a series of 
conformational changes as do other viruses. The first changes are the loss of their VP4 
proteins and conversion into 135S particle (339). This process is mediated by cellular 
receptors and is called the breathing mechanism of poxviruses (203). The next stage is 
when poliovirus VP3 protein and amino terminus of VP1 form protein channels in the host 
membrane of the cell and the virus releases RNA into the cytoplasm. Low pH fusion at 
plasma membranes is observed for many viruses such as HIV, Ebola, SIV, Mo-MLV 
(51 ;92;211 ;334). In some instances, viruses bypass viral entry mediated through the 
cognate virus receptor. In this situation the virus attaches not to the receptors but to ligands 
of the IgG and IgM immunoglobulins and Fc receptors on the surface of the macrophages 
and granulocytic cells (137;138;254). Several cell surface molecules have Fc and 
complement receptors that mediate antibody-dependent enhancement (ADE) during viral 
infection (176;209). It has been demonstrated that virus-antibody complex is necessary to 
initiate ADE (254;347). Many viruses function this way, including members of the 
Flaviviridae, Coronaviridae, Retroviridae, and Togaviridae (46; 137; 176;238;288;347). A 
summary of some viral receptors is listed in Table 1. 
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Table 1. Selected receptors for RNA viruses. 
Receptors Virus (family) References 
Immunoglobulin -like molecu es 
VCAM and I CAM EMCV-D (Picornaviridae) (127; 156) 
CD-4 HIV-1, 2 (Lentiviridae) (67) 
MHCII Visna virus (Lentiviridae) (68) 
Integrins 
VLA-2 ECHO virus 1, 8 (21) 
RGD-binding protein FMDV (Picornaviridae) (99) 
Aminopeptidase N TGEV (Coronaviridae) (73) 
Glycoforin A EMCV (Picornaviridae) (3) 
BLVRcpl Bovine leukemmia virus 
{Retroviridae) 
(13) 
Sialoglycoprotein Sendai virus (Fiaviviridae) (308) 
Sialic acid Influenza virus 
(Orthomixoviridae) 
(149) 
Sialic acid Reoviridae (93) 
Sialic acid Group A porcine 
rotaviruses 
(278) 
Moesin Measles virus 
(Morbilliviridae) 
(84) 
3. Viral RNA transcription 
Positive sense RNA viruses are very efficient in replication and can amplify their 
genome from one single copy of the molecule to tens of thousands of copies in only a few 
hours. Viral genomic RNA itself serves as a template for synthesis of viral proteins when 
earlier viral proteins are made including RNA-dependent RNA polymerase (RdRp). With the 
help of RdRp and other proteins, the same viral RNA will be copied from the 3' end to make 
a complementary strand that is transcribed into new molecules of positive sense genomic 
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RNA. This double function of viral RNA requires help from cellular machinery as well. A 
good example is the poliovirus genome that is around 7.5 kb and contains a polyadenylated 
tail at the 3' end and small peptide VPg at the 5' end untranslated region (UTR) 
(96;271;346). The 5' UTR region has two functions: 1) a highly structured and conserved 
region promotes cap-independent initiation of translation by internal ribosome binding 
(1RES) (255;323) and 2) a shorter region (the cloverleaf RNA) is involved in viral RNA 
replication (7). 
Viral replication in most of the RNA viruses will take place in the cytoplasm of cells. 
During replication, poliovirus accumulates small membranous vesicles that are considered 
to be the site of viral RNA synthesis (229). Viral proteins 2b and 3a block the transport of 
glycoproteins to the cell surface and because of this inhibition vesicles accumulate in the 
cytoplasm and viral RNA synthesis takes place (80;81;327). During viral replication the 
cloverleaf RNA located in the 5'end forms a ternary complex with two proteins: uncleaved 
viral protease polymerase precursor 3CD and the poly(rC) binding protein (PCBP, also 
known as hnRNP E) (6;7;107;245;295). PCBP is a host protein that regulates the stability 
and expression of several cellular mRNA (240) and interacts with poly(A) binding protein 
1(PABP1) (331). The 5'end cloverleaf has two functions: it participates in viral translation 
and viral replication (108;297). When cellular protein PCBP binds to the cloverleaf it results 
in enhancement of viral translation. When the precursor of the viral RNA polymerase (3CD) 
binds to the cloverleaf, it represses viral translation and promotes the synthesis of the 
negative stranded RNA (16; 108). While the mechanism that regulates translation and 
transcription of viral RNA is not yet known, there is evidence that some ribosome and RNA 
polymerase collisions occur which results in physical blockage (53). Some questions still 
remain concerning how regulation works and whether there are some unidentified cis-acting 
elements involved. One of these elements includes a viral poly(A) tail at the 3' end that is 
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c/'s-acting elements for poliovirus replication but it may not be the main one since many 
cellular mRNAs have poly(A) tails as well (15;287). The secondary structure of the 3' end 
has a conserved region that forms a pseudoknot among picornaviruses and plays an 
important role in viral replication acting as c/'s signal during transcription. If the pseudoknot 
of that region is disrupted it will inhibit transcription of poliovirus (164). 
Influenza virus is an RNA virus that has a unique mechanism of replication taking 
place in the nucleus of the cells after uncoating and depends on host (infected cell) 
enzymes for replication. The cellular DNA-dependent RNA polymerase can initiate viral 
mRNA synthesis if primers are provided. These primers have to be capped and normally are 
cleaved by an enzyme from host cell RNA polymerase II transcript. Viral cap-dependent 
endonuclease polymerase cleaves small pieces of capped RNA around 10 to 13 nucleotides 
long from the 5'end (266). These primers initiate viral mRNA synthesis by DNA-dependent 
RNA polymerase (35). The viral RNA of influenza virus is bound to four viral proteins: NP 
protein and three P proteins (PB1, PB2 and PA) (159;326). The P proteins help with mRNA 
synthesis, especially PB2 protein which recognizes the cap of the primer RNA. The PB1 that 
catalyzes nucleotide addition has four conserved sequence motifs of RdRp (27;37). The 
viral RNA binds to the PB1 sequentially and these two ends (5' and 3') have some 
complementary sequence for polymerase binding. Replication of the influenza virus occurs 
in two steps: 1) synthesis of the template RNAs and 2) copying of the template RNAs into 
vRNA. In order to switch from the synthesis of mRNA to vRNA it is necessary to change 
from capped RNA to unprimed RNA and to prevent termination and polyadenylation 
(antitermination) at the poly(A) site. This antitermination has been shown to be associated 
with NP proteins (19). Full-length template RNA is synthesized only when NP protein is 
present (292). After mRNA is made, it is processed by viral and cellular enzymes. 
3.1. RNA processing in the cellular machinery 
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One of the mechanisms of making mRNA, a precursor of viral mRNA, is to use 
cellular enzymes for splicing. Viruses use this pathway for maturation of their own mRNA, 
but they regulate that process in such a way that a full-length transcript is made and spliced 
later. 
Splicing is a complicated biochemical process where regions on cellular or viral 
mRNA are recognized by a ribonuclear complex that forms a complex and one piece of 
nucleic acid (intron) is cleaved and the remaining pieces (exons) of RNA will be ligated 
together into new mRNA. The specificity of site recognition and efficiency of intron removal 
is a hallmark of the pre-mRNA splicing machinery which is made up of spliceosomal 
components including 50-60S ribonucleoprotein particle and general splicing factors (GSFs). 
The border of internal exon is the 5' end splice site, and the 3' terminal exon is defined by 
the presence of cleavage and polyadenylation signal (178;270;293;355). Recognition of the 
5' splice site involves a base-pairing interaction between the consensus sequence and the 
5' end of the U1 small nuclear RNA (UlsnRNA) and GSFs (43). This highly structured U-rich 
conserved region of small nuclear RNAs (snRNA) forms the central component of a 
ribonucleoprotein particle called the U1 snRNP which is part of the spliceosome. The U1 
snRNA and the U1 small ribonucleuoprotein particles (snRNP) include Sm core proteins and 
three other proteins: A, C, and 70K. The U1-C protein plays an important role in stabilizing 
the 5' splice site and U1 snRNA interaction (186). Recognition of the 5' splice site by 
U1 snRNP occurs by several GSFs and members of the group of splicing factors (SR) 
protein family (184). The SR proteins (ASF/SF2 and SC35) interact with U1-70K protein and 
this interaction is critical for stabilizing the U1 snRNP interaction with the 5' splice site 
(72;97;299). The 3' splice site normally is located several thousand bases downstream of 
the 5' splice site and is named as the BP/py tract and 3' splice site. The branching point is 
recognized by two GSFs splicing factors: SF1 and branch point binding protein (BBP) 
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(1;8;22). The specificity for relevant branch point sequences is possible because of the 
interaction between SF1 and heterodimeric factor U2AF (23). The second subunit of U2AF, 
U2AF35 binds the PyAg at the 3' splice site in many introns and the complex between SF1-
U2AF at the 3' end of the intron and the U1 snRNP(+GSF) complex at the 5' splice site 
define the border of the intron (134;340;359). 
In order for the splicing to take place, formation of complex A (pre-spliceosome) is 
necessary and is formed by several GSFs, ATP hydrolysis and U2snRNP (43). U2 snRNP 
and spliceosomal UsnRNP form a complex that recognizes the branch point sequence by 
pairing between the consensus CUPuAPy and a highly conserved stretch in the U2snRNA. 
The U2 snRNP must displace the SF1-U2AF complex from the intron but the SF1-U2AF can 
be associated with the spliceosome (70). Spliceosome formation involves the recruitment to 
the pre-spliceosome of the U5/U4-U6 tri-snRNP particles (234). The spliceosome undergoes 
a metamorphosis that leads to disruption of the U4-U6 base pairing, shading of U1 and U4, 
the recognition of the 5' splice site consensus by U6 snRNA, and action of multiple GSFs 
(43). Two reactions will take place: phosphoryl transfer reaction that mediates precise 
excision of the intron and ligation of the adjacent exons. The mRNA is released from the 
spliceosome complex and ready for translation. 
Viral splisosome complex is formed and mediated by RNA structure, and viral 
proteins determine the extent of splicing of the viral RNA (110). Influenza virus uses cellular 
machinery for splicing of its two full-length viral mRNA; NS1 and M1 RNA are spliced in the 
nucleus of the infected cell to yield the NS2/NEP and M2 mRNA (190; 192). Splicing for 
influenza virus is regulated by c/'s-acting sequence on NS1 mRNA and it is always in the 
same proportion: 10% spliced and the rest unspliced (190; 191). Both spliced and unspliced 
viral mRNA are exported into the cytoplasm. 
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HIV regulates maturation of splicing RNA by making protein of rev gene that acts as 
a regulator and stimulates cytoplasmic accumulation of the unspliced viral mRNA that codes 
for structural proteins (182;212). The rev protein enters the nucleus and binds to viral RNA 
at the rev responsive elements to form a RNA-protein complex which is then recognized by 
the nuclear export machinery (98). Most of the retroviruses export their protein outside the 
nucleus for processing. Other retroviruses have constitutive transport elements (CTE) that 
will bind to RNA helicase A which helps with the export process from the nucleus (314). 
3.2. Post-transcriptional RNA editing and inhibition of cellular transcription 
During infection many viruses inhibit the transcription of cellular genes. In regards to 
RNA viruses that do not use host cell polymerase but code their own polymerase, blocking 
cellular transcription makes more of the ribonucleoside triphosphate pools available for viral 
RNA synthesis. Vesicular stomatitis virus (VSV) or Picornaviridae have been reported to use 
this mechanism (215;333). Cellular RNA synthesis that is catalyzed by three classes of 
DNA-dependent RNA polymerase is inhibited by nostructural viral proteins. For example, it 
has been demonstrated that transcription factors TFIID and TFIIIC of RNA polymerase and 
TATA-binding protein are cleaved by protease 3Cpro of poliovirus (60;61) M protein of VSV 
virus has been reported to inhibit cellular transcription and it is not cell-type specific by 
inhibiting RNA pol II dependent transcription (29). Viral structural proteins of VSV act 
independently in the cells and target transcription by modifying factor ll-D (349). 
The best example of taking advantage of an animal host cell is demonstrated by 
influenza virus where transcription of mRNA from a segmented genome occurs in the 
nucleus of host cells (150). The influenza virus makes an endonuclease that cleaves the 5' 
end of the host transcript which is used as a primer for the synthesis of viral mRNA (called 
cap snatching) (36;266). All eight segments of influenza virus are produced and processed 
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in the nucleus and transported into the cytoplasm using nucleus export machinery (338). It is 
also known that the NS1 protein of influenza virus can bind and inhibit polyA binding protein 
II (PAB-II), causing cleavage of the polyadenylation specificity factor (CPSF) of the cellular 
3' end processing machinery and decreased mRNA production of the host which will lead to 
cell death or cytopathic effect (CPE) (233). Also, influenza virus can shut off proteolytic 
activity of the cell (286). Not all RNA viruses have an effect on transcription of cellular 
genes, but at the same time, viruses will cause CPE and cytolytic effect (CTLE) in the same 
way influenza virus does. 
4. Translation of viral protein 
Many viruses use cellular machinery for translation of their own proteins and most of 
them make mRNA that is capped (7mG(5')ppp(5')N) and has a poly A tail at the 3' end 
(221 ;222;262). Both the poly(A) tail and 5' cap work together to bring the 40S ribosomal 
subunit to the viral mRNA, initiator tRNA(tRNA) and other translation initiation factors (Table 
2) which form the 48S complex that assembles at the initiation codon is joined by the 60(S) 
subunit, forming the 80S subunit following initiation of translation (222) that binds to the 5' 
end of the mRNA and scans the 5' untranslated region (5'UTR) searching for an initiation 
codon. Some known initiation factors that play a role in translation are listed in Table 2. 
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Table 2. Name and activities of the factors associated with translation 
Factor name Characteristic activity or function 
elF-1 Pleiotropic 
elF-1A Stimulate subunit joining 
elF-2 GTP-dependent Met-tRNA binding 
elF-2A AUG-dependent Met-tRNA binding to 40S subunit 
elF-2B Guanine nucleotide exchange factor 
elF-3/A Subunit dissociation 
elF-4A RNA-dependent ATPase 
elF-4B Stimulate activities of elF-4A 
elF-4 Recognize cap of mRNA 
lso-elF4 Recognize cap of mRNA 
elF-5A Stimulates first peptide bond synthesis 
eEF-1a GTP-dependent binding of aminoacyl - tRNA 
eEF-lpy Guanine nucleotide exchange factor for EF-1a 
eEF-2 Translocation, ribosome-dependent GTPase 
eEF-3 Ribosome-dependent ATPase and GTPase 
eRF Codon-dependent release of fMet-tRNA from ribosome 
Initiation factor elF-2 forms a complex with GTP and met-tRNAi delivers initiation 
transfer signal to the 40S ribosomal subunit (221;259). The elF-4 consisting of three 
subunits is a necessary component for the 40S small ribosomal subunit to be recruited to 
the mRNA with a 5'cap structure. Other important factors of the translation and initiation 
complex are elF-3, elF4A, elF4B and poly(A)-binding protein (PABP) (222). 
4.1. Ribosomal frameshifting 
To better utilize mRNA or viral RNA, another mechanism was described for 
translation of proteins from the same RNA molecules called -1 ribosomal frameshifting. Cells 
process mRNA in the regular mechanism starting with one open reading frame (ORF) and 
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when a single ORF is read by the ribosome, produce one protein but sometimes several 
proteins are made from one mRNA. The mechanism of-1 ribosomal frameshifting has been 
described by Jack and Varmus as the slippery model (162). Based on this model there are 
two structural details of mRNA that are important: 1) the slippery site of heptamer, which is 
the site of the frameshift; and 2) the 3' site that forms a strong secondary structure of RNA 
(39). The mRNA is programmed to give a signal to the ribosome to shift from one reading 
frame to another. In this case, the ribosome goes back one nucleotide, resulting in the 
change in reading frame (38;91). A good example of ribosomal frame shifting (-1) occurs in 
retroviruses that most of the time produce gag-pol protein but sometimes only 5 % of the 
retroviral proteins will be produced. Most of the time the translation is terminated at the end 
of the gag gene and this process is regulated by a c/'s-acting mRNA viral signal that changes 
the reading frame (44;91). 
In addition, different secondary structures and formation of pseudoknots result in 
frame shifting in different viruses like infectious bronchitis virus or retroviruses (54;232). It is 
possible that the 80S ribosome is associated with helicase unwinding of RNA forming 
pseudoknot (38). 
4.2. Internal Ribosomal Entry Site 
Another mechanism for translation of proteins is initiated through internal ribosomal 
entry site (1RES). It has been shown that the 40S subunit of ribosome binds to 1RES in an 
independent manner or nonspecifically. Ribosome attachment depends on the structural 
integrity of the 1RES and involves specific interaction between the 1RES and different 
translation components. Formation of 48S complexes on the EMCV 1RES involves binding 
of elF4G to 1RES and does not require elF1, elF1A or elF4E (261 ;263). The 40S subunits 
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and elF3 independently bind to 1RES of HCV and formation of 48S complex does not 
involve elF1, elF1A, elF4A, elF4B, elF4E or elF4G (262). 
Translation of poliovirus' mRNA is 5' end dependent and initiated by 1RES. The 40S 
ribosomal subunit binds directly to the 1RES through interaction with elF3G that binds to the 
C-domain of elF4A (42;229). Other cellular proteins that bind to the 1RES are p57 (PTB), 
p52 and elF-2A/2B that are involved in translation (34; 168). Picornavirus proteins are 
synthesized by the translation of one polycistronic protein that is cleaved by viral-encoded 
proteinase. Picornaviruses code for three proteolytic enzymes: Lpro, 2Apro and 3Cpro 
(77 ;265;276). 
5. Suppression of translation during virus replication 
One of the best examples of how RNA viruses shut off cellular machinery occurs in 
poliovirus. This virus is capable of reducing protein synthesis of the cells within the first few 
hours of infection. Poliovirus, like pestiviruses, does not have 5' cap structures and initiation 
of translation is done by the 40S ribosome subunit that binds directly to the 1RES located in 
the 5'UTR region of the viruses (167;260;275;323;323). Elongation factor (elF-4G) initiates 
40S ribosomal binding to cellular mRNA and is cleaved by poliovirus by Lpro enzyme (77) in 
infected cells (122). This will suppress translation of cellular proteins that require this factor 
(309) and allow the virus to utilize cellular machinery better to make progeny virus. 
Other viruses regulate translation of m RAN of cellular proteins by inactivating or 
phosphorylating some translation initiation factors. When bovine viral diarrhea virus (BVDV) 
infects the cells, it is observed that the Ca2+ amount decreases in the endoplasmic 
reticulum that slows down protein translation and phosphorylation of the elF-2 a by the ER 
kinase PERK (207). This leads to repression of the bcl-2 protein that acts as anti-apoptotic 
protein and apoptosis may be induced. Rotaviruses also down regulate cellular protein 
16 
synthesis by expression of the nonstructural protein NSP3A that binds to the 3' end of viral 
mRNA and to elF-4G at the same site where PABP is binding despite the dissimilarity of the 
two proteins (226). Phosphorylation of the elF-4G is very important for protein synthesis and 
viral infected cells normally have low or no phosphorylation of elF-4E (332). During influenza 
virus infection, the cellular machinery for protein synthesis is shut off because of the 
dephosphorylation and inactivation of elF-4G (118; 181 ). Elongation factor eEF-1 A also is 
inhibited by viral proteins during infection (58;71;341). Two proteins gag!MA interact with 
eEF-1 A and inhibit translation (58) and the TAT protein interacts with the b subunit of elF-
1B and specifically inhibits cellular translation without inhibiting the efficiency of translation 
of the viral proteins (341). 
Some viruses make polycistronic mRNA but translation occurs in one or more 
initiation start codons on the same mRNA (283). According to this model the AUG start 
codon of the 5'-proximal upstream cistron is present in a suboptimal context but the start 
codon in the downstream initiation site is not always present in an optimal context (185). 
The(283) 40S ribosomal subunit skips the suboptional initiation site and begins translation 
downstream within the same or different open reading frame (ORF) (283). Expression of 
different amounts of viral protein in different stages of infection is correlated with the relative 
strength of the initiation codon. 
5.1. Effect on termination of translation 
Some viruses express a small amount of the protein that has an effect on termination 
of translation and allows expression of additional proteins downstream. Alphaviruses, for 
example, can read through stop codons and express nonstructural protein nsp4 that is 
required for RNA polymerase activity (201). In retroviruses, the po/gene also is expressed 
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by reading through the gag stop codon and making reverse transcriptase (264). This 
mechanism also is regulated by c/'s-acting sequence information (2;201). 
There are two RNA processes that have been described: when adenosine is 
changed to inosine by a specific enzyme, and when adenosine is deaminased A-to-l. These 
changes were found on the antisence strand of polyoma virus (189) and during persistent 
infection of the measles virus (49). Also, very specific site modification has been observed 
on viral and cellular RNA transcripts. A good example is hepatitis delta virus (202;269) that 
changes adenosine to inosine at position 1012 and will change the UAG termination codon 
to UGG which expands the ORF (269). 
6. Interferon as cellular response to viral infection 
During viral and cellular evolution, many cells develop some response to the viral 
infection. An example is cytokines, such as interferons. It has been observed that, during 
viral infection cells produce interferons that play important roles in protection against 
homologous and heterologus viral infection (160;231). Those molecules have been named 
interferons. Two types of interferons (IFNs) are currently known: type I IFN(a/(3) and type II 
(y). Interferon responses are considered to be an early defense mechanism of the host. 
Type IIFN (a/(3) is the primary response to viral infection in cells. Their role in protection was 
directly demonstrated using knock-out mice that became very susceptible to the virus even 
with the response of other cells of the immune system (83; 110; 128). On the other hand, 
IFN-y plays an important role in the protective immunity during the period of the viral 
infection. This interferon is very important for cell-mediated immunity via NK cells and 
activated macrophages (10;31). Cellular and humoral immunity mediated by Th1 and Th2 
cells is regulated by INF-y besides production of IL-12 and IL-18 cytokines (90;342). During 
viral infection viruses activate different cellular genes directly by cellular transcriptional 
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factors or by double-stranded RNA activated transcription factor complex (52; 151 ;357). 
Transcription factors such as IFR-3 and IRF-7 are very important regulators for IFN 
synthesis in response to viral infection, but other components of the pathway like Jak-1, Tyk-
2, IRF-9 and Stat-2 are also necessary during dsRNA-mediated signal transduction (14). 
Several pathways of antiviral response are known within the cell where some of the 
molecules regulate cell cycle or cell death and limit virus replication. There are many 
pathways that affect cell growth and metabolism, including: protein kinase R(PKR), 2'-
5'oligoadenylate syntheses, Mx protein, ADAR and cyclin-dependent kinase inhibitor p21. 
Also, viruses try to take advantage of cytokine production. Chemokine functions to promote 
viral propagation and spread in the host. Many viruses produce proteins that inhibit 
synthesis of the IFN-mediated gene activation in cells. One example is Sendai virus of 
Paramyxoviridae that produces protein C that has an inhibitory transcriptional reaction on 
IFN regulatory genes. The ability of cells to induce IFN response plays a key role in Sendai 
virus pathogenicity (79; 111). 
6.1. Protein-kinase R (PKR) 
As was mentioned above, PKR is interferon inducible. This serine/theronine kinase 
has many functions in controlling transcription and translation (62). PKR has two domains: 
one is N-terminal that bind to dsRNA site and another is C-terminal catalytic with conserved 
motifs for protein kinase. PKR is normally inactive but when it is activated it binds to dsRNA 
(223). The active form of PKR is dimmer. Although there are no sequence requirements for 
binding of PKR to dsRNA, it must be larger than 50 base pairs (277). Activated PKR has 
several functions within cells. It phosphorylates the a subunit of the elF2 and interacts with 
elF2B. Recycling of the elF2 stops consequentially inhibiting translation (62;272). It also 
plays a role in mediating the signal in response to dsRNA and other ligands (247) like 
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transcription factors NF-kB, or STAT 1, IRF1, p53 (65;189;273). A high level of PKR helps 
with virus clearance from cells and mediates apoptosis (166;312;313) through Bcl2 and 
caspase-dependent mechanisms (198). PKR also has an indirect role in apoptosis by 
synthesis of protein, especially factor Fas (12; 102;311 ). PKR is important during viral 
infection to mediate some resistance to viruses but other factors are important as well. 
When comparing PKR knock-out mice to the wild type, some differences were observed in 
dose dependent challenge of viruses (343). 
6.2. The 2 -5' oligoadenylated synthesis system 
2'-5' oligoadenylated synthesis are a group of enzymes that are induced by IFN. 
These molecules bind with high affinity to endoribonuclease L (RNase L) and induce its 
activation. RNase L cleaves single-stranded RNA and inhibits protein synthesis from it (296). 
It also can cleave the 28S ribosomal RNA (235). The 2'-5' oligoadenylated 
synthesise/RNase L system has some antiviral activity via IFN-a/|3 against many viruses 
including reovirus and encephalomyocarditis virus (356). It also has been proposed that 
Rnase L plays a role in apoptosis (78). 
6.3. The Mx proteins 
The Mx proteins are higly conserved with GTPase activity and a good homology to 
dynamin that are present in all species (302). They interfere with viral replication by 
inhibiting the activity of the viral polymerases (306) and have an effect on a range of RNA 
viruses at the transcription level and other stages in the virus life-cycle. The murine and 
human Mx1/MxA protein has a suppressing effect on several families of viruses including 
Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Bunyaviridae and Togaviridae 
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(100; 101 ;136;145; 177; 193;251 ;252;289;300;301 ;354). The mutant protein Mx that lacks the 
ability to bind to GTP fails to suppress virus replication (145). 
6.4. The adenosine deaminase (ADAR) 
Other factors also important in IFN-inducible antiviral responses are caspases and 
the dsRNA-dependent (ADAR) pathway. The dsRNA is recognized by ADAR which unwinds 
it and replaces adenosines with inosines (18;236;249;268). Such site-specific editing can 
cause amino acid substitution resulting in synthesis altered proteins. Many RNA viruses 
have dsRNA-based replicative intermediate ADAR enzyme that has a mutagenic effect on 
these viruses (18;48;50; 135; 153). 
6.5. Cyclin-dependent kinase inhibitor p21 
IFN can inhibit cell growth and viral replication all together. Negative regulation of the 
cell life cycle is done by cyclin-dependent kinase inhibitor p21 (57;307) that is crucial in the 
progression from G1 into S phase (113;141). When the level of p21 protein is high, it has a 
negative effect on cell transcription via the elF-2 family of transcription factors 
(103; 161; 180). IFN also acts as a repressor of the cell cycle via p202 gene product by 
forming a complex with elF-2, blocking binding to DNA and interfering with transcription of 
the genes important for G1-S transition (172; 179;200). Also, IFN has a direct 
downregulatory effect on the c-myc genes that are essential for cell cycle progression (273). 
Some of the pathways of cell response to viral infection and the resulting interferon 
production are listed in Figure 2. 
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Figure 2. Interferon (IFN) production - as cell response to viral infection. Adapted from C. E. 
Samuel (284) 
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Viruses quite often mimic one or more cellular components of the IFN transduction 
pathway, such as type I and type II IFN receptors, and viral ISRE-like promoter elements 
that function as a target of cellular IRF transcription factors. Some other viruses can block 
PKR (RNA-dependent protein kinase) (62). Phosphorylation of elF-2a correlates directly 
with inhibition of IFN inducible response of the host (62; 105). The NS1 protein that is made 
by the influenza virus binds to RNA and prevents activation of PKR and inhibits INF 
activation and cellular response to the influenza A virus (105; 110). The temperature 
sensitive influenza A virus has a NS1 defective protein that abolishes RNA binding and as a 
result cannot stop the activation of PKR in infected cells (105;143;285) PKR has a double-
stranded RNA binding motif to which viral RNA will bind and its binding is independent of the 
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sequence information and leads to either activation or inhibition of the kinase enzymatic 
activity (62). Viruses can utilize their own RNA or protein products to catalyze 
phosphorylation of elF-2 (105). For example, influenza virus regulates PKR activities using 
two different mechanisms. One is through NS1 nonstructural protein (105;110) and the other 
is by initiation of the stress related protein p58ipk inhibitors of PKR (221). The virus activates 
P58 ipk protein that is abundant in the cells by promoting disassociation from the negative 
promoter heat shock protein 40 (221). The NS1 protein of influenza virus has many 
functions during viral replication in the cells which include regulation of the synthesis, 
transport, splicing, and translation of the mRNA and prevention of activation of the PKR by 
binding to dsRNA that is the activator (105). At the 5' end of the HIV is located transcript the 
TAR RNA element that activates PKR as well (62;210). HIV virus also has two proteins that 
inhibit PKR activation: TAT and TAR-RNA. These binding proteins that form an inactive 
heterodimer with PKR (55). TAT protein also inhibits autophosphorylation of PKR and 
activates NF-kB factor (74). When PKR is activated it can phosphorylate several proteins 
such as the a subunit of elF-2, transcription factor inhibitor, M phase specific dsRNA-binding 
phosphoprotein MPP4 and itself (247;282;320;321). If RNA viruses have a high degree of 
secondary structure of single stranded RNA they can become an activator of PKR. 
Examples include reovirus s1 mRNA, HIV virus TAR RNA, and hepatitis delta virus (59;284). 
Other viruses like hepatitis C also inhibit the function of PKR by using some of the 
nonstructural proteins NS5A and envelope proteins (104;316). NS5A protein binds to PKR 
at the catalytic domain and inhibits demoralization where E2 protein also binds and inhibits 
PKR and has a similar sequence of information as the phosphorylationrilation site of PKR 
kinase and acts as pseudosubstrate (104;316). Inhibition of PKR by hepatitis C allows the 
virus to replicate in the presence of INF, increase cell growth and promote hepatocellular 
carcinoma (316;319). Treatment with IFN to clear HCV is only 20% effective because of the 
23 
many quasispecies and genotypes that are present in the population. Changes to the 
proteins also contribute to this resistance (219). Changes on the E2 gene nucleotide at 
position 81 on the sequence are important for the mutant viruses to become IFN resistant 
quasispecies (248;253). The HIV and encephalomyocarditis virus downregulate RNase L 
activity by expressing protein which works through the 2'-5'A RNase L pathway (214). 
7. Apoptosis as response to viral infection 
In response to viral infection many cells will go into apoptosis (programmed cell 
death). This is one of the defense mechanisms of cells to viral infection and dsRNA 
formation in the cells. This process is initiated through PKR since this enzyme can activate 
apoptotic gene expression and induce apoptosis by Fas-associated death caspase 8 
pathway and caspase 9 (117;120;330). Apoptosis is manipulated by different viruses to 
benefit viral replication. In some situations viruses block apoptosis or apoptotic pathways by 
making a protein that interacts with the process, while in other situations a virus will induce 
apoptosis in the cells depending on what will benefit viral replication, early cell death or 
prolonged cell propagation and expansion (89;140;294;317). Double stranded RNA together 
with type I IFN and intermediate factors such as PKR kinase and RnaseL can induce 
apoptosis (78;313;356). When apoptosis is induced by PKR some proteins are 
overexpressed such as elF-2 and NF-kB, and Fas receptors will be up-regulated and 
accumulation of PKR will lead to apoptosis (82; 116). Apoptosis can be suppressed or 
reversed if the PKR genes or RNase L are targeted (75;356). Some viruses can trigger 
apoptosis in bystander cells. It has been demonstrated that gp120 by itself can induce 
morphological changes associated with apoptosis in uninfected primary CD4+ cells when 
bound to the cell surface alone (24;133;237). Cells that have receptors such as CXCR4 will 
be affected by apoptosis, including neurons as well. When a cell is infected with HIV virus, 
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expression of the tat gene might provide protection to this virus (218). Other viruses also 
have proteins that can trigger apoptosis. A good example is the reovirus o1 attachment 
protein because this protein can induce apoptosis by binding to surface proteins of the cells 
(325). Inactivated virions can trigger apoptosis as well via cell surface proteins binding to the 
Fas/TNF superfamily (9;290). The avian leukosis retroviruses envelope protein CAR1 binds 
to the new superfamily of the TNF receptors and has domains that trigger cell death (40). 
Transfecting signal from one cell to a neighboring cell of indication of viral infection is done 
by the exposure of death markers on the extracellular face of the plasma membrane of the 
infected cell. Uninfected cells can facilitate the innate immune response by directing death 
stimuli towards infected cells (89). Most signals, if not all, are mediated in the cells during 
viral infection when intermediate dsRNA is formed, and Fas pathway and apoptosis is 
induced via Fas-associated death domain (FADD) signaling cascade (12). 
7.1. Role of mitochondria in apoptosis during viral infection 
Different stimuli that are regulated by the mitochondria involve two families: the first 
one is the caspase family of apoptotic proteases that coordinate proteolytic events during 
apoptosis and the second is the Bcl-2 family of proteins (89). Mitochondria serve as a critical 
response indicator to the oxidative stress with disruption and release of the inner or 
intramembrane proteins such as cytochrome c (125;187;225). All cell death events are 
tightly regulated by the Bcl-2 family of proteins (130; 142) and this family has opposing 
properties and can be antiapoptotic (Bcl-2,Bcl-X) or proapoptotic (Bax, Bak, and Bid). Some 
viruses make proteins that are homologues to Bcl-2 and modulate mitochondria function. 
One example is the Epstein-Barr virus (EBV) that makes BHRF-1 protein that has 
antiapoptotic properties (148) and related EBV protein BALF-1. It is able to prevent 
mitochondrial changes associated with apoptosis and react with Bax and Bak (213). Other 
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viruses produce proteins that are involved in mitochondrial-controlled cell death that are not 
related to Bcl-2 family/homolog. For example, the p13 protein of human T cell leukemia 
directs mitochondria to swell and cluster (66). The protein apoptin that is made by the 
chicken anemia virus can induce apoptosis in caspade-dependent manner (69). HIV 
translates a number of apoptosis-modulator proteins that trigger the mitochondrial cell death 
process (11 ; 17). Expression of the Nef protein in the lymphocyte cell line is sensitive to 
apoptosis. It has been noted that the level of protective proteins such as Bcl2/Bcl-X is 
suppressed and some of the cell-surface receptors are down-regulated indicating that the 
Nef protein has some proapoptotic function during viral infection (274). Tat protein of HIV, 
when expressed in the stable form, induces cell death by many mechanisms including 
mitochondria cell death (caspase-dependent) pathway by increasing the calcium level and 
accumulation of reactive oxygen species (188). T cells were found to go through apoptosis 
when tat protein is expressed and protein accumulation was demonstrated in the 
mitochondria and was caspase-independent (208). During viral infection of the cell, protein 
synthesis is up-regulated and some of the viruses make many viral proteins on the 
endoplasmatic reticulum (ER) that become loaded with viral proteins that are ready for 
export to the cell surface or secretion. The ER normally responds to overloaded activation 
by multiple signal transduction pathways that can induce apoptosis directly (123;358). Other 
viruses use cellular death (apoptosis) to promote their own dissemination and ensure the 
release of progeny virions by the end of assembly of the virus. One example has been 
described with togaviruses (129; 140) where apoptosis induction has been identifyied to E2 
structural glycoprotein virus attachment protein which is timed to coincide with the 
completion of the viral replication cycle. Cell death occurred when the progeny of virions are 
ready to be disseminated within apoptotic bodies (129). The apoptosis pathway is 
summarized in Figure 3. 
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Figure 3. Cellular response to RNA viral infection and sensors that can trigger apoptosis. 
Adapted from H. Everett and G. McFadden (89). 
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When viruses infect immune or epithelia cells one of the first responses is production of 
peptide or antimicrobial peptides that mainly have an effect on bacteria but also on 
enveloped viruses (family Paramixoviridae, Retroviridae) as it has been reported 
(106; 132;353). These peptides are part of the innate immune system and there are several 
families of these peptides including cathelicidin (PR-39, Protegrins, PMAP-23,-36, and -37, 
defensins (a and (3) (32;33;109;199). These peptides induce chemotoxins and stimulate 
adaptive immune response. Their mechanism of action is not very well understood but it is a 
peptide-lipid interaction and involves permeabilization of the cell membrane or viral 
envelope (32;239;353). 
8. Silencing of viruses by dsRNA (intermediate) in infected cells 
In lower organisms like plants there is no evidence of interferon or PKR response to 
viral infection, but living cells develop alternative defensive pathways that are sequence 
specific and known as RNA interference (RNAi). Originally this mechanism was described in 
nematodes and plants (175) where introduction of the sense and antisense RNAs cause 
gene silencing (95;310 158;220;350). Observations were made that when injected, double-
stranded RNA reduces the production of sequence-specific mRNA. It has been suggested 
that only a few molecules are required to reduce a population of the target mRNA and a new 
potent mechanism of action exists (94). In nature, RNAi is initiated when the host cell 
encounters a long dsRNA transcribed from a virus, or from an endogenous source such as a 
mobilized transposon, inappropriately transcribed sequence or newly identified class of 
regulatory, non-coding microRNA (miRNA) (197; 131 ;230) The dsRNAs induce a cascade of 
events involving a cytoplasmic RNase Ill-like protein known as a Dicer and multi-protein 
RNA-induced Silencing Complex (RISC). Dicer is responsible for cleaving double-stranded 
molecules, derived from endogenously expressed miRNAs or from replicating viruses into 
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small inhibitory or interfering RNA duplexes (siRNA) of 19-25 base pairs (bp) (25;86; 139). In 
siRNA-mediated silencing, the cleavage products are released and degraded leaving the 
siRNA-programmed RISC to survey and further deplete the available pool of target mRNA. 
Introduction of dsRNA into mammalian cell lines normally will induce interferon response, 
PKR, 2'5'-AS, TLR3 and cell death but it is not a specific response and depends on how the 
siRNA was made (258). In recent studies it was demonstrated that synthetic duplexes 
mimicking natural 19-25 bp siRNA could be introduced into cells and ihibit the target mRNA 
without the induction of the interferon response (86;45) Some success has been achieved in 
using RNAi-base technologies to inhibit viral replication of HIV and other retroviruses, 
hepatitis B and influenza A virus (63; 114; 155; 165; 196;217). In some studies siRNAs were 
directed against specific Respiratory Syncytial virus (RSV) mRNAs. Suppression of RSV 
mRNA was demonstrated but no full-length viral genome knockdown (28) was reported. 
There are many different ways to develop and introduce siRNAs into cells or animals. 
Simply, siRNA can be synthesized and used in a transfection experiment, or use of the 
expression vector that produces a hairpin-like structure and is later processed by the Dicer 
into functional siRNAs can be suitable. Lentiviviral vector has been described and recently 
CRE-lox-base strategy has been developed for temporal or tissue-specific knockdown 
genes (4;41;241;344;360). 
9. Assembly of the virion and release of viral particles 
Viral replication and transcriptional complexes and their products will be localized in 
different parts of the cell. Viruses assemble in different locations (cytoplasm, cellular 
membrane, endoplasmic reticulum, golgi complex or nucleus) of the cells. It is known that 
viruses may utilize cellular polymerase or protease, membranes, kinase and chaperone 
proteins for protein production (183). As a general rule, the site of virus replication is 
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different from the site of virus maturation but the integrity of the cell structure is very 
important for virus maturation and assembly. 
Some RNA viruses will replicate only in the cytoplasm where a viral particle will be 
made. For example, the viruses belonging to the family Picornaviridea are very independent 
in their replication (267). The last stage of viral replication is packaging viral RNA into newly 
made nucleocapsid and release of the virus. After polycystronic protein P1 is transcribed it 
will be cleaved 3CDpro into protein precursor VPO and capsid proteins VP3 and VP1. 
Cleavage of P1 into such products allows the assembly of 5S promoters into 14S pentamers 
structures, which are specially assembled into 80S procapsids (244). Pentamers are 
important intermediates in the assembly of all picornaviruses (30;279). These pentamers are 
capable of self-assembling into 80S empty capsids and newly synthesized viral RNA is 
inserted into these particles (163). Cleavage of VPO into VP4 and VP2 will take place 
resulting in formation of mature 150S virions (147). This packaging process and 
encapsidaton is very specific to positive strand viral RNA due to the presence of VPg and no 
other types of viral or cellular mRNA are inserted. During poliovirus replication cell apoptosis 
is blocked by viral encoded inhibitors (322) and later product 2A and 3C proteins lead to 
induction of apoptosis (119). During apoptosis the cell will die and viral particles are 
released (spread) to infect another suitable host cell. 
Different viruses will use different mechanisms of release from the cell. Most 
enveloped viruses will bud through the cellular membrane. The strategies that are used in 
this process can be classified into three general mechanisms (112). The first one is when 
extrusion of the virus is driven by the viral envelope alone. The second one, used by 
retroviruses is when the capsid precursor is capable of inducing membrane extrusion and 
releases viral particles without the help of viral glycoproteins. The third mechanism is used 
by alfaviruses and involves interaction of the viral glycoprotein spikes and capsid. Interaction 
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between the cytoplasmic domain and capsid slowly will bend the membrane from the 
spherical particle (112). The last step of budding for enveloped viruses is pinching-off. The 
mechanism is not well understood for many viruses and probably requires interaction of 
some viral proteins and the cell membrane at least for retroviruses. In HIV deletion of the C-
terminus of the Gag protein leads to blocking of the virus released at the pinching-off stage 
(121). 
The influenza virus can bud from from the plasma membrane of infected cells and 
cellular proteins are not incorporated into the virion. Viral integral proteins HA, HEF, NA, M, 
of the influenza virus are normally made on the ribosomal membrane and transformed to 
apical cell surface (157;280;345). The cytoplasmic tails of the HA and NA proteins are very 
important for interaction with internal components of the virion (M1) (169-171). These 
conserved regions of tails are important for normal budding. When the virus is budding from 
the plasma of the cells it contains viral envelope proteins and patches of the cell membrane 
(195;351). For the virus to be released it is necessary that neromidase NA protein is present 
and cleaves HA from the self cell receptors on the surface of the cells (194;242;243). Some 
of the enveloped viruses exit from the cells by budding through the plasma membrane or by 
fusing with secretory vesicles within the plasma of cells, like flaviviruses (305). Pestiviruses 
of Flaviviridea mature in intracellular vesicles and are released by exocytosis or viruses, 
apoptosis and cell destruction often lead to disease (124;227). 
10. Outcome of cell infection by RNA viruses 
Viruses will infect a cell and it is a necessary component of their life cycles. In return 
cells respond in different ways, but how this relationship will end depends on many factors 
especially cell and virus interaction. Most of the mechanisms of viral replication cycles and 
cell response or accommodation of viral needs are described above. In general it is a 
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complicated process and is unique to individual viruses and host cells. There are many 
viruses and all of them are pathogenic, but some of them are pathogenic and cause serious 
disease even when viruses are almost the same genetically. Virus and cell interaction or 
infection is very important for animals and quite often determines the outcome of infection or 
the course of disease. If a virus causes cell destruction it normally leads to fatal disease, 
otherwise the outcome of the infection could be undetectable. The picornaviruses will cause 
apoptosis (119) of the infected cells (neurons) but there are some strains of viruses that 
encode additional proteins that have antiapoptotic properties for a long time and that 
determines if infection will result in acute disease and death or persistence of viral infection 
(115). 
One example is infection of calves with pestiviruses and development of mucosal 
disease (MD). It is known that if calves are persistently infected with noncythopatic (noncp) 
BVD virus, this virus can be isolated from many tissues including central nervous system, 
serum and leukocytes (26;204) but without evidence of disease. If recombination of the BVD 
virus happens and a cytopathic virus is generated that will lead to MD, the number of 
infected cells will increase (126;204;224). Cytopathic pestiviruses kill cells via apoptosis 
(152;291;352) and this cell destruction helps viral spreading and also damages tissues (site 
of replication) and leads to disease. Experimentally it is difficult to reproduce clinical signs 
and MD disease even using cpBVD strain of the virus that was isolated from infected 
animals with clinical signs and lesions. This is because humoral and cellular immune 
response plays a role in protection from infection. It has been proven that animals have to 
be persistently infected with noncythopathic virus and the same virus after recombination 
will become cytopathic and cause disease development (204). Other members of the 
pestiviruses are classical swine fever (CSF) and border disease virus (BDV) that cause 
32 
disease when cythopathic viral particles can be detected. Normally, infection with 
noncythopathic viruses does not cause any lesions. 
Many other RNA viruses are known to cause clinical signs and disease in pigs of 
different ages. These viruses and clinical signs are summarized in Tables 3 and 4 below. 
Table 3. Clinical signs in pigs resulting from infection with RNA viruses 
Name FamilyA/iruses Age of 
Animal 
Clinical signs and tissue for viral replication Refe­
rences 
Picornaviridae 
Enterovirus 
Young 
pigs 
Sows 
Fever, anorexia, listlesness, locomotor atoxid, 
death within 3-4 days. Pneumonia, 
porencephalitis. Pigs that survive waste and 
have some paralysis. Virus replicates in tonsil 
and intestinal tract and central nervous system. 
Infertility, embryonic death, still birth, mummies. 
Virus may replicate in uterus. 
(76) 
Encephalomyocarditis 
(EMCV) 
Cardiovirus 
Young 
pigs 
Sows 
Anorexia, listlessness, trembling, straggering, 
paralysis or dyspnea. 
Severe reproductive problems, fever, anorexia, 
abortion with stillborn and mummies. 
(173) 
Paramyxoviridae 
Rubulavirus 
Young 
piglets 
Ataxia, weakness, muscle tremors, dialated 
pupils, blindness, incoordination, death. 
(304) 
Paramyxoviridae 
Rubulavirus 
Sows Abortion, infertility problems, returning to 
estrus, reduction in farrowing rate, stillbirth, 
mummies. Virus grows in cells of reproductive 
and respiratory tract and nervous system 
(CNS). 
(304) 
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Name Family/Viruses Age of 
Animal 
Clinical signs and tissue for viral replication Refe­
rences 
Coronaviridae 
Heamagglutinating 
Encephalomyelitis 
Young 
pigs 
Encephalitis, anorexia, depression, vomiting, 
wasting, muscle tremors, blindness, dysplnea 
and death. Virus replicates in respiratory tract, 
nasal cavity, trachea and lungs. 
(256) 
Transmissible 
Gastroenteritis 
Porcine Respiratory 
Coronavirus 
Young 
pigs 1-
5 
weeks 
Yellowish diarrhea, rapid loss of weight, 
dehydration, agalactia, vomiting. Virus 
replicates in villous epithelial small intestine 
cells. 
Mild respiratory signs, fever. Virus will replicate 
in cells of respiratory tract, lungs, epithelial, 
trachea, bronchi, alveoli and alveolar 
macrophages. 
(281) 
Togaviridae Eastern 
Equine 
Encephalomylitis 
Japanese B 
encephalitis 
Young 
pigs 
nurser 
y 
Sows 
Depression, anorexia, ataxia, lateral 
recumbency, convulsions and ultimately death 
No clinical signs but mummified fetuses, piglet 
will be weak, still born piglets. Virus replicates 
in central nervous system. 
(87), 
(174) 
Porcine epidemic 
diarrhea 
Young 
pigs 
Dehydration, diarrhea. Virus replicates in vilous 
epithelial cells of small intestine and colon. 
(257) 
Arteriviridae 
Arterivirus 
Porcine Reproductive 
and Respiratory 
Syndrome 
Pigs of 
all 
ages 
Sows 
Listlessness, emaciation/starvation, watery 
diarrhea, anorexia, lethargy, hypernea, 
dyspnea, rough hair coats, CNS signs, 
feverAbortion, irregular return to heat, stillborn, 
dead pigs, mummified fetuses, low conception 
rate. Virus replicates in cells like monocyte. 
(20) 
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Name Family/Viruses Age of 
Animal 
Clinical signs and tissue for viral replication Refe­
rences 
Rhabdoviridae 
Rabies 
All 
ages 
Loss of coordination, dullness, rapid chewing 
movements, excessive salivation, generalized 
chronic muscular spasm, fine tremor and 
death. Virus replicates in cranial nerves. 
(228) 
Reoviridae 
Rotaviruses 
Reoviruses 
1-6 
days 
old 
and 
older 
Diarrhea, vomiting, anorexia, pyrexia, 
sneezing, inappetance and listlessness. Virus 
replicates in cells respiratory and intestinal 
tracts. 
(250) 
Orthomyxoviridae 
Influenza virus 
All 
ages 
Anorexia, inactivity, prostration, huddling, 
piling, fever, conjunctivitis, rhinitis, nasal 
discharge, sneezing, coughing. Virus replicates 
in cells of nasal mucosa, tonsils, trachea, 
tracheobronchial lymph nodes and lungs. 
(85) 
Vesicular disease: 
Picornavidae 
Foot-and-mouth 
disease 
Picornaviridae 
Enterovirus 
Swine vesicular 
disease 
All 
ages 
These viruses produce similar clinical signs. 
Formation of vesicles and erosions, loss of 
epithelium. Vesicles found on the snout, lips, 
tongue, coronary band, soft tissue of feet. Hoof 
may become detached and severe mortality, up 
to 50%. Virus replication sites are epithelium, 
mucosa, myocardium. 
Virus will grow in snout, tongue, coronary band, 
tonsil, cardiac muscle and brain cells. 
(154) 
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Table 4. Clinical signs in pigs cause by Pestiviruses of Flaviviridae family 
Virus Feature or 
virulance 
Age of 
Animal 
Clinical signs Refe­
rences 
Classical 
swine fever 
(CSF) 
Acute All 
pigs 
Short incubation period, severe depression, 
high fever, anorexia, conjunctivitis, 
constipation, diarrhea, convulsion, 
incardination, hemorrhages of skin, death. 
Systemic infection of all tissues but site of 
replication in tonsil (epithelial cell and 
follicles and lymphoid cells like B or T cells. 
This site of replication is common for all 
pestiviruses). 
(328) 
Late-onset All 
pigs 
Late onset of disease, gradually 
aggravating depression and anorexia, 
normal to slightly elevated body 
temperature, conjunctivitis, dermatitis, 
locomotion disturbances. 
Sows Abortion, earlier infertility, return to estrus. 
Chronic Pig all 
ages 
Short incubation period, three phases of 
illness: 1) depression, fever, anorexia. 2) 
Clinical improvement 3) terminal 
exacerbation of disease. Virus replicate in 
epithelial cells and basal cells layer of 
germinal center. Germinal centers are 
depleted and contain only a few 
lymphocytes in pigs that survive for a long 
period of infection. 
(56) 
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Virus Feature or 
virulance 
Age of 
Animal 
Clinical signs Refe­
rences 
Bovine viral 
diarrhea 
(BVD) 
Young 
pig 
Anemia, rough hair coat, growth 
retardation, wasting and congenital tremor. 
Conjunctivitis, diarrhea, polyarthritis, 
petechiae in skin, blue ear tips. 
(318) 
sows Poor conception, abortion, hyperthermia 
and colonic spasm. 
Border 
disease 
(BD) 
Young 
pig 
Growth retardation with respiratory signs, 
diarrhea, including anemia, wasting and 
congenital tremors. 
(329) 
(318) 
Sows Repeat breeding, dead piglets, stillborn and 
mummies, locomotor disorders. 
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Abstract 
Disease outbreaks characterized by reproductive failure and/or neurologic disorders, 
which is commonly referred as "Porcine Reproductive and Neurologic Syndrome (PRNS)", 
have been observed in many swine farms in Iowa and other states. Although an infectious 
cause was suspected to account for the disease, no conclusive diagnosis had been reached 
with respect to conventional infectious agents. Extensive laboratory diagnostic investigation 
on suspect cases repeatedly resulted in the isolation of a cytopathic enveloped virus of 50-
60 nm in size from nervous and second lymphoid tissues and sera which was, to reflect its 
unknown identity, named "Virus X". The presence of virus particles with morphological 
characteristics similar to Virus X in tissues from clinically affected animals was also 
observed on thin-section positive-staining electron microscopy. Isolates of Virus X were not 
recognized by antibodies raised against any known viruses pathogenic to swine but by 
antisera collected from animals surviving clinical episodes, indicating that Virus X is likely a 
previously unrecognized agent. Pregnant sows which were experimentally inoculated with 
Virus X (ISUYP604671) or homogenate (filtrate) of tissues from a clinically affected animal 
developed clinical signs and lesions similar to field observations, including the loss of 
pregnancy. Furthermore, caesarian-derived, colostrum-deprived young pigs developed mild 
encephalomyelitis lesions in their brains after experimental inoculation with the virus or the 
tissue homogenate, although clinical neurologic signs were not observed. More importantly, 
Virus X was re-isolated from all inoculated animals while control pigs remained negative for 
the virus during the study. Collectively, Virus X is a novel viral agent responsible for PRNS 
and remains to be further characterized for its taxonomical identity. 
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1. Introduction 
Wastage of pigs due to reproductive failure causes significant economic losses to 
swine production. Death losses of sexually mature breeding animals and market hogs add 
more economic burden to producers. In many situations, both infectious and non-infectious 
causes can account for reproductive problems and mortality; infectious diseases are 
considerably more important because of rapid transmission between animals and often the 
lack of effective preventive measure. 
Since at least 1995, pork producers and swine practitioners have reported disease 
outbreaks characterized primarily by early infertility, hence commonly referred as "sow 
infertility syndrome" or "growth depression syndrome" (14). Typically, producers have 
observed an acute decline in farrowing rate due to increased early or delayed returns 
followed by a prolonged period (up to 2 years) of sub-optimal farrowing performance. Loss 
of pregnancy most commonly occurs in the early stages of gestation (i.e., 30-55 days) 
although abortion and reproductive failure were also reported on sows at later gestations. 
Affected animals which were confirmed pregnant at 30 days either aborted or demonstrated 
irregular return to estrus. Besides reproductive disorder, many of the affected animals were 
also presented with neurological signs, such as posterior weakness/paralysis, ataxia, bar 
chewing, and head pressing/banging (13). The neurological symptoms in affected 
individuals progress with death in 2 or 3 days as the usual outcome. Central nervous signs 
also were observed in younger pigs such as nursery and fattening pigs. To reflect various 
clinical manifestations, the newly identified disease has also been commonly referred as 
"Porcine Reproductive and Neurologic Syndrome (PRNS)". Reproductive and neurologic 
problems were not, however, always present simultaneously. 
To date, affected animals have been observed in both PRRSV-infected and PRRSV-
free swine herds in many states including Iowa, and the incidence of the problem continues 
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growing (14). Although many cases with similar clinical presentations have been presented 
to the Iowa State University Veterinary Diagnostic Laboratory (ISU-VDL), a conclusive 
diagnosis could not be reached (13). The pattern of spread of the disease within and 
between herds definitely implied the involvement of an infectious agent. However, laboratory 
testing, including serology, has not yet demonstrated a role for any recognized reproductive 
or neurologic pathogens such as porcine reproductive and respiratory syndrome virus 
(PRRSV), group 1 porcine enterovirus (REV), influenza A virus (SIV), porcine parvovirus 
(PPV), pseudorabies virus (PRV), bovine viral diarrhea virus (BVDV), or classical swine 
fever virus (CSFV) (11,13). Furthermore, there was no evidence that the condition is toxin-
related, or associated with any particular management or pig genotype. Therefore, the 
disease was thought to be due to a previously unrecognized agent. With that hypothesis, the 
following extensive laboratory diagnostic investigations were conducted to identify the 
causative agent. 
2. Materials and methods 
2.1. Case definition 
Index animals were selected for diagnostic investigations from herds showing the 
following clinical presentations. Sow farms underwent an unusually high early return or 
abortion after 30 but before 50 days of gestation. Animals were lethargic, restless, and/or 
dyspneic particularly after exercise prior to losing the pregnancy. Some of the affected 
animals were also febrile and pale. Besides reproductive failure, some of affected pregnant 
sows and weaned pigs also showed neurological signs such as posterior weakness, 
paralysis, ataxia, lameness, head pressing or banging, and aggressive behavior often 
leading to abrasions on the forehead, nose and front legs, and abortion. Neonates showed 
"shaking" and many times appeared to be blind as those animals could not walk 
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directionally. Central nervous signs were also observed in grower-finisher pigs. Some pigs 
recovered but the majority of affected animals eventually died within several days after 
showing clinical signs. Sometimes affected animals died suddenly without any overt 
preceeding clinical signs. To avoid any potential confusion, animals from known PRRS-
positive herds were not included in the study. 
2.2. Biological samples 
Serum, whole blood and tissues (brain, secondary lymphoid tissues, kidney, liver, 
lung) were collected from each animal and used for laboratory testing. Secondary lymphoid 
tissues included tonsil, regional lymph nodes, and spleen. When available, fetal thoracic 
fluid and tissues were collected from aborted or freshly dead fetuses. Placenta and uterine 
tissue were also collected from sows. 
Buffy coat cells were fractionated from EDTA blood by a gradient centrifugation and 
used for testing. Sera and fetal thoracic fluids were tested as collected. Tissues were tested 
after 20% (w/v) homogenate was made in Earle's balanced salt solution (Sigma Chemical 
Co., St. Louis, MO) and filter-sterilized through 0.22pm membrane filters (Fisher Scientific 
Co, Houston, TX). 
2.3. Immunofluorescence microscopy on frozen tissue sections 
The fluorescent antibody (FA) test was performed on cryosections of tissues (brain, 
tonsil, kidney, lymph nodes) from clinically affected animals submitted to ISU-VDL to detect 
viral antigens. Thin sections of each tissue were obtained using cryostat and microtome. 
Cryosections were then attached to prepared glass slides and fixed by immersing in 100% 
cold acetone. Fixed tissue sections were stained with polyclonal antibodies for a variety of 
animal viral pathogens purchased from USDA National Veterinary Services Laboratories 
42 
(NVSL, Ames, IA) and American BioResearch Laboratories (Sevierville, TN). All antibodies 
were used after optimally diluted in 0.01 M phosphate-buffered saline (PBS pH7.4) according 
to manufacturers' recommendations. Swine sera collected from naturally or experimentally 
infected pigs were used (i.e., convalescent sera). Slides flooded with each of the antibodies 
were incubated at 37°C for one hour in a humid condition and then rinsed with PBS three 
times. The antigen-antibody reaction in tissues was visualized by staining tissue sections 
with optimally diluted goat anti-species specific IgG (H+L) conjugated with fluorescein 
isothiocyanate (FITC) (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD). Slides 
were then observed under a fluorescence microscope. 
2.4. Polymerase chain reaction assays 
All clinical specimens were tested by polymerase chain reaction (PGR) based tests 
for known swine viral pathogens, such as porcine reproductive and respiratory syndrome 
virus (PRRSV) of North American and European genotypes, porcine circovirus (PCV) type 1 
and 2, group 1 porcine enterovirus (PEV), influenza A virus, porcine parvovirus (PPV), 
porcine reovirus type 1, 2 and 3, porcine cytomegalovirus (PCMV), pseudorabies virus 
(PRV), transmissible gastroenteritis virus (TGEV), porcine respiratory coronavirus (PRCV), 
porcine epidemic diarrhea virus (PEDV), Japanese encephalitis B virus (JEV), porcine 
endogenous retrovirus (PERV), porcine lymphotropic herpesvirus type 1 (PLHV-1), swine 
hepatitis E virus (sHEV), bovine viral diarrhea virus (BVDV), West Nile virus (WNV), 
classical swine fever virus (CSFV), bovine viral diarrhea virus (BVDV), border disease virus 
(BDV), and members of alpha Togavirus. A multiplex PGR was used for detecting PCV DNA 
as previously described (7). PGR assays previously described (2) were employed for 
detecting PPV DNA. Reverse transcription (RT)-PCR assays were used for detecting RNA 
of PRRSV (16), group I PEV (17), CSFV (5; 12), JEV and WNV (10), BVDV (9), PERV (1), 
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and alpha-togaviruses (8). Detection of SIV orTGEV/PRCV genome in samples was 
attempted using multiplex RT-PCR assays established in ISU-VDL (3;4). All PGR reaction 
was done using QIAGEN® OneStep RT-PCR kit (QIAGEN Inc. Valencia, CA). 
2.5. Virus isolation attempts 
Virus isolation was attempted on all samples using various cell lines and primary 
cells of porcine origin. All cell lines and primary cells were confirmed by virus isolation 
technique, polymerase chain reaction (PCR) based assay and antigen-capturing ELISA 
(Syracuse Bioanalytical, Inc., Ithaca, NY) to be free of bovine viral diarrhea virus (BVDV) 
prior to and during use. All cell lines also were confirmed by a commercial PCR test 
(American Tissue Culture Collection, Manassas, VA) to be free of Mycoplasma spp. 
Cells were prepared in 48-well plates and 25cm2 tissue culture flasks and grown in 
Minimum Essential Medium (MEM, Mediatech, Inc., Herdon, VA) supplemented with 10% 
(v/v) BVDV-free fetal bovine serum (Sigma Chemical Co., St. Louis, MO) or 5% (v/v) horse 
serum (Sigma Chemical Co., St. Louis, MO), 20mM L-glutamine (Gibco/BRL Life Science, 
Grand Island, NY), and an antibiotic-antimycotic mixture that consisted of 100 lU/ml 
penicillin, 10 |jg/ml streptomycin, 50jjg/ml gentamicin (Sigma Chemical Co., St. Louis, MO). 
After confluent monolayer was formed, samples (0.25 ml/well and 1 ml/flask) were inoculated 
to each cell in duplicate or triplicate. After one-hour incubation at 37°C, cells were rinsed 
with fresh MEM supplemented with 5% horse serum (Sigma Chemical Co., St. Louis, MO) 
and were incubated further in a humid 37°C incubator with 5% C02 supply. Alternatively, 
samples were inoculated to cell suspension and left for 24 hours before material was 
removed. Inoculated cells were then observed daily for cytopathic effect (CPE) until 7 days 
post inoculation (PI). When CPE was evident in more than 70% of cell monolayer, cell 
culture medium was harvested and inoculated onto freshly prepared cells in duplicate. In 
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cases where no CPE was evident by 7 days PI, cells were subjected to 2 cycles of freeze-
thawing at -70°C and 35°C respectively, and then cell lysate was inoculated to freshly 
prepared cells in the same manner as above. 
At day 2 to 4 PI regardless of the presence or absence of CPE, one set of the 
inoculated cells were fixed after cell culture media were harvested by immersing them in 
cold 80% aqueous acetone and subjected to immunofluorescence microscopy using FITC-
labeled antibodies (USDA NVSL, Ames, IA; Rural Technologies, Inc., Brookings, SD; 
American Bioresearch, Inc., Seymour, TN) raised against known swine viral pathogens, 
such as North American and European strains of PRRSV, PRV, PCMV, PCV, PPV, 
encephalomyocarditis virus (EMCV), PEV, TGEV, hemagglutinating encephalomyelitis virus 
(HEV), swine influenza virus (SIV) of H1N1 and H3N2 subtypes, influenza A virus, porcine 
reovirus, rabies virus and BVDV. In addition, the cells were reacted with sera collected from 
animals that were clinically affected but survived during the course of natural infection. 
Depending upon animal species, the origin of each primary antibody, anti-porcine IgG (H+L) 
or anti-bovine IgG (H+L) conjugated with FITC (Kirkegaard and Perry Laboratories, Inc., 
Gaithersburg, MD) was used as secondary antibody to visualize specific antigen-antibody 
complexes. At the same time, another set of the inoculated cells were subjected to freeze-
thawing and then cell lysates were tested by PCR assays for known swine viral pathogens 
described above under PCR. 
Cell culture fluid and corresponding cell lysate from each culture that was negative 
for all known viral agents described above but positive by I FA using convalescent serum 
and/or pan-pestivirus antiserum were combined and inoculated again on each cell for further 
propagation of the virus for use in other laboratory testing such as electron microscopy (EM) 
or animal study. 
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2.6. Electron microscopy (EM) 
To assess morphological characteristics of viral isolates, cells inoculated with 
potential virus material and cell culture fluid containing the virus, as well as pig tissues, were 
examined by electron microscopic techniques. Inoculated cells and tissues were examined 
by thin-section positive-staining EM. Inoculated cells were incubated at 37°C in a humid 5% 
C02 atmosphere for up to 120 hours PI. At between 48 and 120 hours PI respectively, the 
cells were harvested using a cell scraper and pelleted by low-speed centrifugation at 3000 
rpm for 20 minutes. Each cell pellet was fixed in 2% (w/v) glutaraldehyde and 2% (w/v) 
paraformaldehyde in 0.05M phosphate-buffered saline (PBS, pH 7.2) for 48 hours at 4°C. 
Samples were rinsed once in PBS followed by 2 washes in 0.1 M cacodylate buffer (pH 7.2) 
and then fixed in 1% osmium tetroxidate in 0.1 M cacodylate buffer for 1 hour at ambient 
temperature. The samples then were dehydrated in a graded ethanol series, cleared with 
ultra pure acetone, and then infiltrated and embedded using a modified EPON epoxy resin 
(Embed 812, Electron Microscopy Science, Fort Washington, PA). Resin blocks were 
polymerized for 48 hours at 70°C. Thick and ultra-thin sections were made using a Reichert 
Ultracut S ultra microtome (Leeds Precision Instruments, Minneapolis, MN). Ultra-thin 
sections were collected onto copper grids and counterstained with 5% uranyl acetate in 
100% methanol for 15 minutes followed by Sato's lead stain for 10 minutes. The grids were 
observed under a JEOL 1200EX II scanning and transmission electron microscope (Japan 
Electron Optic Laboratories, Peabody, MA). Images were captured using a Megaview III 
digital camera and SIS Pro software (Soft Imaging Systems Incorporated, LLC, Lakewood, 
CO). 
Viruses in cell culture fluid were examined by a negative-staining EM as previously 
described (6). Viral particles were pelleted by centrifugation using SW41 swinging-bucket 
rotor in an ultracentrifuge (Optima LE 80K, Beckman, Fullerton, CA) for 3 hours at 160,000 x 
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g. and resuspended in a small quantity of PBS. Ten pi of the virus suspension were applied 
to carbon-coated grids. Excessive PBS was dried out from the grids with an absorbent 
paper, and the grids were stained with 4% potassium phosphotungstic acid (PTA) for 5 min 
at ambient temperature. The grids then were examined under the JEOL 1200EX II scanning 
and transmission electron microscope. Images were captured using the Megaview III digital 
camera and SIS Pro software. 
2.7. Animal trials 
2.7.1. Trial 1: Inoculation of pregnant sows. Seven sows at 4th or 5th parity were 
purchased from a high-health-status commercial vendor and transferred to an animal 
holding facility with farrowing crates and bred through artificial insemination. The facility was 
operated and managed at the compliance of biosafety level 2. Once pregnancy was 
confirmed on day 30-31 by an ultrasound technique, 5 sows were selected and used for the 
study. Four of the 5 sows at 30 days of gestation were inoculated intranasally, 
subcutaneously and intramuscularly with one of the following biological materials: a) cell 
culture fluid containing virus isolate designated ISUYP604671; b) homogenate of tissues 
collected form a clinically affected sow; or c) serum collected from the clinically affected sow. 
The ISUYP60467 was isolated from that sow. All inoculated animals were kept in the same 
room but individually without direct contact in farrowing crates for 30 days. The one 
remaining sow served as a sham-inoculated control and was kept in a separate room. After 
inoculation, all animals were monitored for changes in behavior and any reproductive 
problems. In addition, the sows were bled every seven days. At the termination of the study, 
all sows were euthanized, and various tissues (brain, tonsil, lung, spleen, lymph nodes, 
kidney, liver, placenta, spinal cord, uterus, uterine fluid) and, if present, fetuses were 
collected from each sow for histopathology, virus isolation and/or serology. 
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2.7.2. Trial 2: Inoculation of caesarian-derived-colostrum-deprived (CDCD) 
pigs. Seven 7-week-old CDCD pigs were used to evaluate the clinical effect of Virus X on 
young swine. Animals were divided to 3 groups. Group 1 (n=3) was inoculated with cell 
culture material containing the virus isolate ISUYP604671 via intranasal, intramuscular and 
intravenous routes. Group 2 (n=3) was inoculated via the same routes with serum from an 
animal (Sow 800) which was experimentally infected with the virus in the previous animal 
study with pregnant sows. Group 3 (n=1) was inoculated with virus-free cell culture fluid and 
served as a sham-inoculated negative control. All animals were monitored for the first 2 
weeks after inoculation for changes in rectal temperature and behavior and for clinical signs. 
One pig per group except group 3 was euthanized and necropsied on days 7 and 10 PI. 
Tissues (brain, tonsil, lung, spleen, kidney, lymph nodes) were collected from each pig for 
both virus assays and histopathology. Animals were bled at days 0,7, 10 and 14 PI to 
collect whole blood and serum. At day 14 PI all remaining animals were euthanized and 
necropsied. 
2.8. Histopathology 
Tissues were fixed by immersing in 10% neutral buffered formalin immediately after 
collection for 24 hours. Fixed tissues were processed, embedded in paraffin, and sectioned 
according to the standard protocol established in the ISU-VDL. Sections then were stained 
with hematoxylin and eosin for microscopic examination. 
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3. Results 
3.1. Gross and microscopic evaluation of clinical cases 
In many cases, external examination revealed trauma to the face and head of 
clinically affected pigs probably as a result of head-banging and head-pressing. Traumatic 
lesions also were seen in extremities or shoulders possibly due to ataxia or recumbency. 
While affected animals showed distinct clinical signs, gross lesions were not present 
except for the presence of petechial hemorrhage in lymph nodes and sometimes on the 
serosa of many organs. Microscopically, some lesions were limited to the brain as mild focal 
to locally extensive nonsuppurative perivascular cuffing, gliosis, and lymphoplasmacytic 
encephalitis. Hepatitis and interstitial pneumonia were additional lesions frequently observed 
in the affected animals. 
3.2. Virus isolation attempts and preliminary characterization of virus isolates 
A cytopathic agent that could pass through a 0.22 |jm membrane filter was 
repeatedly and consistently isolated from serum, tonsil, lymph nodes and/or brain from 
clinically affected animals. Because of unknown identity, the agent was tentatively named 
"Virus X". Two initial isolates were designated ISUKJY96 and ISUYP604671, respectively. 
Besides Virus X, several other viruses, such as REV, porcine reovirus and PRRSV (North 
American genotype), were also inconsistently and infrequently isolated from suspect 
animals. Regardless of clinical status, type 1 PERV was detected in all animals examined in 
this study. Occasionally, Haemophilus spp., Streptococcus spp, Salmonella spp, 
Actinobacillus spp. were cultured from affected animals. 
Morphologically, Virus X was an enveloped virus with approximately 45-55 nm in 
diameter. As shown in Figure 1, the virion contains an icosahedral core and acquires its 
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envelope by budding through the endoplasmic reticulum of infected cells. Overall Virus X 
resembled members of the family Arteriviridae, Flaviviridae or Togaviridae. 
Various cell lines and primary cells of porcine origin were permissive to Virus X and 
supported productive infection of the virus (Figure 2). On immunofluorescence tests, Virus X 
did not cross-react with antibody (polyclonal or monoclonal) raised against PRRSV, PRV, 
SIV (both H1 and H3), TGEV, PPV, PCV, porcine reovirus, EMCV, PEV, HEV, PCMV and 
rabies virus. Interestingly, however, the virus appeared to be recognized to a degree by the 
polyclonal antiserum specific for BVDV as weak positive fluorescence was observed when 
Virus X infected cells were stained with that antiserum (Figure 3). Nonetheless, PGR testing 
did not support that virus X was BVDV (both type 1 and 2), BDV and CSFV. Furthermore, 
PGR assays demonstrated that virus X was not PRRSV (both North American and 
European genotypes), PCV (both type 1 and 2), PEV (groups 1, 2 and 3), influenza A virus, 
TGEV, PRCV, PEDV, PPV, sHEV, WNV, JEV, PERV, PLHV-1 or alpha-togaviruses. 
3.3. Outcome of experimental inoculation 
3.3.1. Sow study. Clinical, pathological and virological observations on pregnant 
sows after experimental inoculation are summarized in Table 1. During the 30-day 
observation period, all inoculated sows became viremic although the animals remained 
normal in their behavior during the study period. No abortion was observed in any of the 
inoculated sows. 
At the termination of the study, no lesions were observed in the control sow. In 
contrast, gross lesions, such as hemorrhages in inguinal lymph node, decolorization of the 
uterus (green and brown), were observed in the sows inoculated with materials containing 
Virus X ISUYP604671. One of the 4 inoculated sows did not have any fetus at necropsy; 
however, no significant lesions were observed. Microscopically, necrotic edema in the lymph 
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node, mineralization plaques in the uterus and necrotic debris in the lumen of the uterus 
were observed, supporting the possibility of embryonic death and/or fetal absorption. 
Virus X was recovered from tissues (spleen, liver, jejunum, uterus, serum, tonsil) of 
the inoculated sows, confirming the replication of Virus X in the animals, particularly 
secondary lymphoid organs. In addition, the virus also was isolated from fetal tissues such 
as lung, spleen, heart, kidney and fetal thoracic fluid, suggesting transplacental transmission 
of the virus. 
3.3.2. CDCD pig study. All inoculated pigs became viremic during the 14-day 
observation period but did not show any overt clinical signs by the end of the study. The 
sham-inoculated negative control pig remained negative for Virus X in blood circulation 
(Table 2). 
At each necropsy, significant gross lesions were not apparent although spleen and 
lymph nodes collected from pigs at days 7 or 10 PI looked edematous. Microscopically, 
nonsuppurative meningoencephalitis was observed in 5 of the 6 inoculated pigs (Figure 4). 
Nonsuppurative interstitial pneumonia (Figure 5) and nonsuppurative periportal hepatitis 
were other lesions commonly observed in the inoculated pigs. Neither gross nor microscopic 
lesions were present in tissues/organs of the control pig. 
Virus X was recovered from tissues of all inoculated pigs regardless of the presence 
or absence of detectable lesions. Brain tissues from 4 of the 5 pigs with meningitis or 
encephalitis were positive for Virus X. The presence of virus particles with morphological 
characteristics similar to Virus X in brain tissues was confirmed by EM (Figure 1). The virus 
was most frequently recovered from tonsils. Spleens and lymph nodes also harbored the 
virus. 
4. Discussion and Conclusions 
Porcine reproductive and neurologie syndrome brought a challenge to the diagnostic 
community since no definitive diagnosis as to the cause could be made. Although death loss 
and reproductive failure in breeding females was not an unusual event in many farms for 
various reasons, clinical presentations of reproductive problems along with neurologic 
disorder was a unique feature of PRNS. Unfortunately, diagnostic investigations focusing on 
all conventional infectious agents that had been implicated in reproductive and/or neurologic 
problems of pigs at various ages have been unfruitful and yielded inconsistent results. With 
the hypothesis that a previously unknown infectious agent was responsible for the disease, 
extensive laboratory testing resulted in frequent isolation of a relatively small cytopathic 
enveloped virus from clinically affected animals. Although this virus could be a "red herring" 
and not a pathogen, the isolation of the virus from nervous tissues collected from clinically ill 
animals with CNS signs was convincing evidence suggesting that the newly identified virus 
named 'Virus X is likely responsible for the disease. 
Observations from the animal inoculation study with pregnant sows clearly indicated 
that Virus X is capable of crossing the placental barrier and causing the loss of pregnancy 
more likely due to embryonic or fetal death as evident by recovery of the virus from fetal 
tissues. Furthermore, development of meningitis or encephalitis lesions in brains of young 
CDCD pigs after inoculation of Virus X also indicated that the virus may be able to cause 
neurologic disorder in infected animals, although the inoculated CDCD pigs did not show 
clinical central nervous signs under experimental conditions. Those lesions were due to the 
attack by Virus X since the virus was detected in and recovered from brain tissues. Since all 
these experimental findings match well with field observations of PRNS, Virus X is 
postulated to be the causative agent for PRNS as Koch's postulates were partially fulfilled. 
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Under a laboratory setting, Virus X could not be recognized by antibodies raised 
against various viral agents that have been implicated in diseases of swine except anti-
BVDV polyclonal antibody. The positive cross reactivity of Virus X with anti-BVDV antibody, 
even though it was weak, is of particular interest with respect to taxonomical identification of 
the virus. The possibility that Virus X could be CSFV was ruled out at the beginning of the 
investigation since US swine populations are known to be free of CSFV. Furthermore, 
diagnostic testing on some early PRNS suspect cases at the Foreign Animal Disease 
Diagnostic Laboratory of the National Veterinary Services Laboratories ruled out the 
presence of CSFV or its infection in those animals as well as the involvement of other 
foreign animals disease agents (Data not shown). Besides porcine pestivirus (i.e., CSFV), 
pigs are also known to be susceptible to ruminant pestiviruses such as BVDV and BDV. 
Although BVDV infection of pigs has been demonstrated both in the field and under 
experimental conditions, BVDV has not been considered to be a significant pathogen for 
pigs. In contrast, BDV is known to cause diseases in infected pigs with clinical signs similar 
to those seen in pigs affected by PRNS. Nonetheless, pigs would be considered to be the 
dead end host for both BVDV and BDV since pig-to-pig contact transmission of these 
viruses has been rare. Considering that Virus X is readily spread among pigs and there is 
very minimum contact between pigs and ruminants in US, it would be hard to believe that 
Virus X is BVDV or BDV. This argument is supported by negative PCR results on isolates of 
Virus X for BVDV, BDV and CSFV. However, Virus X should be considered as a pestivirus 
until proven otherwise based on its morphological similarity with pestiviruses and cross 
reactivity with anti-BVDV antibody. At the time of writing this manuscript, Virus X is proposed 
to be a novel swine pestivirus which remains to be further characterized for its conclusive 
taxonomical identification. As a pestivirus is suspected to be responsible for PRNS, 
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development of a specific diagnostic reagent for Virus X is also prudent since antigenic 
cross reactivity among pestiviruses is known to exist. 
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Table 1. Summary of reproductive record and lesions of sows experimentally infected with 
Virus X isolate ISUYP604671 at early gestation. 
Sows # 
(inoculum) 
Average # 
of litter in 
previous 
gestations 
# of 
fetuses 
recovered 
at 
necropsy 
Significant 
gross lesions 
Significant 
microscopic 
lesions 
Recovery 
of Virus X 
from 
Sow/fetus 
800 
(serum) 
11.4 3 Yes Yes Yes/Yes 
21622 
(virus isolate, 
2nd passage) 
13.3 0 No No Yes/NA* 
30021 
(virus isolate, 
2nd passage) 
11.2 13 No No Yes/Yes 
30172 
(virus isolate, 
1st passage ) 
8.4 10 Yes Yes Yes/Yes 
30120 
(sham 
10.2 6 No No No/No 
inoculum) 
*NA: not applicable 
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Table 2. Summary of clinical, pathological and virological observations on CDCD pigs 
infected with either Virus X isolate or clinical material containing the virus. 
Pig # Inoculums DPI at necropsy Clinical Lesions Virus X in 
signs serum/tissue 
274 Serum 604671 7 No Yes Pos/Pos 
275 Isolate ISUYP604671 7 No Yes Neg/Pos 
302 Isolate ISUYP604671 10 No No Pos/Pos 
303 Serum 604671 14 No Yes Pos/Pos 
304 Serum 604671 10 No Yes Pos/Pos 
675 Isolate ISUYP604671 14 No Yes Pos/Pos 
273 Medium 14 No No Neg/Neg 
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Figure 1. Electron photomicrographs of Virus X in CL ISUVDL13b cells (A) infected with 
isolate ISUYP604671, cell culture fluid (B) harvested from the infected cells, and nerve cell 
(C) of the brain from an experimentally infected pig. Bar represents 100 nm (A) and 200nm 
(B and C) in scale. 
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Figure 2. Cytopathology In cell line CL ISUVDL44 infected with Virus X (A) in comparison to 
uninfected cells (B) at 24 hours post inoculation. 
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Figure 3. Immunofluorescence photomicroscopy of CL ISUVDL13b cells infected (A, C) and 
not infected (B) with Virus X at 100x magnification. The cells were fixed at approximately 48 
hours post inoculation and stained with an anti-BVD bovine polyclonal serum. Panel C is 
presented at 200X magnification. 
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Figure 4. Photomicrographs of representative lesions in cerebrum of CDCD pigs inoculated 
with Virus X. 
A. Moderate multifocal perivascular accumulations of mononuclear cells in meninges. 
B. Occasional neurons appear in early stages of necrosis. 
C. Mild edema with occasional degenerating neurons 
D. Normal brain tissue 
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Figure 5. Photomicrographs of representative lung lesions in CDCD pigs experimentally 
infected animals with Virus X. Panel A and B show different degrees of interstitial 
pneumonia while panel C and D are a section of normal lung at different magnification. 
A- Infiltration of mixed cells in interlobular septa as well as alveolar septa 
B- Extensive nonsuppurative interstitial pneumonia with congestion 
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Abstract 
Porcine reproductive and neurologic syndrome (PRNS) in sows and young pigs has 
newly emerged in the U.S. swine industry. A small enveloped virus which appeared to be 
novel was frequently isolated from pigs affected by PRNS and named 'Virus X due to 
unknown identity. The following study was conducted to characterize physico-chemical and 
biological properties of Virus X (ISUYP604671) and determine its taxonomical identification. 
Morphologically Virus X was an enveloped virion 45-55 nm in diameter, containing an 
icosahedral core. The density of the virus was 1.12-1.15 g/ml on sucrose and CsCI gradient. 
The virus was determined to possess positive-sense RNA genome by a transfection study. 
On Western immunoblotting, several viral peptides with molecular mass of 25, 53 and 
SOkDa were recognized by rabbit polyclonal antiserum raised against ISUYP60467. Virus 
infectivity was not stable at 56°C and acidic and alkaline pH. While the virus was not 
recognized by antibodies raised against numerous viral agents pathogenic to swine, two-
way weak cross reactivity was demonstrated between Virus X and ruminant pestiviruses 
(i.e., BVDV and BDV) and Virus X infection to a permissive cell line was partially blocked by 
anti-BDV polyclonal antibody, suggesting that Virus X is likely a pestivirus. Partial sequence 
analysis of Virus X for NS3 region showed a relatively good homology with that of the 
existing pestiviruses. However, NS3 gene of Virus X was phylogenetically distinct from the 
known pestiviruses. Furthermore, no positive amplification was made out of Virus X when 
the virus was tested by PCR specifically designed for BVDV, BD and CSF. Therefore, Virus 
X is postulated to be a novel swine pestivirus. 
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1. Introduction 
Recently, the U.S. swine industry faced the emergence of a disease which appeared 
to be previously unrecognized based on clinical presentations and the lack of conclusive 
diagnosis for the cause. Since 1995, pork producers and swine practitioners have reported 
disease outbreaks characterized primarily by early infertility (25). Typically, producers have 
observed an acute decline in farrowing rate due to increased early or delayed returns 
followed by a prolonged period (up to 2 years) of sub-optimal farrowing performance. Loss 
of pregnancy most commonly occurs in the early stages of gestation (i.e., 30-55 days) 
although abortion and reproductive failure also were reported on sows at later gestations. 
Affected animals which were confirmed pregnant at 30 days either aborted or demonstrated 
irregular return to estrus. Besides reproductive disorder, some of the affected animals were 
presented with central nervous signs, such as posterior weakness/paralysis, ataxia, 
lameness, bar chewing, and head pressing/banging (24). Reproductive and neurologic 
problems were not, however, always present simultaneously. The neurologic symptoms in 
affected individuals progress with death in 2 or 3 days as the usual outcome. Such 
neurological disorders also were observed in younger pigs such as nursery and fattening 
pigs. To reflect various clinical manifestations, the newly identified disease was tentatively 
named "Porcine Reproductive and Neurologic Syndrome (PRNS)" due to the lack of better 
terminology. 
Although the incidence of the problem appeared to continue growing and the pattern 
of spread within and between herds implied the involvement of an infectious agent, routine 
diagnostic investigations could not demonstrate an association between any of conventional 
infectious agents pathogenic to swine and the disease. Recently, ISU-VDL laboratory 
repeatedly isolated a small enveloped virus tentatively named 'Virus X from animals with 
similar clinical presentations or problems. The virus did not cross-react with monoclonal 
and/or polyclonal antibodies raised against known viral pathogens of swine, and its genome 
could not be amplified by PCR assays designed to detect various viruses. While its identity 
remained to be solved, animal studies with pregnant sows and young CDCD pigs 
demonstrated that Virus X could induce clinical signs and lesions in experimentally 
inoculated pigs. As Virus X was postulated to be a previously unrecognized viral agent, the 
following study was conducted to characterize the virus. 
2. Materials and Methods 
2.1. Virus and cells 
An isolate of Virus X designated ISUYP604671 was used for the study. The virus 
was isolated from the brain of a sow affected by PRNS. The virus was propagated in cell 
line CL ISUVDL13b or CL ISUVDL44 which were determined to be the most permissive cells 
in a previous study (12). The cells were cultured in MDBK-MM media (Sigma Chemical Co., 
St. Louis, MO) supplemented with 5% horse serum (Sigma Chemical Co., St. Louis, MO), 
200mM L-glutamine (GIBCO/BRL Life Science, Grand Island, NY) and an antibiotic-
antimycotic mixture that included 100 lU/ml penicillin, 10 jjg/ml streptomycin, SOpg/ml 
gentamicin (Sigma Chemical Co., St. Louis, MO). Virus stock was determined to contain the 
virus of 1 o3 5-4 0 TCIDso/ml and represented one passage in cell culture. 
Virus material also was prepared directly from the homogenate of clinical specimens 
by a gradient ultracentrifugation using sucrose and cesium chloride (CsCI) as previously 
described (8). Gradients were formed in Tris-HCI buffer (pH 7.4) using a gradient delivery 
system (Model 475, Bio-Rad, Hercules, CA). Ultracentrifugation was done using SW41 rotor 
for 24 hours at 260,000 x g. The same approach also was used to purify and concentrate 
the virus from cell culture fluid when necessary. As a control, bovine viral diarrhea virus 
(BVDV) type 2 strain 125 and border disease virus (BDV) strain 31 ( ATCC, Manassas, VA) 
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were propagated using cell line CL ISUVDL1152 in MDBK-MM protein free media 
supplemented with 5% horse serum and L-glutamine (Sigma Chemical Co., St. Louis, MO). 
The BVDV 125 stock was determined to contain 106 TCip50/ml and the BDV 31 stock 104 
TCID50/ml after three passages in cell cultures. 
2.2. Antibodies 
Two types of polyclonal antibodies were used to identify the presence of Virus X in 
samples. One was the pool of sera from sows which were experimentally inoculated with the 
isolate ISUYP604671 at 30 days of gestation. The serum was collected from each sow after 
30 days post inoculation (PI). The sows became viremic after inoculation and embryonic or 
fetal deaths were apparent in some of the sows. Virus X was isolated from both sow and 
fetal tissues. 
The other was polyclonal antisera generated in rabbits immunized with the virus 
isolate ISUYP604671. For immunization, virions were purified from cell culture fluid by a 
gradient ultracentrifugation and then disrupted by mixing with 1% Triton X-100 and 
incubated overnight at 4°C. After clarification by centrifugation, the supernatant was 
harvested and used as antigen for immunizing rabbits after mixing with an equal volume of 
Freund's complete adjuvant. The rabbits were injected with viral antigen three times before 
being euthanized for total bleeding. Freund's incomplete adjuvant was used for booster 
injections subsequent to the first injection. 
Both antisera were tested against many viral agents in cell culture or clinical 
specimens by an indirect fluorescent antibody test and, if needed, virus neutralization assay, 
including porcine reproductive and respiratory syndrome virus (PRRSV), pseudorabies virus 
(PRV), porcine cytomegalovirus (PCMV), porcine circovirus (PCV), porcine parvovirus 
(PPV), encephalomyocarditis virus (EMCV), porcine enterovirus (PEV), transmissible 
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gastroenteritis virus (TGEV), hemagglutinating encephalomyelitis virus (HEV), swine 
influenza virus (SIV), porcine reovirus, rabies virus, West Nile virus (WNV), BVDV and BDV. 
Rabbit polyclonal antisera also were produced against a cytopathic BVDV-2 and 
BDV in a similar manner as described above. Anti-BVDV polyclonal reference serum and 
pan-BVDV monoclonal antibody were purchased from the USDA National Veterinary 
Services Laboratories (Ames, IA) and Cornell University (Ithaca, NY), respectively, and used 
for the study. 
2.3. Indirect fluorescent antibody test (IFA) and virus neutralization assay (VN) 
Antigens for IFA test were prepared by infecting cells with virus materials and 
incubating the inoculated cells for 48 hours PI. After that, the cells were fixed by immersing 
them in cold 80% aqueous acetone and air drying. For the test, sera were diluted by a serial 
2-fold dilution method in 0.01 M phosphate-buffered saline (PBS) at pH 7.4 and 100pl of 
each diluted sample was applied to virus-infected and uninfected cells. After staining with 
the appropriate secondary antibody conjugated with fluorescent isothiocynate (FITC)-
labeled antibodies (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD), cells were 
examined under a fluorescence microscope. 
For virus neutralization assay, serums were diluted in MEM media using a serial 2-
fold dilution method in a 96-well plate. Each diluted antibody was mixed with an equal 
volume (100 (jl) of virus at a rate of 100 TCID50. Antibody-virus mixtures were incubated for 
1 hour at 37°C. After that, 10Ojjl of the suspension of cells which were the most appropriate 
for the target virus were added to wells and incubated for another 48 hours. Each sample 
was run in duplicate. Cells were examined daily for CPE for up to 96 hours. The presence or 
absence of virus replication was determined by CPE and immunofluorescence testing on 
fixed cells at the end of a 96-hour incubation period or when CPE was visible. 
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2.4. Negative-staining, immuno-staining electron microscopy 
The ultrastructure of Virus X was visualized and characterized by an electron 
microscopic technique. Two approaches were used: direct and indirect methods. The direct 
method was done according to the procedure published elsewhere (9). In brief, a virus 
preparation which was purified and concentrated from cell culture fluid by gradient 
ultracentrifugation was mixed with optimally diluted rabbit polyclonal antiserum specific for 
virus X or BVD type 2 virus and incubated for 30 min at ambient temperature. Then viruses 
were pelleted by centrifugation at 12,000 rpm for 30 min. The resulting pellet was 
resuspended in distilled water. One drop (approximately 10 pi of the suspension) was 
applied to formovar-coated EM grids (Ted Pella, Inc., Redding, CA) and stained with one 
drop of 4% potassium phosphotungstic acid (PTA) for 5 min. Then, the grid was examined 
under a JEOL 1200EX II scanning and transmission electron microscope (Japan Electron 
Optic Laboratories, Peabody, MA). Images were captured using a Megaview III digital 
camera and SIS Pro software (Soft Imaging Systems Incorporated, LLC, Lakewood, CO). 
For indirect testing, viruses were pelleted down through a 20% sucrose cushion by 
ultracentrifugation using SW28 swinging-bucket rotor in an ultracentrifuge (Optima® LE 80K, 
Beckman, Fullerton, CA) for 3 hours at 130,000 x g. The resulting pellet was resuspended in 
a small quantity of 0.05M PBS (pH 7.2) and applied on formovar-coated EM grids. The grids 
were stained with optimally diluted anti-Virus X rabbit polyclonal antiserum. After 30 min 
incubation at ambient temperature, excessive primary antibodies were rinsed 5 times by 
placing the grid in a droplet of 100 pi PBS containing 0.1% bovine serum albumin. The virus-
antibody mixture was mixed with anti-rabbit IgG conjugated to 5nm gold-labeled particles 
(Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD) and with protein A conjugated 
to 20nm gold-labeled particles (Sigma Chemical Co., St. Louis, MO) and incubated for 30 
min at ambient temperature. After washing 5 times in PBS by placing the grid in a 100-pl 
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droplet and 3 times in deionized water for 3 min each, the grids were then counter-stained 
with 4% PTA and examined under the electron microscope. 
2.5. Density of virus particle 
The density of Virus X was determined as previously described (8) with some 
modification. In brief, sucrose and CsCI gradient was formed in the Tris-HCI buffer (pH 7.4) 
using a gradient delivery system (model 475, Bio-Rad, Hercules, CA). Ten ml of the 
continuous gradient were poured into Ultra-Clear® nitrocellulose tubes (Beckman Fullerton, 
CA). Two ml of virus suspension were overlaid on top of the gradient and centrifuged using 
SW41 rotor in an ultracentrifuge (Optima LE 80K, Beckman, Fullerton, CA) for 18 hours at 
260,000 x g. All visible bands were collected using a syringe with a needle (25G, 1.5cm 
long) and checked for the presence of Virus X by virus isolation as described above. At the 
same time, the reflective index (Rl) of each fraction was determined using a digital 
refractometer AR200 (Leica, Buffalo, NY). The density of virus in the virus-enriched fraction 
was calculated from Rl using the formula provided by the manufacturer. 
2.6. Effect of DNA inhibitors on virus growth 
To determine if Virus X contains a DNA genome, virus titration was performed using 
a microtitration infectivity assay in the presence and absence of ô-bromo-2-deoxyuridine 
(BUDR) or mitomycin C as previously described (3). In brief, confluent monolayers of CL 
ISUVDL33 and CL ISUVDL99 cells were prepared in 96-well plates and inoculated with 
virus suspensions (100|jl/well) which were prepared by a serial 10-fold dilution technique. 
After 1-hour of absorption at 37°C, the virus inoculums were removed and cells replenished 
with MEM supplemented with 40 or 160 |jg/ml of BUDR (Sigma Chemical Co., St. Louis, 
MO) or 2 or 20 |jg/ml of mitomycin C (Sigma Chemical Co., St. Louis, MO). Plates were 
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incubated for an additional 48 hours. Virus titer was determined by the presence of visible 
CPE and then confirmed by I FA staining using the rabbit anti-Virus X polyclonal antiserum. 
As controls for RNA and DNA viruses, PRRSV and PRV, respectively, were concurrently 
titrated under the same conditions described above. 
2.7. Transfection assay with Rnase A treatment 
Viral nucleic acid was extracted using TRIzol® extraction method (Invitrogen, 
Cartsbad, CA) from 250jj! of Virus X suspension which was purified from cell culture 
supernatant by gradient ultracentrifugation. The total amount of RNA in the extract (10 to 14 
ljg) was determined by spectrophotometry. The extract then was divided into two aliquots of 
6 jjg/ml total nucleic acid each. One was treated with 10 pi of Rnase A (Qiagen, Santa 
Clarita, CA), which is sufficient to digest 10pg RNA in 1ml of an extract, as previously 
described (26) and the other left as untreated. Each preparation was mixed with 100|jl of 
MDBK-MM protein free media and 100 pi of 1mg/ml Lipofectin® (Invitrogen, Cartsbad, CA) 
and then incubated for 15 min at ambient temperature. The media and Lipofectin® were 
added again to each preparation and cocktails incubated for another 30 min at ambient 
temperature. Then, 50 pi of each cocktail was transfected into CL ISUVDL13b cells 
prepared in a 96-well plate. After 48 hrs of incubation, the cells were rinsed with PBS, fixed 
in cold 80% (v/v) aqueous acetone or 3.5% (v/v) paraformaldehyde (21), and subjected to 
an indirect fluorescent antibody test using anti-Virus X rabbit polyclonal antiserum and anti-
rabbit IgG conjugated with FITC to determine if there was virus replication in the cells. BVD 
virus was used as control for RNA virus. 
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2.8. Chloroform treatment 
The presence of envelope structure on Virus X virions was determined using a lipid 
solvent such as chloroform as previously described (3). Jn brief, cell culture fluid and tissue 
homogenate containing Virus X, PRRSV or BVDV were mixed with an equal volume of 
chloroform and incubated for 30 min at ambient temperature. Another set of the same virus 
materials were treated in the same manner without chloroform. All materials were 
centrifuged at 1000 x g for 20 min in a refrigerating condition. After centrifugation, aqueous 
phase of each treated sample was harvested and diluted using a serial 10-fold dilution 
method. One hundred |jl of each diluted sample was inoculated to monolayers of cells highly 
permissive to each virus which were prepared in 96-well plates. The treatment was 
considered significant when 100-fold or higher reduction in virus titer was observed in 
comparison to untreated samples. 
2.9. Thermal and pH stability of virus. 
The stability of Virus X in different pH and temperatures was assessed as described 
elsewhere (1). For thermal stability of virus, the virus material with titer of 104TCID50/ml was 
suspended at a ratio of 1:5 in MEM without any supplement (i.e., serum, antibiotics, L-
glutamine) and aliquoted in 4 ml each. Each aliquot was incubated at 4, 25, 37 or 56°C 
using a refrigerator or incubators. At 30, 60, 120, 360, 1440, 2880 and 4320 minutes of 
incubation, 0.6 ml of the fluid was taken out of each of the virus aliquots and subjected to 
virus titration using a microtitration infectivity assay (3). The experiment was repeated once. 
To assess pH stability of Virus X, the same virus material as described above was 
suspended at a rate of 1:5 in MEM with HEPES buffer and aliquoted in 3 ml each. The pH of 
media for each aliquot was adjusted by adding HCI (1N) or NaOH (0.1 M) to 2, 4, 5, 6, 7 or 8 
and kept at ambient temperature for 30, 60, 120, 240 and 360 minutes. Each treatment was 
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run in duplicate. The titer of infectious virus in each aliquot was determined by a 
microtitration infectivity assay (3). 
2.10. SDS-PAGE and Western immunoblot 
2.10.1. Antigen preparation. The virus was prepared in CL ISUVDL13b cells. 
Infected cells were harvested and pelleted by low speed centrifugation. The resulting cell 
pellet was then resuspended in a lysis buffer (10mM Tris, 0.15M NaCI, 0.04% CHAPS, 
0.001% aprotinin and 1mM EDTA, pH 8.0) which was mixed with the virus material at a ratio 
of 1 ml buffer per one 165cm2 flask. Mixtures were incubated overnight at 4°C with gentle 
stirring and clarified by centrifugation at 3,000 x g for 10 minutes in a refrigerating condition. 
Each supernatant was then used for SDS-PAGE and Western immunoblotting. 
Viral antigens also were prepared from the virus material purified and concentrated 
from tonsil tissue homogenate by gradient ultracentrifugation as described above. The 
gradient purified material was mixed with the lysis buffer at 1:1 ratio and, after that, 
processed in a similar manner as above. The supernatant was harvested and used for SDS-
PAGE and Western immunoblotting. 
The protein concentration in each sample preparation was determined using a 
protein assay kit (Bio-Rad Laboratories, Richmond, CA) following the manufacturer's 
recommended procedures and adjusted to 2 mg/ml. 
2.10.2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). A modified Laemmli's procedure (10) was used for protein separation on a 
discontinuous 12% slab gel (70 x 80 x 0.75 mm) (Bio-Rad Laboratories, Richmond, CA). 
The viral and cellular antigen preparations were solubilized in a sample buffer (pH 6.9) 
containing 0.0625M Tris, 2% SOS, 5% 2-mercaptoethanol, 0.05% bromophenol blue, and 
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10% glycerol by boiling at 95°C for 5 minutes. Twenty to forty microliters of each denatured 
sample (approximately 20-30 (ig of protein) and 6 jut of prestained SDS-PAGE molecular 
weight standards (SeeBlue®Plus2, Invitrogen, Carlsbad, CA) were loaded in the gel. The 
molecular weight standard contained 10 proteins with molecular masses of approximately 
250, 148, 98, 64, 50, 36, 22, 16, 6 and 4 kDa. Electrophoresis was carried out using a 
vertical mini-PROTEAN® electrophoresis cell (Bio-Rad Laboratories, Richmond, CA) as 
directed by the manufacturer. 
2.10.3. Electrophoretic transfer of the proteins. A Ready Gel® system I (Bio-Rad 
Laboratories, Richmond, CA) was used by following the procedures recommended by the 
manufacturer. Viral and cellular proteins, along with the molecular weight markers that were 
separated in a gel, were electrophoretically transferred to a 0.2|um nitrocellulose membrane 
(Bio-Rad Laboratories, Richmond, CA). Transfer was carried out at 4°C for 90 minutes in a 
transfer buffer (pH 8.3) consisting of 25mM Tris, 192mM glycine, and 20% (v/v) methanol. 
Nitrocellulose membranes containing viral and control cellular antigens were blocked at 
ambient temperature for 60 min with 2.5 % dry skim milk in Tris-buffered saline (TBS, pH 
7.5) containing 20mM Tris and 0.05% Tween 20. 
2.10.4. Western immunoblotting. Blocked membranes containing viral and cellular 
antigens and molecular weight standards were washed twice for 5 minutes each in gently 
agitating TBS. Antigen-specific antisera were diluted 1:200 in TBS containing 0.05% Tween 
20 (TTBS) and 0.1% dry milk and applied on each membrane. Following incubation, the 
membranes were washed 3 times in TTBS by gently agitating for 5 minutes each. Species-
specific secondary antibodies conjugated to HRP were diluted 1:2000 in TTBS containing 
0.1% dry milk and applied on the membranes. Following 1 hour incubation at room 
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temperature, the membranes were washed 3 times in TTBS by gently agitating for 5 minutes 
each. Antigen-antibody reactions were visualized with TMB membrane peroxide substrate 
(Kirkegard and Perry Laboratories, Inc., Gaithersburg, MD). The color reaction was stopped 
by brief washes in deionized water. The appearance of virus-specific reactivity was 
assessed by comparing the antibody responses to the viral and cellular antigens. Polyclonal 
rabbit antisera raised against Virus X (12) and BVDV-specific monoclonal antibodies 15c5 
and 20.10.6 (Cornell University, Ithaca, NY) (5) were used in this study. 
2.11. Peptide sequencing 
Antigens were prepared as described above for Western immunoblotting with two 
modifications: a) the antigen preparation was incubated at 37°C for 15 minutes or 95°C for 5 
minutes in the sample buffer before electrophoresis; and b) peptides separated on a 
membrane were transfer to an Immun-Blot™ PVDF membrane.(Bio-Rad Laboratories, 
Richmond, CA) instead of a nitrocellulose membrane. Total protein was stained using 
0.025% Coomassie® Blue R-250 (Bio-Rad Laboratories, Richmond, CA) dissolved in 40% 
methanol for 10-15 minutes and destained in 50% methanol. Visualized protein bands were 
cut off and sent to the Protein Facility at Iowa State University for sequencing. Sequence 
data were then proofread, aligned, and analyzed using DNASTAR software (DNASTAR, 
Inc., Madison, Wl). 
2.12. PGR amplification at 5'UTR and at NS3 region 
PCR condition and primers used to amplify 5'UTR were described elsewhere (19) 
with some modifications. RNA was extracted using QIAamp® Viral kit (Qiagen, Santa Clarita, 
CA) and Qiagen® RT-PCR kit was used for amplification. The following modifications were 
made to meet some recommended conditions by the manufacturer. Reverse transcription 
was run at 42°C for 60 minutes followed by 15 minutes at 95°C and next 35 cycles were run 
at following condition: denaturation at 94°C for 15 seconds; annealing at 56°C for 30 
seconds; amplification at 72°C for 60 seconds and then extension at 72°C for 10 minutes. 
For amplification of the NS3 region, similar running conditions as described above 
were employed with an exception that annealing temperature was dropped to 50°C. Primers 
were designed based on the alignment of multiple sequences of BDV available from 
Genbank as follows: 
FNS3959: 5-TAG ATG AA(G)T ACC ACT GTG C-3' 
RNS31140: 5 -AGA TCT TCA CCC TTC ATC AC-3' 
PGR product of approximately 181 bp was purified by a gel extraction kit (Qiagen, Santa 
Clarita, CA) and sequenced using an automated sequencer (Applied Biosystems, Forest 
City, CA) at the ISU Nucleic Acid Facility. Sequencing results were then analyzed using 
DNASTAR software (DNASTAR, Inc., Madison, Wl). 
3. Results 
3.1. Growth characteristics of Virus X in cell culture 
Different types of cells supported virus replication to various degrees and proprietary 
cell lines designated CL ISUVDL44 and CL ISUVDL13b were considered to be the best for 
isolation and propagation of Virus X. Cytopathic effect (CPE) by the virus in the CL 
ISUVDL44 cells was initially evident within 24 hours after inoculation and became 100% by 
2 days PI. Cytopathology by Virus X was characterized by rounding, death or lysis and 
detachment, resulting in floating of many rounded apoptotic cells in the medium (Figurel). 
No changes were observed in negative control cells. Visible CPE, however, disappeared 
after 3 or 4 passages of the isolate in cell culture. 
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3.2 Antigenic cross reactivity 
On an indirect fluorescent antibody (IFA) assay using anti-Virus X rabbit polyclonal 
antiserum, cells infected with Virus X showed very bright perinucleus cytoplasmic staining 
while negative control cells remained negative (Figure 2A and 2B). While no positive signal 
was observed when cells infected with various swine viral pathogens RPV, PRRSV, PRV, 
PEV, PCV2, were stained with the rabbit antiserum for Virus X, weak positive cytoplasmic 
staining was demonstrated when anti-Virus X rabbit serum was applied to BVDV-infected 
cells (Figure 2C). A similar observation also was made with BDV-infected cells. When virus 
X was stained with rabbit antiserum specific for BVD and BD virus some cytoplasmic 
staining was demonstrated. The cross reactivity between Virus X and anti-BVDV antibody 
also was demonstrated in cryosections of tissues collected from pigs experimentally infected 
with Virus X when the tissue sections were stained with NVSL reference anti-BVDV 
polyclonal antibody (Figure 3A). This serum does not react on I FA with other viral pathogens 
such as PCV2, PRRS, PEV, PRV and PPV. 
The rabbit anti-Virus X polyclonal serum neutralized the infection of Virus X 
(ISUYP604671) to CL ISUVDL13b cells; but neutralizing antibody titer of the antiserum was 
low (1:4). The serum also showed a very weak cross neutralizing activity (1:2) against BDV 
but not to BVDV. Reciprocal but very weak cross neutralization of Virus X by rabbit 
polyclonal antiserum raised against BDV strain 31 also was observed. Virus neutralizing 
antibody titer of this serum against BDV (i.e., homologous virus) was 1:16 whereas VN titers 
against Virus X and BVDV-2 were only 1:2. On Western immunoblot analysis with rabbit 
anti-Virus X serum, 4 viral proteins with molecular masses of 25, 48, 53 and BOkDa were 
visualized in Virus X, BVDV and BDV antigen preparations (Figure 4). Monoclonal 
antibodies specific for BVD virus (5) revealed that peptides with 53 and BOkDa molecular 
size were E1 and NS3 proteins, respectively (Figure 5). 
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3.3. Morphology and density of Virus X 
As shown in Figure 6, Virus X (ISUYP604671) is an enveloped virion of 
approximately 45-55 nm in diameter. On average the size of the virus was estimated to be 
50 nm in diameter. The presence of the envelope on the virion was also confirmed by pre-
treating the virus with a lipid solvent such as chloroform. The infectious virus titer of the 
stock virus material was reduced from 104 to 101 TCID50/ml or lower after chloroform 
treatment. 
Negative-staining EM on gradient-purified virus materials prepared from both cell 
culture material and tissue homogenate demonstrated the presence of virus particles in two 
different sizes although those were morphologically identical (Figure 6). The immunostaining 
EM revealed that both viruses could be recognized by rabbit polyclonal antiserum raised 
against ISUYP604671 (Figure 6), suggesting that the smaller virus is likely a detective 
interfering particle. 
Several virus bands were formed on both sucrose and CsCI gradients. Different virus 
titer was recovered from different fractions, with a range of 104-106 TCID50/ml (Figure 7). 
Buoyant density of the virus in sucrose and CsCI was estimated to be 1.12-1.15 g/ml. 
3.4. Stability of Virus X 
Infectivity of Virus X decreased over time at different temperature although no 
substantial change was observed in virus infectivity titer when the virus was kept at 4°C 
(Figure 9). The virus infectivity was completely inactivated at 56°C within 2 hours. 
Infectivity of Virus X remained without change at neutral pH when the virus was kept 
at ambient temperature. A strong acidic pH (i.e., 2) instantly depleted the infectivity of Virus 
X from 103 TCID50/ml to undetectable. Alkaline pHs were also detrimental to the infectivity of 
Virus X (Figure 8). 
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3.5. Genome of Virus X. 
As summarized in Table 1, replication of the virus ISUYP604671, like PRRSV (a 
single-stranded, positive-sense RNA virus), was not negatively affected by the presence of 
BUDR and mitomycin C in cell culture media while replication of PRV (double-stranded DNA 
virus) was substantially inhibited by the same treatment. Furthermore, the replication of virus 
X did not occur in transfected cells after pre-treatment with Rnase A. In contrast, the 
replication and gene expression that could be detected by the anti-Virus X rabbit polyclonal 
antiserum was apparent in cells transfected with nucleic acid of Virus X without RNase A 
treatment. 
No part of the genome of Virus X could be amplified by PGR assays specifically 
designed to detect PRRSV (North American and European genotype), PCV (type 1 and 2), 
porcine enterovirus (PEV), influenza A virus, porcine parvovirus (PPV), porcine reovirus type 
1, 2 and 3, porcine cytomegalovirus (PCMV), pseudorabies virus (PRV), transmissible 
gastroenteritis virus (TGEV), porcine respiratory coronavirus (PRCV), porcine epidemic 
diarrhea virus (PEDV), Japanese encephalitis B virus (JEV), porcine endogenous retrovirus 
(PERV) type 1, porcine lymphotropic herpesvirus type 1 (PLHV-1), swine hepatitis E virus 
(sHEV), West Nile virus (WNV), and members of genus Pestivirus and Alpha Togavirus. 
In contrast, an amplicon was repeatedly obtained from the virus ISUYP604671 when 
a pan-pestivirus PGR assay was performed specific for the 5' UTR region of pestiviruses. 
PGR product with the correct size was also obtained from Virus X by a pestivirus PGR 
designed for NS3 gene of BDV 31 (Figure 10). As summarized in Table 2 and Figure 9, 
partial deduced amino acid sequences of the PGR product from Virus X showed 89.1-95.7% 
homology with NS3 gene of the known pestiviruses while the known pestiviruses shared 91-
97.5 % homology with each other for the same region (2; 15). Phylogenetic analysis of partial 
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NS3 gene sequences, however, revealed that Virus X formed its own branch separated from 
the known pestiviruses (Table 3 and Figure 10). 
3.6. Viral protein profile 
By Western immunoblotting, several peptides reactive to the rabbit anti-Virus X 
polyclonal antibody were observed from virus materials purified from infected cell culture 
and tissues of experimentally infected pigs: 14, 25, 48, 55, and 80kDa (Figure 4A). Some of 
the immunologically recognized peptides were sequenced directly from the membrane. 
Peptide sequences obtained from the 80kDa protein shared 55 - 71% homology with NS3 
gene product of the known pestiviruses while overall homology of NS3 protein among the 
known pestiviruses was 90 - 98%. Other peptides with molecular masses of 55kDa and 
14kDa, respectively, showed much lower amino acid sequence homology with the known 
pestiviruses. 
4. Discussion and Conclusions 
Many practitioners have reported disease outbreaks characterized primarily by early 
abortion and frequently neurologic disorder, commonly referred as "porcine reproductive and 
neurologic syndrome (PRNS)". A cytopathic small enveloped virus which could not be 
recognized by antibodies raised against conventional swine viral pathogens was repeatedly 
isolated from clinical cases of PRNS and named "Virus X" due to unknown identity. As the 
potential causative role of the newly identified virus for PRNS was demonstrated in 
experimentally infected sows and young pigs, the preceding study was conducted to 
characterize Virus X and to determine its taxonomical identification. 
Ultrastructurally, Virus X was an enveloped virion of 45-ôônm in size with an 
icosahedral core, showing morphological characteristics similar to the family Arteriviridae, 
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Flaviviridae and Togaviridae (3;6) Observations from pretreatment of Virus X with Rnase A 
and DNA inhibitors demonstrated that Virus X contains a positive-sense RNA genome, 
further supporting that Virus X could be a member of the families described above. 
However, due to relatively poor growth of the virus in cell culture system, the genome could 
not be further characterized with respect to its size, the number of copies and the 
presence/absence of a poly A tail. Although Virus X was suspected to be one of 
arteriviruses, flaviviruses or togaviruses, a portion of the viral genome could not be amplified 
by pan-family PGR assays for these viruses (4; 13; 17). Antigenically, Virus X was not 
recognized by antibodies raised against various viral agents that have been implicated in 
diseases of swine except polyclonal antiserum raised against BVDV. Infection of Virus X to 
a permissive cell line was also partially neutralized by anti-Border disease virus (BDV) 
antibodies. A low level of two-way cross reactivity between Virus X with ruminant 
pestiviruses, which is expected among pestiviruses to a degree (18;23), suggested that 
Virus X is likely a pestivirus. In support, the protein profile of Virus X as determined by 
Western immunoblotting is similar to that of pestiviruses. Furthermore, partial sequences of 
Virus X's NS3 gene, which is known to be highly conserved among pestiviruses (14), 
showed a relatively high sequence homology with the known pestiviruses as compared to 
other common swine viral pathogens. 
The possibility that Virus X is classical swine fever virus (CSFV) can be ruled out 
since US swine populations are free of CSF. Furthermore, initial diagnostic investigation on 
PRNS suspect cases which was conducted by the Foreign Animal Disease Diagnostic 
Laboratory of the National Veterinary Services Laboratories ruled out the involvement of 
CSFV in the disease (Data not shown). Virus X could not be BVDV, BDV for three reasons. 
First, no part of genomic RNA could be specifically amplified by PGR assays designed to 
detect BVDV, CSF or BDV (7;16;20). Second, field observations have suggested that Virus 
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X can be readily spread among pigs whereas pigs are generally considered to be the dead 
end host for ruminant pestiviruses. Third, the majority of hog operations in the United States 
have very minimal contact with ruminants. Therefore, Virus X is postulated to be a novel 
swine pestivirus. 
While pathogenesis is unknown and specific control measures are unavailable, our 
study demonstrated that Virus X, like any other enveloped viruses, can be easily inactivated 
by lipid solvents or detergents and that the virus also was fragile to acidic environments and 
high temperatures, which provides insight into how contaminated premises should be 
cleaned. Diagnostically, good stability of virus infectivity at 4°C should be taken into 
consideration for handling clinical specimens in the field for laboratory testing for PRNS. 
Nonetheless, as Virus X is postulated to be a novel swine pestivirus, the development of 
diagnostic reagents specific for Virus X for differential diagnostics among pestiviruses will 
be required as recommended by OIE (11 ;22). 
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Figure 1. Photomicroscopy of cytopathology of CL ISUVDL44 infected with (A) and without 
(B) Virus X at approximately 36 hours post inoculation. 
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Figure 2. Immunofluorescence photomicroscopy of CL ISUVDL13b infected with (A) and 
without (B) Virus X (ISUYP604671) and of CL ISUVDL 1152 cells infected with a cytopathic 
bovine viral diarrhea virus type 2 (C) and without (D) at approximately 24 to 48 hours post 
inoculation. All cells were stained with anti X rabbit polyclonal serum. 
A B 
C D 
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Figure 3. Immunofluorescence photomicroscopy of tonsil tissue sections stained with 
polyclonal antiserum to bovine viral Diarrhea (BVD) virus (A) or with anti-rabbit polyclonal 
antibodies specific for Virus X (B). The sample was collected from an animal clinically 
affected by Virus X. 
B 
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Figure 4. Western immunoblot analysis of Virus X's protein profile recognized by a rabbit 
polyclonal antiserum generated against Virus X (ID 3598 and 3606). 
Legend: Lanes: 1; 9;10;11;19;20-molecular marker label in kDa.; 2-BVDT2 antigen 
concentrated in continues gradient; 3- virus X propagated in the CL ISUVDL 13b cell culture 
and concentrated in continues gradient; 4-6 virus X propagated in CL ISUVDL13b cell 
line(cell lyses); 7- virus X propagated in the CL ISUVDL44 cell culture and concentrated in 
continues gradient; 8- virus X concentrated by continues gradient from the tissue of infected 
animals; lane-12 same as 2 and lane 13 same as 8; lane 14 - media(MEM); lane 15-18 
represent not infected CL ISUVDL13b, CL ISUVDL 44, CL ISUVDL 13b, CL ISUVDL 1152 
cell lines in the lysis buffer respectively. 
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Figure 5. Western immunoblot analysis of BVDV and BDV's protein profile detected by 
polyclonal and monoclonal antibodies on membrane R and A respectively 
R 
4 BOkDa 
4 53kDa 
^4/48kDa 
25kDa 4 
,BOkDa 
,53kDa 
1 2 3 4 5 6 1 a 2a 3a 4a 5a 6a 
Legend: Immunoblot with two of monoclonal Abs specific for BVD protein (p80/p53) 
(membrane A) and rabbit polyclonal Abs against virus X(membrane R). Lane 1 and la-
molecular weight; lane 2 and 2a - CL ISUVDL 1152 cell control, lane 3 and 3a BD31 
antigen, lane 4 and 4a ncpBVD Draper strain typel, lane 5 and 5a cpBVD 125 strain type2, 
lane 6 and 6a cpBVD NADL typel. 
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Figure 6. Electron photomicroscopy of Virus X purified on sucrose gradient by 
ultracentrifugation without (A) and with labeling with secondary antibody only (B), anti-BVD 
polyclonal rabbit serum (C), and anti-X polyclonal rabbit serum (D). E and F panels show 
bovine viral diarrhea virus labeled with anti-BVD polyclonal rabbit serum and polyclonal X 
rabbit antiserum respectively. 
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Figure 7. Buoyant density of the virus in sucrose gradient. 
Density 
•—Fractions 
_T 1 1 1 1 1 
1.17 1.16 1.14 1.12 1.09 1.06 1.04 1.02 
Density 
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Figure 8. Immunofluorescence photomicrocopy of which cells CL ISUVDL 13b transfected 
with Virus X genomic material at 24 (A), 48 (B), 72 (C) hours post transfection. 0 is negative 
control. All pictures are at 100x magnification. 
94 
Table 1. Effect of mitomycin C and 5-bromo-2 deoxyuridine (BUDR) on the replication of 
Virus X, porcine reproductive and respiratory syndrome virus (PRRSV) and pseudorabies 
virus (PRV) in CL ISUVDL 33, CL ISUVDL13b cells. Virus titer is expressed as TCID5o/ml. 
Viruses Untreated BUDR (pg/ml) Mitomycin C (pg/ml) 
40 160 2 20 
PRRSV 106 10° 10e 106 10e 
Virus X 104 104 104 104 104 
PRV 108 10e 103 106 103 
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Figure 9. Temperature (upper panel) and pH stability (lower panel) of Virus X. The stability 
of Virus X at different pH was measured at ambient temperature. 
virus X in 
4 °C 
I virus X in 
25 °C 
virus X in 
37 °C 
S Q 
0.5 virus X in 
56 °C 
0 0.5 hr 1 hr 2 hrs 6 hrs 24 hrs 48 hrs 72 hrs 
5? 1.5 
pH 2 
pH 4 
pH 6 
pH 7 
pH 8 
pH 10 
0.5 hr 1 hr 2 hrs 4 hrs 6 hrs 
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Table 2. Paired identity matrix of deduced amino acid homology for NS3 regions between 
virus X and known pestiviruses. 
1 2 3 4 5 6 7 8 9 10 11 12 
Virus XI SU 
VOL 13385-04 78.3 95.7 91.3 95.7 95.7 93.5 95.7 89.1 93.5 93.5 95.7 1 
Virus XISU 
YP604671 0 94.4 88.9 94.4 94.4 94.4 94.4 86.1 94.4 91.7 94.4 2 
BDV-2(V60) 
MF02524 4.5 5.8 *** 95.7 100 100 97.8 100 91.3 93.5 93.5 95.7 3 
Giraffe-
1 (H138) 
AAF02523 9.3 12.1 4.5 *** 95.7 95.7 93.5 95.7 87 89.1 89.1 91.3 4 
BDV-1 
NP777541 4.5 5.8 0 4.5 *** 100 97.8 100 91.3 93.5 93.5 95.7 5 
BDV-1 (31) 
AAB37578 4.5 5.8 0 4.5 0 97.8 100 91.3 93.5 93.5 95.7 6 
BDV-1 (31) 4.6 5.8 0 4.6 0 0 *** 100 91.1 93.3 93.3 95.6 7 
BDV -1(x818) 
AAC16444 4.5 5.8 0 4.5 0 0 0 *** 91.3 93.5 93.5 95.7 8 
BVDV-1 
AAG00378 12 15.4 9.3 14.4 9.3 9.3 9.5 9.3 87 87 89.1 9 
BVDV-2 
AAA82981 6.8 5.8 6.8 11.8 6.8 6.8 7 6.8 14.4 91.3 93.5 10 
CSFV(KC) 
AAC98302 6.8 8.9 6.8 11.8 6.8 6.8 7 6.8 14.4 9.3 *** 97.8 11 
CSFV 
AAA43844 4.5 5.8 4.5 9.3 4.5 4.5 4.6 4.5 11.8 6.8 2.2 12 
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Table 3. Alignment of amino acid sequence for partial NS3 gene from Virus X and other 
pestiviruses. 
Mms X ISU VDL 13385-04 
Virus X ISU YPB04671 
BD\A2£V6D) AAFD2524 
Giraffe-1 (HI 38) AAF02523 
BDV-1 NP777541 
BDV1(31) AAB37578 
B0V1(31) 
BDV-1(x818)AAC 16444 
BVDV1 AAGDD378 
BVDV2 AAA32981 
i 
10 
i 
20 
i 
30 
i 
40 
EOLAI I GKI HRF AEN .RWAMTATPAGTVTTTGQKHPI EEFI APE 
EQLAI I GKI HRFAPN.RWAMTATPAGTVTTTGQKl 
EQLAI I GKI HRFSEQLRWAMTATPAGTVTTTGQKHPI EEFI APE 
A^QLAl I GKI HRFS|QLRWAMTATPAGTVTTTGQKHPI EEFI APE 
EQLAI I GKI HRF S EQL RWAMTATPAGTVTTTGQKHPI EEFI APE 
EQLAI I GKI HRF S EQL RWAMTATPAGTVTTTGQKHPI EEFI APE 
EQLAI I GKI HRF S EQL RWAMTATPAGTVTTTGQKHPI EEFI APf 
EQLAI I GKI HRF S EQL RWAMTATPAGTVTTTGQKHPI EEFI APE 
EQL/fl GKI HRF S dsîJWAMTAT PAGQZTTTGQKHP I EEFI APE 
EQLAI I GKI HRFS#RWAMTATPAGT|GjrTTGQKHPI E^s) APE 
38 
373 
373 
373 
373 
48 
373 
373 
373 
Figure 10. Phylogenetic relationship between Virus X and known pestiviruses based on 
partial amino acid sequences of NS3 gene. 
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Abstract 
Recently, a previously unrecognized viral agent, formally named 'Virus X', was 
identified in conjunction with reproductive and neurologic disorder in pigs. As the virus was 
postulated to be a previously unrecognized pestivirus, attempts were made to develop a 
diagnostic reagent specific for the virus which could be used for differentiation of the new 
swine pestivirus from other existing pestiviruses. A murine monoclonal antibody (MAb) 
designated 15A2-3E9 was produced. The MAb did not cross-react with any viral pathogens 
known to be pathogenic to swine including bovine viral diarrhea virus and border disease 
virus, but recognized all field isolates of the novel swine pestivirus by immunofluorescence 
testing on both infected cells and tissues which were determined to be positive for Virus X 
by virus isolation technique. However, the MAb did not neutralize the infection of the new 
swine pestivirus to a highly permissive cell line. On Western immunoblotting under reducing 
conditions, the MAb reacted with a viral peptide with molecular mass of SOkDa, which is 
believed to be the product of NS3 gene, in lysates of infected cells or homogenates of 
tissues from experimentally infected pigs but not in purified virions. Collectively, MAb 15A2-
3E9 represents a linear epitope in a non-structural protein of the newly identified swine 
pestivirus which is highly conserved among field isolates of the virus, indicating that the MAb 
can be used in various diagnostic tests for specific detection of this novel swine pestivirus in 
clinical cases. 
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1. Introduction 
Pestivirus infections are economically significant diseases for pigs, cattle and sheep 
in many countries. To date all pestiviruses belong to the genus Pestivirus in the family 
Flaviviridae which includes bovine viral diarrhea virus (BVDV), border disease virus (BDV), 
and classical swine fever virus (CSFV) (4). Pigs are known to be susceptible to all these 
viruses although CSFV causes the most devastating disease in pigs. Depending on different 
factors such as the virulence of infecting virus and age and immunocompetence of animals, 
CSFV may cause peracute, acute, chronic and subclinical infection or latent infection with 
different presentations of clinical signs and lesions (8; 15). BVDV infections of pigs under 
field and experimental conditions have been reported but do not lead to any clinical disease 
(17; 18). In contrast, BDV can cause clinical disorders in pigs. In sows and neonates, BDV 
infection has been reported to cause anemia, rough hair coat, growth retardation, wasting 
and tremors (14). In breeding pigs, BDV infection also has been implicated in early or 
delayed return to heat and abortion. Similar to CSFV infection, congenital infection with BDV 
can lead to stillbirth, fetal mummification, malformation, tremors, and skin hemorrhages (17). 
Recently, a disease referred to as 'Porcine Reproductive and Neurologic Syndrome 
(PRNS)' has newly emerged in U.S. swine populations (23). Clinical manifestations of the 
syndrome are characterized by reproductive failure in breeding females mainly at early to 
mid gestation and neurologic disorders in all ages. Some affected animals also suffer from 
respiratory distress and some degree of growth retardation. Many affected animals with 
central nervous signs frequently progress to death shortly after clinical onset. 
A small enveloped RNA virus, formerly named 'Virus X', has been repeatedly 
isolated from animals affected by PRNS (11) and shown to have the ability to cause the 
disease in experimentally infected animals. The virus was postulated to be a novel pestivirus 
as the virus had morphological characteristics similar to pestivirus and cross reacted to a 
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degree with antisera raised against known pestiviruses; however, its genome could not be 
amplified by reverse transcription polymerase chain reaction (RT-PCR) assays designed to 
specifically detect BVDV, BDV and/or CSFV. 
It is very common that detection and characterization of a pestivirus is mainly 
through serologic assays with polyclonal and monoclonal antibodies (3;9) or by molecular 
diagnostic techniques such as PGR and sequencing (5;13;20;22). A differential diagnosis is 
required when pestivirus infection is suspected since CSF among pestivirus infections is OIE 
reportable diseases; hence, use or availability of a specific reagent is critical for the accurate 
diagnosis of pestivirus-associated disease. Such an importance was demonstrated in a 
recent episode of disease outbreaks in Europe where a virus isolated from congenitally 
infected piglets was not detected by a panel of different monoclonal antibodies for CSFV or 
BVDV but for BDV (19). The following study was conducted to develop a diagnostic reagent 
specific for the newly identified swine pestivirus associated with PRNS. 
2. Materials and methods 
2.1. Virus and cells 
An isolate of the new swine pestivirus designated ISUYP604671 was used as 
antigen to produce murine monoclonal antibodies. The virus was isolated from the brain of a 
sow affected by PRNS. The virus was propagated in a proprietary cell line CL ISUVDL13b 
which was determined to be the most permissive in a previous study in our laboratory (11). 
The cells were cultured in Minimum Essential Medium (MEM, Mediatech, Inc., Herdon, VA) 
supplemented with 5% horse serum (Sigma Chemical Co., St. Louis, MO), 200mM L-
glutamine (GIBCO/BRL Life Science, Grand Island, NY) and an antibiotic-antimycotic 
mixture that includes 100 lU/ml penicillin, 10 ug/ml streptomycin, 50ug/ml gentamicin (Sigma 
102 
Chemical Co., St. Louis, MO). Virus propagation was done using stationary culture 
technique. 
Purified virus material was prepared from cell culture fluid and also directly from the 
homogenate of tonsils of clinically affected pigs from which ISUYP604671 was isolated by a 
gradient ultracentrifugation as previously described (6) with some modifications. Sucrose or 
cesium chloride (CsCI) gradient was formed in Tris-HCL buffer (pH 7.4) using a gradient 
delivery system (Model 475, Bio-Rad, Hercules, CA). Ten ml of continuous gradient were 
poured into Ultra-clear® nitrocellulose tubes (Beckman, Fullerton, CA). Two ml of samples 
were overlaid on the top of the gradient and then centrifuged using SW41 rotor in an 
ultracentrifuge (Optima® LE 80K, Beckman, Fullerton, CA) for 24hr at 39,000 rpm (260,000 x 
g). All visible bands were collected using a syringe with a needle (20G, 1.5cm). The 
presence of the novel swine pestivirus and virus titer in each fraction was determined in cell 
culture by immunofluorescence microscopy using convalescent sera from experimentally 
infected pigs (11) or hyperimmune serum generated against the new swine pestivirus in 
rabbits (10). The presence of the virus in selected fractions also was confirmed by a 
negative-straining electron microscopy. Then, a fraction with the highest virus titer was used 
to immunize mice. 
2.2. Production of murine monoclonal antibodies 
Viruses purified and concentrated from cell culture fluid or tissue homogenate were 
disrupted by mixing with 1% Triton X-100 in Tris-HCI buffer (0.025mM, pH 7.2) and 
incubated overnight at 4°C. After clarification by centrifugation, the supernatant was 
harvested from each preparation and aliquoted in a small quantity. Each aliquot was mixed 
with an equal volume of Freund's complete adjuvant (Sigma Chemical Co., St. Louis, MO) 
for the first immunization of mice and with Freund's incomplete adjuvant for subsequent 
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booster injections. Mouse immunization and production of hybridomas were carried out by 
the Iowa State University Hybridoma Facility by following the previously published protocol 
(1). In brief, BALb/c mice were used to produce primed splenic lymphocytes. Viral antigens 
were delivered to each mouse via subcutaneous route every 3 weeks for 9 weeks. All mice 
were monitored for antibody development by an indirect fluorescent antibody (IFA) test 
before each additional immunization was made. Three days after the third immunization, 
mice were euthanized and spleens were collected. Splenic lymphocytes were harvested by 
disrupting spleens and subjected to fusion with Sp2/0 murine myeloma cells in the presence 
of PEG6000. Successful hybridomas were screened for the production of the antibody 
specific for the novel swine pestivirus by testing culture supernatant by an 
immunofluorescence test. Strong positive hybridomas were then subjected to cloning. 
Clones producing antibody specific for the novel swine pestivirus were expanded using a 
miniPerm® bioreactor (Heraeus Inc., Edgewood, NY). Immunoglobulins were then purified 
from culture fluid using affinity column chromatography, some of which was conjugated with 
FITC or peroxidase by a biomedical commercial vendor (Maine Biotechnology Service, Inc., 
Portland, ME). 
2.3. Characterization of monoclonal antibody 
The class of each of the monoclonal antibodies (MAbs) produced was determined by 
an isotyping kit (IsoStrip®, Roche, Indianapolis, IN). The specificity of each MAb for the novel 
swine pestivirus was assessed using an indirect fluorescent antibody (IFA) test and virus 
neutralization (VN) assay against a variety of viral agents including BVDV and BDV, and FA 
test on cryosections of tissues collected from caesarian-derived-colostrum-deprived (CDCD) 
pigs experimentally infected with the novel swine pestivirus. The I FA test also was used to 
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determine the level of virus-specific antibodies. The viral protein specificity of each MAb was 
determined by Western immunoblotting. 
2.4. Indirect fluorescent antibody test and virus neutralization assay 
To prepare viral and cell control antigens for I FA test, cells were inoculated with virus 
materials and monitored daily for cytopathic effect (CPE) for 48 hours PI. Then, the cells 
were fixed by immerging them in cold 80% aqueous acetone, air dried, and stored at -20°C 
until use. Alternatively infected and uninfected cells were fixed in freshly prepared 3.5% of 
paraformaldehyde (Sigma Chemical Co., St. Louis, MO) in PBS pH7.5 for 10 minutes as 
described (21) and treated with 0.5% Triton X-100 (Sigma Chemical Co., St. Louis, MO) in 
PBS (pH 7.5) for one hour at 4°C. For testing, each MAb was diluted 1:10 first and then 
serially 2-fold in PBS. Each diluted sample (100|jl/well) was applied to a pair of wells (one 
with virus-infected cells and the other with uninfected control cells). After a 30-minute 
incubation period at ambient temperature, samples were removed and each well rinsed with 
PBS. Antigen-antibody reaction in each well was visualized by adding goat anti-mouse 
immunoglobulin (IgG and IgM) conjugated with FITC (Kirkegard and Perry Laboratories, 
Inc., Gaithersburg, MD) and incubating for 30 min at ambient temperature. Plates were 
examined under a fluorescent microscope. 
For VN assay, MAbs were diluted in MEM media using a serial 2-fold dilution method 
in a 96-well plate. Each diluted antibody was mixed an equal volume (100 pi) of virus at a 
rate of 100 TCID50. Antibody-virus mixtures were incubated for 1 hour at 37°C. After that, 
100|jl of the suspension of cells which were the most appropriate for the target virus were 
added to wells and incubated for another 48 hours. Each sample was run in duplicate. Cells 
were examined daily for CPE for 48 hours. The presence or absence of virus replication was 
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determined by CPE and immunofluorescence testing on fixed cells at the end of 48 hours 
incubation period. 
2.5. SDS-PAGE and Western immunoblot 
2.5.1. Antigen preparation. The virus was prepared in different cell lines CL 
ISUVDL13b, CL 1SUVDL44 and CL ISUVDL1152. Infected cells were harvested and 
pelleted by low speed centrifugation (3000 rmp for 20 min). The resulting cell pellet was then 
resuspended in a lysis buffer (10mM M Tris, 0.15 M NaCI, 0.04% CHAPS, 0.001% aprotinin 
and 1mM EDTA), pH 8.0, at a ratio of 1 ml of buffer per one 165cm2 flask. Mixtures were 
incubated overnight at 4°C with gentle stirring and centrifuged at 3,000 x g for 10 minutes at 
4°C. Each supernatant was then used for SDS-PAGE and Western immunoblotting. 
Viral antigen also was prepared from the virus purified and concentrated from tissues 
by gradient ultracentrifugation as described above. The gradient purified material was mixed 
with the lysis buffer at 1:1 ratio and processed in the same manner as above. The 
supernatant was harvested and used for SDS-PAGE and Western immunoblotting. 
The protein concentration of each sample preparation was determined using a 
protein assay kit (Bio-Rad Laboratories, Richmond, CA) following the manufacturer's 
recommended procedures and adjusted to 2 mg/ml. 
2.5.2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
A modified Laemmli's procedure (7) was used for protein separation on a discontinuous 
12% slab gel (70 x 80 x 0.75 mm) purchased from a commercial vendor (Bio-Rad 
Laboratories, Richmond, CA). The viral and cell antigen preparations were solubilized in a 
sample buffer (pH 6.9) containing 0.0625M Tris, 2% SOS, 5% 2-mercaptoethanol, 0.05% 
bromophenol blue, and 10% glycerol by boiling at 95°C for 5 minutes. Twenty to forty 
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microliters of each denatured sample (approximately 20-30 p,g of protein) and 6 )il of pre-
stained SDS-PAGE molecular weight standards (SeeBlue®Plus2, Invitrogen, Carlsbad, CA) 
were loaded in the gel. The molecular weight standards contained 10 different peptides with 
molecular masses of approximately 250, 148, 98, 64, 50, 36, 22, 16, 6 and 4 kDa, 
respectively. Electrophoresis was carried out using a vertical mini-gel apparatus as directed 
by the manufacturer (Bio-Rad Laboratories, Richmond, CA). 
2.5.3. Electrophoretic transfer of the proteins. A Ready Gel® system I (Bio-Rad 
Laboratories, Richmond, CA) was used by following the procedures recommended by the 
manufacturer. Viral and cellular proteins along with molecular weight markers which were 
separated on a polyacrylamide gel were electrophoretically transferred to a 0.2 (im 
nitrocellulose membrane (Bio-Rad Laboratories, Richmond, CA). Transfer was carried out at 
4°C for 90 minutes in a transfer buffer (pH 8.3) consisting of 25mM Tris, 192mM glycine and 
20% (v/v) methanol. Nitrocellulose membranes containing viral and control cellular antigens 
were blocked at ambient temperature for 60 min with 2.5% dry skim milk in 20mM Tris-buffer 
saline (TBS, pH 7.5) containing 0.05% Tween 20 (TTBS). 
2.5.4. Western immunoblotting. Blocked membranes were washed twice for 5 
minutes each in gently agitating TBS and cut into strips containing viral antigens, cellular 
antigens, and molecular weight standards. Murine monoclonal antibodies were diluted 
1:2000 in TTBS containing 0.1% dry skim milk. Following incubation at ambient temperature 
for 1 hour, the membranes were washed 3 times in TTBS by gently agitating for 5 minutes 
each. Antigen-antibody reactions were visualized with optimally diluted goat anti-mouse IgG 
labeled with horse radish peroxidase and TMB substrate (Kirkegard and Perry Laboratories, 
Inc., Gaithersburg, MD). When MAbs conjugated with peroxidase was used, the secondary 
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antibody was not used. The color reaction was stopped by brief washes in deionized water. 
The appearance of virus-specific reactivity was assessed by comparing the antibody 
responses to the viral and cellular antigens. Polyclonal rabbit antisera raised against Virus X 
(ISUYP604671) was used as a reference serum. 
2.6. Biological samples 
Field isolates of the newly identified swine pestivirus and tissues (brain, secondary 
lymphoid tissues, kidney, liver, lung, spleen, tonsil) collected from both experimentally 
infected pigs and clinically affected pigs in the field were used to evaluate the diagnostic 
application of MAbs. Clinically affected pigs were selected from diagnostic submissions to 
the Iowa State University Veterinary Diagnostic Laboratory based on clinical presentation. 
Virus isolation attempts for the novel swine pestivirus were made in addition to other 
diagnostic testing. Experimental samples were collected from CDCD pigs experimentally 
infected with the virus ISUYP604671 or serum from a viremic sow after inoculation of 
ISUYP604671. All these samples were previously tested by virus isolation technique for the 
presence and absence of the novel swine pestivirus (11). 
2.7. Immunofluorescence microscopy on cryosections of tissues 
Thin sections of each tissue were obtained using a cryostat and microtome. 
Cryosections were attached to pretreated glass slides and fixed by immersing in 100% cold 
acetone. Fixed tissue sections were then stained with the newly produced MAb against the 
novel swine pestivirus which was conjugated with fluorescein isothiocyanate (FITC). FA 
conjugate of MAb was used after diluted 1:80-1:100 in the 0.01M phosphate-buffered saline 
(PBS) at pH 7.4. After incubation at 37°C for 30 minutes in a humid condition, excessive 
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MAb FA conjugate was rinsed off with PBS three times. The slides were then observed 
under a fluorescent microscope Olympus IX70 (Olympus Optical Co., Tokyo, Japan). 
3. Results 
3.1 Production and characterization of monoclonal antibodies 
A total of 5 hybridomas secreting antibody reactive to the swine pestivirus 
ISUYP604671 on I FA test were produced and subjected to cloning and expansion. Two of 
the 5 hybridomas were determined to secrete IgG and the remaining 3 hybridomas IgM. 
Two hybridomas were designated 15A2 and 6F9, respectively. On Western immunoblotting, 
only supematants from the hybridoma 15A2 recognized the viral polypeptide with molecular 
masses of 80kDa while the supernatant from the 6F9 hybridoma cross-reacted with non-viral 
protein. The hybridoma 15A2 was selected and subcloned to 15A2-3E9. 
MAb15A2-3E9 reacted with the novel swine pestivirus on both I FA test (Figure 1) and 
Western immunoblot (Figure 2), demonstrating the MAb detects a linear epitope of the newly 
identified swine pestivirus. The 80kDa protein which was recognized by the MAb 15A2-3E9 
was present only in the lysate of infected cells or virus antigen preparation purified from 
tissues of infected pigs, suggesting that this protein might be a non-structural protein. MAb 
15A2-3E9, however, did not neutralize infection of the virus ISUYP604671 to several 
permissive cell lines. 
3.2. Diagnostic application of MAb 15A2-3E9 
MAb 15A2-3E9 recognized all field isolates of the novel swine pestivirus from clinical 
cases and experimentally infected pigs on an immunofluorescence assay. The MAb also 
detected the presence of ISUYP604671 in tissues from CDCD pigs experimentally infected 
with the novel pestivirus when FA conjugate was applied to cryosections of the tissues 
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(Table 1). Specific staining was observed in neuronal cells of brain, epithelial cells of tonsil, 
spleen, germinal center of lymph node, and renal tubular epithelium of kidney from the 
infected pigs (Figure 1) while no background staining was observed in any of the tissues 
collected from a negative control pig. All specific staining was cytoplasmic although 
occasionally nuclear staining was seen. 
4. Discussion and Conclusions 
Diagnosis and recognition of a newly emerging disease is very complex. Ideally 
diagnosticians should be able to recognize the disease, isolate a pathogen and reproduce 
the disease under experimental conditions. This requires the development of a reagent 
specific for the pathogen to make a reliable diagnosis. As PRNS is a previously 
unrecognized disease and a novel pestivirus was postulated to be responsible for this 
disease, the preceding study was to develop a diagnostic reagent specific for the virus. Our 
attempts were to develop a virus-specific monoclonal antibody. Monoclonal antibodies are 
considered a key tool for the detection and differentiation of pestiviruses since these viruses 
share common antigenic epitopes. For example, BVD and CSF viruses can only be 
differentiated by an immunofluorescence test using monoclonal antibodies unless molecular 
testing is used (5;9;13;19). 
As a result of this work, the MAb 15A2-3E9 that specifically recognized the newly 
identified swine pestivirus was produced. No cross reactivity was demonstrated with other 
viral agents such as BVDV, BDV, PRV, PCV, PRRSV, PEV, porcine reovirus and SIV. The 
target antigen was a protein of SOkDa in size according to the reactivity pattern observed by 
Western immunoblot. In comparison to known pestiviruses, this protein is expected to be the 
product of NS3 gene which is one of the non-structural proteins of pestiviruses (2). 
Observations that the reactivity with this protein was not demonstrated in the purified virions 
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but in lysates of infected cells support that the 80kDa protein should be a non-structural 
protein. The MAb 15A2-3E9 is believed to recognize a linear epitope of the SOkDa protein 
since the reactivity of the epitope with the MAb was not disrupted even after antigen was 
prepared under reducing conditions for SDS-PAGE and Western immunoblotting. 
There are several advantages identified using MAb 15A2-3E9. First, as MAb 15A2-
3E9 likely recognizes a non-structural protein, the MAb should be able to detect a replicating 
virus since non-structural proteins of viruses are expressed during active replication in cells. 
This would be a reason that MAb 15A2-3E9 worked well in FA testing on virus-infected cells 
and cryosections of tissues. Second, the MAb recognizes a linear epitope of the target 
protein which means that the MAb would maintain its broad spectrum of reactivity and can 
be used for a variety of diagnostic testing. Third and most importantly, MAb 15A2-3E9 can 
be used for differentiation of the new swine pestivirus from other pestiviruses known to exist 
in the field (9). The NS3 product of pestivirus is known to be antigenically conserved among 
known pestiviruses as compared to other gene products (2; 12). However, no cross reactivity 
with BVDV and BDV was demonstrated by MAb 15A2-3E9 on Western immunoblotting and 
FA (Figurel), suggesting that the MAb is highly specific for the novel swine pestivirus. In 
summary, MAb 15A2-3E9 has a great diagnostic potential for specific detection of the new 
swine pestivirus in association with PRNS. 
Knowing the specificity of MAb 15A2-3E9 for the new swine pestivirus, application of 
MAb 15A2-3E9 to immunofluorescence testing on cryosections of tissues from CDCD pigs 
experimentally infected with the new swine pestivirus clearly demonstrated the presence of 
the new pestivirus in brains (particularly neurons) from infected animals (Figure *\h) that had 
meningoencephalitis lesions (11). This observation further confirmed the causative role of 
the newly identified virus in PRNS. The similarity in FA staining patterns of tonsilar epithelial 
111 
cells between pigs infected with the new virus and CSFV (16) also supports that this new 
virus should be a member of genus Pestivirus. 
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Table 1. Summary of immunofluorescence tests (FATS) using monoclonal antibody on 
cryosections of various tissues collected from 7-week-old CDCD pigs experimentally 
infected with an isolate of the novel swine pestivirus (ISUYP604671) or serum containing 
the virus. 
Pig# Inoculum DPI at 
necropsy 
Lesions3 Isolation of 
Virus Xb 
FATS 
for Virus X 
274 A (serum 604671) 7 Yes Yes Positive0 
275 B (isolate 604671) 7 Yes Yes Positive 
302 B (isolate 604671) 10 No Yes Positive 
303 A (serum 604671) 14 Yes Yes Positive 
304 A (serum 604671) 10 Yes Yes Positive 
675 B (isolate 604671) 14 Yes Yes Positive 
273 Cell culture medium 14 No No Negative 
aLesions were present in tonsil, lymph nodes, spleen, lung, brain and liver. 
bSwine pestivirus was isolated from tonsil, brain, lymph node, serum, spleen and lung. 
fluorescent intensity staining rated 3 or 4 plus. 
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Figure 1. Photomicroscopy of immunofluorescence testing on cryosections of brain (A), 
tonsil (B) and kidney (C) from CDCD pigs experimentally infected with a newly identified 
swine pestivirus (ISUYP604671) and on CL ISUVDLISb cells infected (D) and uninfected 
(E). Monoclonal antibody 15A2-3E9 was used for testing after conjugated with fluorescein 
isothiocyanate. 
A B 
C 
d E 
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Figure 2. Western immunoblot analysis for the protein specificity of monoclonal antibody 
15A2-3E9 for the novel swine pestivirus (ISUYP604671). All proteins were separated on a 
12% polyacrylamide gel. 
Lanes 0 and 3: molecular weight marker 
Lanes 1 and 2: homogenate of brain tissue from a horse infected with West Nile virus 
Lane 4: homogenate of tissues from a pig infected with swine pestivirus which is mixed with 
lysate of cells infected with the virus 
Lane 5: new swine pestivirus purified from cell culture by continuous gradient 
ultracentrifugation 
Lanes 6 and 7: lysate of two different cell lines (CL ISUVDL1152 and CLISUVDL13b) 
infected with swine pestivirus 
Lanes 8 and 9: lysates of uninfected cells lines (CL ISUVDL1152 and CLISUVDL13b) 
Lane 10: BVDV purified from cell culture by a continuous gradient ultracentrifugation 
Lane 11: combined lysate of cells infected BVDV and BDV 
* ' 
22 •**|g 
10 • - ** 
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Figure 3. Specificity of monoclonal antibody 15A2-3E9 for the novel swine pestivirus as 
determined by Western immunoblot. All proteins were separated on a 12% polyacrylamide 
slab gel. The monoclonal antibody was used after labeled with horseradish peroxidase 
Lanel- Mouse IgG 
Lanes 2 and 3- uninfected cell lines (CL ISUVDL1152 and CLISUVDL13b) 
immunoprecipitated with rabbit anti serum specific for the new swine pestivirus and BVDV 
Lane 4- rabbit IgG 
Lane 5- BVDV type 2 antigens concentrated from a lysate of infected cells by 
ultracentrifugation through sucrose cushion 
Lane 6- BVDV immunoprecipitated with rabbit antiserum specific for the new swine 
pestivirus 
Lane 7- BVDV immunoprecipitated with rabbit antiserum specific for BVDV 
Lanes 8 and 12- molecular weight marker 
Lane 9- Swine pestivirus immunoprecipitated with rabbit antiserum specific for the swine 
pestivirus 
Lane 10 - Swine pestivirus immunoprecipitated with rabbit antiserum specific for BVDV 
Lane 11 - Swine pestivirus antigens concentrated from a lysate of infected cells by 
ultracentrifugation through sucrose cushion 
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GENERAL DISCUSSION 
Sow death is not an unusual event. However, reproductive failure and neurological 
disorders in sows with mortality in an area free of pseudorabies and where exposure to 
exotic disease is very minimal attract the attention of pork producers and veterinarians. The 
recent emergence of the disease commonly referred as "Sow infertility syndrome" or 
"Porcine Reproductive and Neurologic Syndrome (PRNS)" brought a new challenge to the 
U.S. swine industry. 
Extensive diagnostic investigations resulted in the repeated and consistent isolation 
of a cytopathic enveloped virus (Virus X) 45-55nm in size from clinical cases, which was 
later determined to contain a positive-sense RNA genome. Observations from an animal 
inoculation study with pregnant sows clearly demonstrated that Virus X is capable of 
crossing the placental barrier and causing the loss of pregnancy most likely due to 
embryonic or fetal death as evident by recovery of the virus from fetal tissues. Furthermore, 
development of meningitis or encephalitis lesions in the brains of young cesarean-derived, 
colostrum-deprived (CDCD) pigs after inoculation with Virus X also indicated that the virus 
may be able to cause neurologic disorder in infected animals. All these pathological 
changes are considered to be due to the attack of Virus X since the virus was recovered 
from brain tissues. In short, Koch's postulates were fulfilled with Virus X and all these 
experimental findings well match with field observations of PRNS. Therefore, Virus X is 
postulated to be the causative agent for PRNS. 
Virus X could not be recognized by antibodies raised against various viral agents that 
have been implicated in diseases of swine except polyclonal antiserum raised against 
bovine viral diarrhea virus (BVDV). Infection of Virus X to a permissive cell line also was 
neutralized partially by anti-border disease virus (BDV) antibodies. The cross reactivity of 
Virus X with anti-BVDV or anti-BDV antibodies suggested that Virus X is likely a pestivirus. 
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In support, the protein profile of Virus X as determined by Western immunoblotting is similar 
to that of pestiviruses. Furthermore, partial sequences of Virus X's NS3 gene, which is 
known to be highly conserved among pestiviruses, showed a relatively high sequence 
homology with known pestiviruses as compared to other common swine viral pathogens. 
Based on the serological evidence and amino acid analysis the virus was tentatively 
classified to the genus Pestivirus in the family Flaviviridae. 
The possibility that Virus X is classical swine fever virus (CSFV) can be ruled out 
since U.S. swine populations are free of CSF. Virus X is not BVDV, BDV or their variant for 
three reasons. One, no part of genomic RNA could be amplified by PGR assays specifically 
designed to detect BVDV or CSFV. Two, field observations have suggested that Virus X can 
be readily spread among pigs whereas pigs are considered to be the dead end host for 
ruminant pestiviruses. Third, the majority of hog operations in the United States have very 
minimal contact with ruminants. Therefore, Virus X is postulated to be a novel swine 
pestivirus. A monoclonal antibody developed in this study, which was determined to be 
specific for NS3 protein of the virus, will be of help for specific detection of this novel swine 
pestivirus as no cross reaction with existing pestiviruses which were available during the 
study was observed. 
With respect to control of PRNS, this study demonstrated that Virus X, like any other 
envelopee virus, can be easily inactivated by lipid solvents or detergents. The virus also was 
fragile to acidic environments and high temperatures. Good stability of virus infectivity at 4°C 
should be taken into consideration for handling samples for diagnostics. Nonetheless, the 
ability of Virus X to cross the placental barrier (i.e., in utero infection) and infect lymphocytes 
is of a great concern for effective prevention and control of Virus X infection. 
This study has been a good example of responding as a member of the diagnostic 
community to a newly emerging disease in order to identify the etiology of the problem. As 
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demonstrated throughout the study, conventional laboratory methodologies still hold their 
usefulness in diagnostic investigations which can be greatly enhanced by molecular aid. 
Therefore, it is imperative that diagnostic labs maintain the balance between conventional 
and molecular tools. This study also raised the great need of diagnosticians to be aware 
about and deal with new problems. In this study, a previously unrecognized pestivirus-like 
virus was identified as the etiological agent for the newly emerged disease, PRNS. The virus 
was partially characterized; the virus-specific reagent was prepared to aid the diagnosis of 
the novel swine pestivirus associated diseases; and Koch's postulates were fulfilled. Yet, 
epidemiological studies remain to be conducted to assess the prevalence of disease and 
understand the transmission of the virus. Pathogenesis studies also are in order to better 
understand the disease. As control of pestivirus-associated diseases has been proven to be 
difficult, extensive immunobiological studies are needed. For this virus, further molecular 
characterization is required for comparative studies with other pestiviruses and development 
of an effective vaccine. 
121 
REFERENCES 
1. Abovich, N. and M. Rosbash. 1997. Cross-intron bridging interactions in the yeast 
commitment complex are conserved in mammals. Cell 89:403-412. 
2. Alam, S.L., N.M. Wills, J.A. Ingram, J.F. Atkins, and R.F. Gesteland. 1999. 
Structural studies of the RNA pseudoknot required for readthrough of the gag-termination 
codon of murine leukemia virus. J Mol Biol 288:837-852. 
3. Allaway, G.P. and A.T. Burness. 1986. Site of attachment of encephalomyocarditis 
virus on human erythrocytes. J Virol 59:768-770. 
4. An, O.S., Y. Xie, S.H. Mao, K. Morizono, S.K. Kung, and I S. Chen. 2003. Efficient 
lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 14:1207-
1212. 
5. Anderson, R.G., M.S. Brown, and J.L. Goldstein. 1977. Role of the coated 
endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human 
fibroblasts. Cell 10:351-364. 
6. Andino, R., G.E. Rieckhof, P.L. Achacoso, and D. Baltimore. 1993. Poliovirus 
RNA synthesis utilizes an RNP complex formed around the 5'-end of viral RNA. EMBO J 12 
:3587-3598. 
7. Andino, R., G.E. Rieckhof, and D. Baltimore. 1990. Afunctional ribonucleoprotein 
complex forms around the 5' end of poliovirus RNA. Cell 63:369-380. 
8. Arning, S., P. Gruter, G. Bilbe, and A. Kramer. 1996. Mammalian splicing factor 
SF1 is encoded by variant cDNAs and binds to RNA. RNA 2:794-810. 
9. Ashkenazi, A. and V.M. Dixit. 1998. Death receptors: signaling and modulation. 
Science 281:1305-1308. 
10. Bach, E.A., M. Aguet, and R.D. Schreiber. 1997. The IFN gamma receptor: a 
paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591. 
11. Badley, A.D., A.A. Pilon, A. Landay, and D.H. Lynch. 2000. Mechanisms of HIV-
associated lymphocyte apoptosis. Blood 96:2951-2964. 
122 
12. Balachandran, S., C.N. Kim, W.C. Yeh, T.W. Mak, K. Bhalla, and G.N. Barber. 
1998. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through 
FADD-mediated death signaling. EMBO J 17:6888-6902. 
13. Ban, J., D. Portetelle, C. Altaner, B. Horion, D. Milan, V. Krchnak, A. Burny, and 
R. Kettmann. 1993. Isolation and characterization of a 2.3-kilobase-pair cDNA fragment 
encoding the binding domain of the bovine leukemia virus cell receptor. J Virol 67:1050-
1057. 
14. Bandyopadhyay, S.K., G.T. Leonard Jr, T. Bandyopadhyay, G.R. Stark, and 
G.C. Sen. 1995. Transcriptional induction by double-stranded RNA is mediated by 
interferon-stimulated response elements without activation of interferon-stimulated gene 
factor 3. J Biol Chem 270:19624-19629. 
15. Barton, D.J., B.J. Morasco, and J.B. Flanegan. 1996. Assays for poliovirus 
polymerase, 3D(Pol), and authentic RNA replication in HeLa S10 extracts. Methods 
Enzymol 275:35-57. 
16. Barton, D.J., B.J. Morasco, and J.B. Flanegan. 1999. Translating ribosomes inhibit 
poliovirus negative-strand RNA synthesis. J Virol 73:10104-10112. 
17. Basanez, G. and J. Zimmerberg. 2001. HIV and apoptosis death and the 
mitochondrion. J Exp Med 193:F11-14. 
18. Bass, B.L., H. Weintraub, R. Cattaneo, and M .A. Billeter. 1989. Biased 
hypermutation of viral RNA genomes could be due to unwinding/modification of double-
stranded RNA. Cell 56:331 
19. Beaton, A.R. and R.M. Krug. 1986. Transcription antitermination during influenza 
viral template RNA synthesis requires the nucleocapsid protein and the absence of a 5' 
capped end. Proc Natl Acad Sci U S A 83:6282-6286. 
20. Bergelson, J.M. and R.W. Finberg. 1993. Integrins as receptors for virus 
attachment and cell entry. Trends Microbiol 1:287-288. 
21. Bergelson, J.M., M.P. Shepley, B.M. Chan, M.E. Hemler, and R.W. Finberg. 
1992. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science 255:1718-
2170. 
22. Berglund, J.A., K. Chua, N. Abovich, R. Reed, and M. Rosbash. 1997. The 
123 
splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence 
UACUAAC. Cell 89:781-787. 
23. Berglund, J.A., M.L. Fleming, and M. Rosbash. 1998. The KH domain of the 
branchpoint sequence binding protein determines specificity for the pre-mRNA branchpoint 
sequence. RNA 4:998-1006. 
24. Berndt, C., B. Mopps, S. Angermuller, P. Gierschik, and P H. Krammer. 1998. 
CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc Natl 
Acad Sci U S A 95:12556-12561. 
25. Bernstein, E., A.A. Caudy, S.M. Hammond, and G.J. Hannon. 2001. Role for a 
bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366. 
26. Bielefeldt Ohmann, H., L. Ronsholt, and B. Bloch. 1987. Demonstration of bovine 
viral diarrhoea virus in peripheral blood mononuclear cells of persistently infected, clinically 
normal cattle. J Gen Virol 68 ( Pt 7): 1971-1982. 
27. Biswas, S.K. and O.P. Nayak. 1994. Mutational analysis of the conserved motifs of 
influenza A virus polymerase basic protein 1. J Virol 68:1819-1826. 
28. Bitko, V. and S. Barik. 2001. Phenotypic silencing of cytoplasmic genes using 
sequence-specific double-stranded short interfering RNA and its application in the reverse 
genetics of wild type negative-strand RNA viruses. BMC Microbiol 1:34 
29. Black, B.L. and O.S. Lyles. 1992. Vesicular stomatitis virus matrix protein inhibits 
host cell-directed transcription of target genes in vivo. J Virol 66:4058-4064. 
30. Boege, U., O.S. Ko, and D.G. Scraba. 1986. Toward an in vitro system for 
picornavirus assembly: purification of mengovirus 14S capsid precursor particles. J Virol 
57:275-284. 
31. Boehm, U., T. Klamp, M. G root, and J.C. Howard. 1997. Cellular responses to 
interferon-gamma. Annu Rev Immunol 15:749-795. 
32. Boman, H.G. 1995. Peptide antibiotics and their role in innate immunity. Annu Rev 
Immunol 13:61-92. 
33. Boman, H.G. 1998. Gene-encoded peptide antibiotics and the concept of innate 
124 
immunity: an update review. Scand J Immunol 48:15-25. 
34. Borovjagin, A.V., M.V. Ezrokhi, V.M. Rostapshov, T.Y.u. Ugarova, T.F. Bystrova, 
and I.N. Shatsky. 1991. RNA-protein interactions within the internal translation initiation 
region of encephalomyocarditis virus RNA. Nucleic Acids Res 19:4999-5005. 
35. Bouloy, M., M.A. Morgan, A.J. Shatkin, and R.M. Krug. 1979. Cap and internal 
nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary 
RNA during transcription in vitro. J Virol 32:895-904. 
36. Bouloy, M., S.J. Plotch, and R.M. Krug. 1978. Globin mRNAs are primers for the 
transcription of influenza viral RNA in vitro. Proc Natl Acad Sci U S A 75:4886-4890. 
37. Braam, J., I. Ulmanen, and R.M. Krug. 1983. Molecular model of a eucaryotic 
transcription complex: functions and movements of influenza P proteins during capped 
RNA-primed transcription. Cell 34:609-618. 
38. Brierley, 1.1995. Ribosomal frameshifting viral RNAs. J Gen Virol 76 ( Pt 8): 1885-
1892. 
39. Brierley, I., P. Digard, and S C. Inglis. 1989. Characterization of an efficient 
coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell 
57:537-547. 
40. Brojatsch, J., J. Naughton, M.M. Rolls, K. Zingler, and J.A. Young. 1996. CAR1, 
a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses 
and mediates apoptosis. Cell 87:845-855. 
41. Brummelkamp, T.R., R. Bernards, and R. Agami. 2002. A system for stable 
expression of short interfering RNAs in mammalian cells. Science 296:550-553. 
42. Buckley, B. and E. Ehrenfeld. 1987. The cap-binding protein complex in uninfected 
and poliovirus-infected HeLa cells. J Biol Chem 262:13599-13606. 
43. Burge, C.B., T. Tuschl, and P.A. Sharp. 1999. Splicing of precursors to mRNAs by 
spliceosomes. In: Gesteland, R.F. et al. (Eds.), The RNA world , Cold Spring Harbor 
Laboratory Press. Cold Spring Harbor, NY. pp. 525-560. 
44. Bushman, F.D. 2003. Targeting survival: integration site selection by retroviruses 
125 
and LTR-retrotransposons. Cell 115:135-138. 
45. Caplen, N.J., S. Parrish, F. Imani, A. Fire, and R.A. Morgan. 2001. Specific 
inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate 
systems. Proc Natl Acad Sci U S A 98:9742-9747. 
46. Cardosa, M.J., J.S. Porterfield, and S. Gordon. 1983. Complement receptor 
mediates enhanced flavivirus replication in macrophages. J Exp Med 158:258-263. 
47. Carr, C.M. and P.S. Kim. 1993. A spring-loaded mechanism for the conformational 
change of influenza hemagglutinin. Cell 73:823-832. 
48. Casey, J.L. and J.L. Gerin. 1995. Hepatitis D virus RNA editing: specific 
modification of adenosine in the antigenomic RNA. J Virol 69:7593-7600. 
49. Cathomen, T., H.Y. Nairn, and R. Cattaneo. 1998. Measles viruses with altered 
envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72:1224-1234. 
50. Cattaneo, R. 1994. Biased (A~>l) hypermutation of animal RNA virus genomes. 
Curr Opin Genet Dev 4:895-900. 
51. Chan, D.C., D. Pass, J.M. Berger, and P.S. Kim. 1997. Core structure of gp41 from 
the HIV envelope glycoprotein. Cell 89:263-273. 
52. Chang, Y.E. and L.A. Laimins. 2000. Microarray analysis identifies interferon-
inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. 
J Virol 74:4174-4182. 
53. Charini, W.A., S. Todd, G.A. Gutman, and B.L. Semler. 1994. Transduction of a 
human RNA sequence by poliovirus. J Virol 68:6547-6552. 
54. Chen, X., H. Kang, L.X. Shen, M. Chamorro, H.E. Varmus, and I. Tinoco Jr. 
1996. A characteristic bent conformation of RNA pseudoknots promotes -1 frameshifting 
during translation of retroviral RNA. J Mol Biol 260:479-483. 
55. Cheneau, Y., P.L. Roeder, T.U. Obi, M.M. Rweyemamu, A. Benkirane, and K.J. 
Wojciechowski. 1999. Disease prevention and preparedness: the Food and Agriculture 
Organization Emergency Prevention System. Rev Sci Tech 18:122-134. 
126 
56. Cheville, N.F. and W.L. Mengeling. 1969. The pathogenesis of chronic hog cholera 
(swine fever). Histologic, immunofluorescent, and electron microscopic studies. Lab Invest 
20:261-274. 
57. Chin, Y.E., M. Kitagawa, W.C. Su, Z.H. You, Y. Iwamoto, and X.Y. Fu. 1996. Cell 
growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated 
by STAT1. Science 272:719-722. 
58. Cimarelli, A. and J. Luban. 1999. Translation elongation factor 1-alpha interacts 
specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol 73:5388-
5401. 
59. Circle, D.A., O.D. Neel, H.D. Robertson, P.A. Clarke, and M.B. Mathews. 1997. 
Surprising specificity of PKR binding to delta agent genomic RNA. RNA 3:438-448. 
60. Clark, M.E., T. Hammerle, E. Wimmer, and A. Dasgupta. 1991. Poliovirus 
proteinase 3C converts an active form of transcription factor IMC to an inactive form: a 
mechanism for inhibition of host cell polymerase III transcription by poliovirus. EMBO J 
10:2941-2947. 
61. Clark, M.E., P.M. Lieberman, A.J. Berk, and A. Dasgupta. 1993. Direct cleavage 
of human TATA-binding protein by poliovirus protease 3C in vivo and in vitro. Mol Cell Biol 
13:1232-1237. 
62. Clemens, M.J. and A. Elia. 1997. The double-stranded RNA-dependent protein 
kinase PKR: structure and function. J Interferon Cytokine Res 17:503-524. 
63. Coburn, G.A. and B.R. Cullen. 2002. Potent and specific inhibition of human 
immunodeficiency virus type 1 replication by RNA interference. J Virol 76:9225-9231. 
64. Condit, R.C. 2001. Principles of virology, In 0.M. Knipe et. al (ed) Fields Virology 4th 
edition. Lippincott Williams & Wilkins, Philadelphia, PA. 1:19-52. 
65. Cuddihy, A.R., S. Li, N.W. Tarn, A.M. Wong, Y. Taya, N. Abraham, J.C. Bell, and 
A.E. Koromilas. 1999. Double-stranded-RNA-activated protein kinase PKR enhances 
transcriptional activation by tumor suppressor p53. Mol Cell Biol 19:2475-2484. 
66. D'Agostino, D.M., L. Zotti, T. Ferro, G. Franchini, L. Chieco-Bianchi, and V. 
Ciminale. 2000. The p13ll protein of HTLV type 1: comparison with mitochondrial proteins 
coded by other human viruses. AIDS Res Hum Retroviruses 16:1765-1770. 
127 
67. Dalgleish, A.G., P.C. Beverley, P.R. Clapham, D.H. Crawford, M.F. Greaves , and 
R.A. Weiss. 1984-1985. The CD4 (T4) antigen is an essential component of the receptor for 
the AIDS retrovirus. Nature 312:763-767. 
68. Dalziel, R.G., J. Hopkins, N.J. Watt, B.M. Dutia, H.A. Clarke, and I. McConnell 
1991. Identification of a putative cellular receptor for the lentivirus visna virus. J Gen Virol 
72 ( Pt 8): 1905-1911. 
69. Danen-van Oorschot, A.A., A.J. van Der Eb, and M.H. Noteborn. 2000. The 
chicken anemia virus-derived protein apoptin requires activation of caspases for induction of 
apoptosis in human tumor cells. J Virol 74:7072-7078. 
70. Das, R., Z. Zhou, and R. Reed. 2000. Functional association of U2 snRNP with the 
ATR-independent spliceosomal complex E. Mol Cell 5:779-787. 
71. Das, T., M. Mathur, A.K. Gupta, G.M. Janssen, and A.K. Banerjee. 1998. RNA 
polymerase of vesicular stomatitis virus specifically associates with translation elongation 
factor-1 alphabetagamma for its activity. Proc Natl Acad Sci U S A 95:1449-1454. 
72. Del Gatto-Konczak, F., C.F. Bourgeois, C. Le Guiner, L. Kister, M.C. Gesnel, J. 
Stevenin, and R. Breathnach. 2000. The RNA-binding protein TIA-1 is a novel mammalian 
splicing regulator acting through intron sequences adjacent to a 5' splice site. Mol Cell Biol 
20:6287-6299. 
73. Delmas, B., J. Gelfi, R. L'Haridon, L.K. Vogel, H. Sjostrom, O. Noren, and H. 
Laude. 1992. Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus 
TGEV. Nature 357:417-420. 
74. Demarchi, F., M.I. Gutierrez, and M. Giacca. 1999. Human immunodeficiency virus 
type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-
inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 73:7080-7086. 
75. Der, S.D., Y.L. Yang, C. Weissmann, and B.R. Williams. 1997. A double-stranded 
RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc 
Natl Acad Sci U S A 94:3279-3283. 
76. Derbyshire, J.B. 1999. Enterovirus, ln\N. L. Mengeling (ed.) Diseases of Swine, 
Iowa State University Press/Ames, Iowa. 145-150. 
77. Devaney, M.A., V.N. Vakharia, R.E. Lloyd, E. Ehrenfeld, and M.J. Grubman. 
128 
1988. Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 
component of the cap-binding protein complex. J Virol 62:4407-4409. 
78. Diaz-Guerra, M., C. Rivas, and M. Esteban. 1997. Activation of the IFN-inducible 
enzyme RNase L causes apoptosis of animal cells . Virology 236:354-363. 
79. Didcock, L., D.F. Young, S. Goodbourn, and R E. Randall. 1999. Sendai virus and 
simian virus 5 block activation of interferon-responsive genes: importance for virus 
pathogenesis. J Virol 73:3125-3133. 
80. Doedens, J.R., T.H. Giddings Jr, and K. Kirkegaard. 1997. Inhibition of 
endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: genetic and ultrastructural 
analysis. J Virol 71:9054-9064. 
81. Doedens, J R. and K. Kirkegaard. 1995. Inhibition of cellular protein secretion by 
poliovirus proteins 2B and 3A. EMBO J 14:894-907. 
82. Donze, O., J. Dostie, and N. Sonenberg. 1999. Regulatable expression of the 
interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis 
and fas receptor expression. Virology 256:322-329. 
83. Drenth, J.P., R.J. Powell, N.S. Brown, and J.W. Van der Meer. 1995. Interferon-
gamma and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic 
fever syndrome. Eur J Clin Invest 25:683-686. 
84. Dunster, L.M., J. Schneider-Schaulies, S. Loffler, W. Lankes, R. Schwartz-
Albiez, F. Lottspeich, and V. ter Meulen. 1994. Moesin: a cell membrane protein linked 
with susceptibility to measles virus infection. Virology 198:265-274. 
85. Easterday, B.C. and K. Van Reeth. 1999. Swine Influenza, In W. L. Mengeling (ed.) 
Diseases of Swine, Iowa State University Press/ Ames, Iowa. 277-290. 
86. Elbashir, S.M., W. Lendeckel, and T. Tuschl. 2001. RNA interference is mediated 
by 21- and 22-nucleotide RNAs. Genes Dev 15:188-200. 
87. Elvinger, F. and C.A. Baldwin. 1999. Eastern Equine Encephalomyelitis, In W. L. 
Mengeling (ed.) Diseases of Swine, Iowa State University Press/ Ames, Iowa. 133-137. 
88. ENDERS, J.F. 1954. Cytopathology of virus infections: particular reference to tissue 
129 
culture studies. Annu Rev Microbiol 8:473-502. 
89. Everett, H. and G. McFadden. 1999. Apoptosis: an innate immune response to 
virus infection. Trends Microbiol 7:160-165. 
90. Fantuzzi, G., D.A. Reed, and C.A. Dinarello. 1999. IL-12-induced IFN-gamma is 
dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 104:761-767. 
91. Farabaugh, P.J. 1996. Programmed translational frameshifting. Microbiol Rev 
60:103-134. 
92. Fass, D., S C. Harrison, and P.S. Kim. 1996. Retrovirus envelope domain at 1.7 
angstrom resolution. Nat Struct Biol 3:465-469. 
93. Fernandes, J., D. Tang, G. Leone, and P.W. Lee. 1994. Binding of reovirus to 
receptor leads to conformational changes in viral capsid proteins that are reversible upon 
virus detachment. J Biol Chem 269:17043-17047. 
94. Fire, A. 1999. RNA-triggered gene silencing. Trends Genet 15:358-363. 
95. Fire, A., S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello. 
1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis 
elegans. Nature 391:806-811. 
96. Flanegan, J.B., R.F. Petterson, V. Ambros, N.J. Hewlett, and 0. Baltimore. 1977. 
Covalent linkage of a protein to a defined nucleotide sequence at the ô'-terminus of virion 
and replicative intermediate RNAs of poliovirus. Proc Natl Acad Sci U S A 74:961-965. 
97. Forch, P., O. Puig, N. Kedersha, C. Martinez, S. Granneman, B. Séraphin, P. 
Anderson, and J. Valcarcel. 2000. The apoptosis-promoting factor TIA-1 is a regulator of 
alternative pre-mRNA splicing. Mol Cell 6:1089-1098. 
98. Fornerod, M., M. Ohno, M. Yoshida, and I.W. Mattaj. 1997. CRM1 is an export 
receptor for leucine-rich nuclear export signals. Cell 90:1051 -1060. 
99. Fox, G., N.R. Parry, P.V. Barnett, B. McGinn, D.J. Rowlands, and F. Brown. 
1989. The cell attachment site on foot-and-mouth disease virus includes the amino acid 
sequence RGD (arginine-glycine-aspartic acid). J Gen Virol 70 ( Pt 3):625-637. 
130 
100. Frese, M., G. Kochs, U. Meier-Dieter, J. Siebler, and O. Haller. 1995. Human MxA 
protein inhibits tick-borne Thogoto virus but not Dhori virus. J Virol 69:3904-3909. 
101. Frese, M., M. Weeber, F. Weber, V. Speth, and O. Haller. 1997. Mx1 sensitivity: 
Batken virus is an orthomyxovirus closely related to Dhori virus. J Gen Virol 78 ( Pt 
10):2453-2458. 
102. Fujimoto, I., T. Takizawa, Y. Ohba, and Y. Nakanishi. 1998. Co-expression of Fas 
and Fas-ligand on the surface of influenza virus-infected cells. Cell Death Differ 5:426-431. 
103. Furukawa, Y., S. Iwase, J. Kikuchi, M. Nakamura, H. Yamada, and M. Matsuda. 
1999. Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through 
induction of E2F-4/pRB and E2F-4/p130 complexes. Oncogene 18:2003-2014. 
104. Gale, M. Jr, C.M. Blakely, B. Kwieciszewski, S.L. Tan, M. Dossett, N.M. Tang, 
M.J. Korth, S.J. Polyak, D R. Gretch, and M.G. Katze. 1998. Control of PKR protein 
kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase 
regulation. Mol Cell Biol 18:5208-5218. 
105. Gale, M. Jr and M.G. Katze. 1998. Molecular mechanisms of interferon resistance 
mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase . 
Pharmacol Ther 78:29-46. 
106. Gallo, R.L., M. Murakami, T. Ohtake, and M. Zaiou. 2002. Biology and clinical 
relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 110:823-831. 
107. Gamarnik, A.V. and R. Andino. 1997. Two functional complexes formed by KH 
domain containing proteins with the 5' noncoding region of poliovirus RNA. RNA 3:882-892. 
108. Gamarnik, A.V. and R. Andino. 1998. Switch from translation to RNA replication in 
a positive-stranded RNA virus. Genes Dev 12:2293-2304. 
109. Ganz, T. 1999. Defensins and host defense. Science 286:420-421. 
110. Garcia-Sastre, A., A. Egorov, D. Matassov, S. Brandt, 0.E. Levy, J.E. Durbin, P. 
Palese, and T. Muster 1998. Influenza A virus lacking the NS1 gene replicates in 
interferon-deficient systems. Virology 252:324-330. 
111. Garcin, D., P. Latorre, and 0. Kolakofsky. 1999. Sendai virus C proteins 
131 
counteract the interferon-mediated induction of an antiviral state. J Virol 73:6559-6565. 
112. Garoff, H., R. Hewson, and D.J. Opstelten. 1998. Virus maturation by budding. 
Microbiol Mol Biol Rev 62:1171-1190. 
113. Cartel, A.L., M.S. Serfas, and A.L. Tyner. 1996. p21 -negative regulator of the cell 
cycle. Proc Soc Exp Biol Med 213:138-149. 
114. Ge, Q., L. Filip, A. Bai, T. Nguyen, H.N. Eisen, and J. Chen. 2004. Inhibition of 
influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U 
S A 101:8676-8681. 
115. Ghadge, G.D., L. Ma, S. Sato, J. Kim, and R.P. Roos. 1998. A protein critical for a 
Theiler's virus-induced immune system-mediated demyelinating disease has a cell type-
specific antiapoptotic effect and a key role in virus persistence. J Virol 72:8605-8612. 
116. Gil, J., J. Alcami, and M. Esteban. 1999. Induction of apoptosis by double-
stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic 
translation initiation factor 2 and NF-kappaB. Mol Cell Biol 19:4653-4663. 
117. Gil, J. and M. Esteban. 2000. Induction of apoptosis by the dsRNA-dependent 
protein kinase (PKR): mechanism of action. Apoptosis 5:107-114. 
118. Gingras, A C., B. Raught, and N. Sonenberg. 1999. elF4 initiation factors: 
effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev 
Biochem 68:913-963. 
119. Girard, S., T. Couderc, J. Destombes, D. Thiesson, F. Delpeyroux, and B. 
Blondel. 1999. Poliovirus induces apoptosis in the mouse central nervous system . J Virol 
73:6066-6072. 
120. Goodbourn, S., L. Didcock, and R.E. Randall. 2000. Interferons: cell signalling, 
immune modulation, antiviral response and virus countermeasures. J Gen Virol 81:2341-
2364. 
121. Gottlinger, H.G., T. Dorfman, J.G. Sodroski, and W.A. Haseltine. 1991. Effect of 
mutations affecting the p6 gag protein on human immunodeficiency virus particle release. 
Proc Natl Acad Sci U S A 88:3195-3199. 
132 
122. Gradi, A., Y.V. Svitkin, H. Imataka, and N. Sonenberg. 1998. Proteolysis of human 
eukaryotic translation initiation factor elF4GII, but not elF4GI, coincides with the shutoff of 
host protein synthesis after poliovirus infection. Proc Natl Acad Sci U S A 95:11089-11094. 
123. Granville, D.J., C.M. Carthy, D. Yang, D.W. Hunt, and B.M. McManus. 1998. 
Interaction of viral proteins with host cell death machinery. Cell Death Differ 5:653-659. 
124. Gray, E.W. and P.F. Nettleton. 1987. The ultrastructure of cell cultures infected with 
border disease and bovine virus diarrhoea viruses. J Gen Virol 68:2339-2346. 
125. Green, D.R. and J.C. Reed. 1998. Mitochondria and apoptosis. Science 281:1309-
1312. 
126. Greiser-Wilke, I., L. Haas, K. Dittmar, B. Liess, and V. Moennig. 1993. RNA 
insertions and gene duplications in the nonstructural protein p125 region of pestivirus strains 
and isolates in vitro and in vivo. Virology 193:977-980. 
127. Greve, J.M., G. Davis, A.M. Meyer, C P. Forte, S C. Yost, C.W. Marlor, M.E. 
Kamarck, and A. McClelland. 1989. The major human rhinovirus receptor is ICAM-1. Cell 
56:839-847. 
128. Grieder, F.B. and S.N. Vogel. 1999. Role of interferon and interferon regulatory 
factors in early protection against Venezuelan equine encephalitis virus infection. Virology 
257:106-118. 
129. Griffin, 0.E. and J.M. Hardwick. 1999. Perspective: virus infections and the death 
of neurons. Trends Microbiol 7:155-160. 
130. Gross, A., J.M. McDonnell, and S.J. Korsmeyer. 1999. BCL-2 family members and 
the mitochondria in apoptosis. Genes Dev 13:1899-1911. 
131. Grosshans, H. and F.J. Slack. 2002. Micro-RNAs: small is plentiful. J Cell Biol 
156:17-21. 
132. Grubor, B., J.M. Gallup, O.K. Meyerholz, E.C. Crouch, R.B. Evans, K.A. 
Brogden, H.0. Lehmkuhl, and M.R. Ackermann. 2004. Enhanced surfactant protein and 
defensin m RNA levels and reduced viral replication during parainfluenza virus type 3 
pneumonia in neonatal lambs. Clin Diagn Lab Immunol 11 :599-607. 
133 
133. Guillerm, C., V. Robert-Hebmann, U. Hibner, M. Hirn, and C. Devaux. 1998. An 
anti-CD4 (CDR3-loop) monoclonal antibody inhibits human immunodeficiency virus type 1 
envelope glycoprotein-induced apoptosis. Virology 248:254-263. 
134. Guth, S., C. Martinez, R.K. Gaur, and J. Valcarcel. 1999. Evidence for substrate-
specific requirement of the splicing factor U2AF(35) and for its function after polypyrimidine 
tract recognition by U2AF(65). Mol Cell Biol 19:8263-8271. 
135. Najjar, A.M. and M.L. Linial. 1995. Modification of retroviral RNA by double-
stranded RNA adenosine deaminase. J Virol 69:5878-5882. 
136. Haller, O., M. Frese, D. Rost, R.A. Nuttall, and G. Kochs. 1995. Tick-borne thogoto 
virus infection in mice is inhibited by the orthomyxovirus resistance gene product Mx1. J 
Virol 69:2596-2601. 
137. Halstead, S B. 1982. Immune enhancement of viral infection. Prog Allergy 31:301-
364. 
138. Halstead, S B. and E.J. O'Rourke. 1977. Antibody-enhanced dengue virus infection 
in primate leukocytes. Nature 265:739-741. 
139. Hammond, S.M., E. Bernstein, D. Beach, and G.J. Hannon. 2000. An RNA-
directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 
404:293-296. 
140. Hardwick, J.M. 1998. Viral interference with apoptosis. Semin Cell Dev Biol 9:339-
349. 
141. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 
Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 
75:805-816. 
142. Harris, M.H. and C.B. Thompson. 2000. The role of the Bcl-2 family in the 
regulation of outer mitochondrial membrane permeability. Cell Death Differ 7:1182-1191. 
143. Hatada, E., S. Saito, and R. Fukuda. 1999. Mutant influenza viruses with a 
defective NS1 protein cannot block the activation of PKR in infected cells. J Virol 73:2425-
2433. 
134 
144. Haywood, A.M. 1994. Virus receptors: binding, adhesion strengthening, and 
changes in viral structure. J Virol 68:1-5. 
145. Hefti, H.P., M. Frese, H. Landis, C. Di Paolo, A. Aguzzi, O. Haller, and J. 
Pavlovic. 1999. Human MxA protein protects mice lacking a functional alpha/beta interferon 
system against La crosse virus and other lethal viral infections. J Virol 73:6984-6991. 
146. Helenius, A., B. Morein, E. Fries, K. Simons, P. Robinson, V. Schirrmacher, C. 
Terhorst, and J.L. Strominger. 1978. Human (HLA-A and HLA-B) and murine (H-2K and 
H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus. Proc 
Natl Acad Sci U S A 75:3846-3850. 
147. Hellen, C.U. and E. Wimmer. 1992. Maturation of poliovirus capsid proteins. 
Virology 187:391-397. 
148. Henderson, S., D. Huen, M. Rowe, C. Dawson, G. Johnson, and A. Rickinson. 
1993. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human 
B cells from programmed cell death. Proc Natl Acad Sci U S A 90:8479-8483. 
149. Herrler, G., R. Rott, H.0. Klenk, H.P. Muller, A.K. Shukla, and R. Schauer. 1985. 
The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. 
EMBO J 4:1503-1506. 
150. Herz, C., E. Stavnezer, R. Krug, and T. Gurney Jr. 1981. Influenza virus, an RNA 
virus, synthesizes its messenger RNA in the nucleus of infected cells. Cell 26:391-400. 
151. Hiscott, J., P. Pitha, P. Genin, H. Nguyen, C. Heylbroeck, Y. Mamane, M. 
Algarte, and R. Lin. 1999. Triggering the interferon response: the role of IRF-3 transcription 
factor. J Interferon Cytokine Res 19:1-13. 
152. H off, H.S. and R.O. Donis. 1997. Induction of apoptosis and cleavage of poly(ADP-
ribose) polymerase by cytopathic bovine viral diarrhea virus infection. Virus Res 49:101-
113. 
153. Horikami, S.M. and S.A. Moyer. 1995. Double-stranded RNA adenosine deaminase 
activity during measles virus infection. Virus Res 36:87-96. 
154. House, J.A. and C.A. House. 1999. Vesicular Diseases, In W. L. Mengeling (ed.) 
Diseases of Swine, Iowa State University Press/Ames, Iowa. 327-340. 
135 
155. Hu, W.Y., C P. Myers, J.M. Kilzer, S.L. Pfaff, and F.D. Bushman. 2002. Inhibition 
of retroviral pathogenesis by RNA interference. Curr Biol 12:1301-1311. 
156. Huber, S.A. 1994. VCAM-1 is a receptor for encephalomyocarditis virus on murine 
vascular endothelial cells. J Virol 68:3453-3458. 
157. Hughey, P.G., R.W. Compans, S.L. Zebedee, and R.A. Lamb. 1992. Expression of 
the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells. J 
Virol 66:5542-5552. 
158. Hutvagner, G. and P.O. Zamore. 2002. RNAi: nature abhors a double-strand. Curr 
Opin Genet Dev 12:225-232. 
159. Inglis, S C., T. Barrett, C.M. Brown, and J.W. Almond. 1979. The smallest 
genome RNA segment of influenza virus contains two genes that may overlap. Proc Natl 
Acad Sci U S A 76:3790-3794. 
160. Isaacs, A. and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc R 
Soc Lond B Biol Sci 147:258-267. 
161. Iwase, S., Y. Furukawa, J. Kikuchi, M. Nagai, Y. Terui, M. Nakamura, and H. 
Yamada. 1997. Modulation of E2F activity is linked to interferon-induced growth 
suppression of hematopoietic cells. J Biol Chem 272:12406-12414. 
162. Jacks, T. and H.E. Varmus. 1985. Expression of the Rous sarcoma virus pol gene 
by ribosomal frameshifting. Science 230:1237-1242. 
163. Jacobson, M.F. and D. Baltimore. 1968. Morphogenesis of poliovirus. I. 
Association of the viral RNA with coat protein. J Mol Biol 33:369-378. 
164. Jacobson, S.J., D.A. Konings, and P. Sarnow. 1993. Biochemical and genetic 
evidence for a pseudoknot structure at the 3' terminus of the poliovirus RNA genome and its 
role in viral RNA amplification. J Virol 67:2961-2971. 
165. Jacque, J.M., K. Triques, and M. Stevenson. 2002. Modulation of HIV-1 replication 
by RNA interference. Nature 418:435-438. 
166. Jagus, R., B. Joshi, and G.N. Barber. 1999. PKR, apoptosis and cancer. Int J 
Biochem Cell Biol 31:123-138. 
136 
167. Jang, S.K., H.G. Krausslich, M.J. Nicklin, G.M. Duke, A C. Palmenberg, and E. 
Wimmer. 1988. A segment of the 5' nontranslated region of encephalomyocarditis virus 
RNA directs internal entry of ribosomes during in vitro translation. J Virol 62:2636-2643. 
168. Jang, S.K., T V. Pestova, C.U. Hellen, G.W. Withered, and E. Wimmer. 1990. 
Cap-independent translation of picornavirus RNAs: structure and function of the internal 
ribosomal entry site. Enzyme 44:292-309. 
169. Jin, H., G.P. Leser, and R.A. Lamb. 1994. The influenza virus hemagglutinin 
cytoplasmic tail is not essential for virus assembly or infectivity. EMBO J 13:5504-5515. 
170. Jin, H., G.P. Leser, J. Zhang, and R.A. Lamb. 1997. Influenza virus hemagglutinin 
and neuraminidase cytoplasmic tails control particle shape. EMBO J 16:1236-1247. 
171. Jin, H., K. Subbarao, S. Bagai, G.P. Leser, B.R. Murphy, and R.A. Lamb. 1996. 
Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or 
infectivity. J Virol 70:1406-1414. 
172. Johnstone, R.W., J.A. Kerry, and J.A. Trapani. 1998. The human interferon-
inducible protein, IFI 16, is a repressor of transcription. J Biol Chem 273:17172-17177. 
173. Joo, H.S. 1999. Encephalomyocarditis Virus, In W. L. Mengeling (ed.) Diseases of 
Swine, Iowa State University Press/Ames, Iowa. 139-144. 
174. Joo, H.S. and R.M. Chu. 1999. Japanese B Encephalitis, In W. L. Mengeling (ed.) 
Diseases of Swine, Iowa State University Press/ Ames, Iowa. 173-178. 
175. Jorgensen, R. 1990. Altered gene expression in plants due to trans interactions 
between homologous genes. Trends Biotechnol 8:340-344. 
176. June, R.A., S.Z. Schade, M.J. Bankowski, M. Kuhns, A. McNamara, T.F. Lint, 
A.L. Landay, and G.T. Spear. 1991. Complement and antibody mediate enhancement of 
HIV infection by increasing virus binding and provirus formation. AIDS 5:269-274. 
177. Kanerva, M., K. Melen, A. Vaheri, and I. Julkunen. 1996. Inhibition of puumala and 
tula hantaviruses in Vero cells by MxA protein. Virology 224:55-62. 
178. Keller, W. and L. Minvielle-Sebastia 1997. A comparison of mammalian and yeast 
pre-mRNA 3'-end processing. Curr Opin Cell Biol 9:329-336. 
137 
179. Kingsmore, S.F., J. Snoddy, D. Choubey, P. Lengyel, and M.F. Seldin. 1989. 
Physical mapping of a family of interferon-activated genes, serum amyloid P-component, 
and alpha-spectrin on mouse chromosome 1. Immunogenetics 30:169-174. 
180. Kirch, H.C., B. Putzer, D. Brockmann, H. Esche, and O. Kloke. 1997. Formation 
of the early-region-2 transcription-factor-1-retinoblastoma-protein (E2F-1-RB) transrepressor 
and release of the retinoblastoma protein from nuclear complexes containing cyclin A is 
induced by interferon alpha in U937V cells but not in interferon-alpha-resistant U937VR cells 
. Eur J Biochem 246:736-744. 
181. Kleijn, M., C.L. Vrins, H.O. Voorma, and A.A. Thomas. 1996. Phosphorylation 
state of the cap-binding protein elF4E during viral infection. Virology 217:486-494. 
182. Knight, D.M., F.A. Flomerfelt, and J. Ghrayeb. 1987. Expression of the art/trs 
protein of HIV and study of its role in viral envelope synthesis. Science 236:837-840. 
183. Knipe, D.M. 1989. The role of viral and cellular nuclear proteins in herpes simplex 
virus replication. Adv Virus Res 37:85-123. 
184. Kohtz, J.D., S.F. Jamison, C.L. Will, P. Zuo, R. Luhrmann, M.A. Garcia-Blanco, 
and J.L. Manley. 1994. Protein-protein interactions and 5'-splice-site recognition in 
mammalian m RNA precursors. Nature 368:119-124. 
185. Kozak, M. 1999. Initiation of translation in prokaryotes and eukaryotes. Gene 
234:187-208. 
186. Kramer, A. 1996. The structure and function of proteins involved in mammalian pre-
mRNA splicing. Annu Rev Biochem 65:367-409. 
187. Kroemer, G., B. Dallaporta, and M. Resche-Rigon. 1998. The mitochondrial 
death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60:619-642. 
188. Kruman, 1.1., A. Nath, and M.P. Mattson. 1998. HIV-1 protein Tat induces apoptosis 
of hippocampal neurons by a mechanism involving caspase activation, calcium overload, 
and oxidative stress. Exp Neurol 154:276-288. 
189. Kumar, M. and G.G. Carmichael. 1997. Nuclear antisense RNA induces extensive 
adenosine modifications and nuclear retention of target transcripts. Proc Natl Acad Sci U S 
A 94:3542-3547. 
138 
190. Lamb, R.A., P.W. Choppin, R.M. Chanock, and C.J. Lai. 1980. Mapping of the two 
overlapping genes for polypeptides NS1 and NS2 on RNA segment 8 of influenza virus 
genome. Proc Natl Acad Sci U S A 77:1857-1861. 
191. Lamb, R.A. and C.J. Lai. 1981. Conservation of the influenza virus membrane 
protein (M1) amino acid sequence and an open reading frame of RNA segment 7 encoding 
a second protein (M2) in H1N1 and H3N2 strains. Virology 112:746-751. 
192. Lamb, R.A., C.J. Lai, and P.W. Choppin. 1981. Sequences of mRNAs derived from 
genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for 
overlapping proteins. Proc Natl Acad Sci U S A 78:4170-4174. 
193. Landis, H., A. Simon-Jodicke, A. Kloti, C. Di Paolo, J.J. Schnorr, S. Schneider-
Schaulies, H.P. Hefti, and J. Pavlovic. 1998. Human MxA protein confers resistance to 
Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in 
the absence of viral structural proteins. J Virol 72:1516-1522. 
194. Laver, W.G., N. Bischofberger, and R.G. Webster. 1999. Disarming flu viruses. 
Sci Am 280:78-87. 
195. Laver, W.G., P.M. Colman, R.G. Webster, V S. Hinshaw, and G.M. Air. 1984. 
Influenza virus neuraminidase with hemagglutinin activity. Virology 137:314-323. 
196. Lee, N.S., T. Dohjima, G. Bauer, H. Li, M.J. Li, A. Ehsani, P. Salvaterra, and J. 
Rossi. 2002. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in 
human cells. Nat Biotechnol 20:500-505. 
197. Lee, R.C. and V. Ambros. 2001. An extensive class of small RNAs in 
Caenorhabditis elegans. Science 294:862-864. 
198. Lee, S B., D. Rodriguez, J.R. Rodriguez, and M. Esteban. 1997. The apoptosis 
pathway triggered by the interferon-induced protein kinase PKR requires the third basic 
domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Virology 231:81-88. 
199. Lemaitre, B., E. Nicolas, L. Michaut, J.M. Reichhart, and J.A. Hoffmann. 1996. 
The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal 
response in Drosophila adults. Cell 86:973-983. 
200. Lembo, D., A. Angeretti, S. Benefazio, L. Hertel, M. Gariglio, F. Novelli, and S. 
Landolfo. 1995. Constitutive expression of the interferon-inducible protein p202 in NIH 3T3 
139 
cells affects cell cycle progression. J Biol Regul Homeost Agents 9:42-46. 
201. Li, G. and C.M. Rice. 1993. The signal for translational readthrough of a UGA codon 
in Sindbis virus RNA involves a single cytidine residue immediately downstream of the 
termination codon. J Virol 67:5062-5067. 
202. Li, H., X. Liu, X. Li, X. Han, C. Tu, and Z. Yin. 1999. [Molecular clone and sequence 
analysis of cDNA fragments of hog cholera virus strain C], Wei Sheng Wu Xue Bao 39:554-
558. 
203. Li, Q., A.G. Yafal, Y.M. Lee, J. Hogle, and M. Chow. 1994. Poliovirus neutralization 
by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these 
sequences at physiological temperature. J Virol 68:3965-3970. 
204. Liebler, E.M., J. Waschbusch, J.F. Pohlenz, V. Moennig, and B. Liess. 1991. 
Distribution of antigen of noncytopathogenic and cytopathogenic bovine virus diarrhea virus 
biotypes in the intestinal tract of calves following experimental production of mucosal 
disease. Arch Virol Suppl 3:109-124. 
205. Lonberg-Holm, K., R.L. Crowell, and L. Philipson. 1976. Unrelated animal viruses 
share receptors. Nature 259:679-681. 
206. Lusso, P. and R.C. Gallo. 1994. Human herpesvirus 6 in AIDS. Lancet 343:555-
556. 
207. Ma, K., K.M. Vattem, and R.C. Wek. 2002. Dimerization and release of molecular 
chaperone inhibition facilitate activation of eukaryotic initiation factor-2 kinase in response to 
endoplasmic reticulum stress. J Biol Chem 277:18728-18735. 
208. Macho, A., M.A. Calzado, L. Jimenez-Reina, E. Ceballos, J. Leon, and E. Munoz. 
1999. Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical 
mechanisms. Oncogene 18:7543-7551. 
209. Mady, B.J., D.V. Erbe, I. Kurane, M.W. Fanger, and F A. Ennis. 1991. Antibody-
dependent enhancement of dengue virus infection mediated by bispecific antibodies against 
cell surface molecules other than Fc gamma receptors. J Immunol 147:3139-3144. 
210. Maitra, R.K., N.A. McMillan, S. Desai, J. McSwiggen, A.G. Hovanessian, G. Sen, 
B.R. Williams, and R.H. Silverman. 1994. HIV-1 TAR RNA has an intrinsic ability to 
activate interferon-inducible enzymes. Virology 204:823-827. 
140 
211. Malashkevich, V.N., B.J. Schneider, M.L. McNally, M.A. Milhollen, J.X. Pang, 
and P.S. Kim. 1999. Core structure of the envelope glycoprotein GP2 from Ebola virus at 
1,9-A resolution. Proc Natl Acad Sci U S A 96:2662-2667. 
212. Malim, M.H., J. Hauber, S.Y. Le, J.V. Maizel, and B.R. Cullen. 1989. The HIV-1 rev 
trans-activator acts through a structured target sequence to activate nuclear export of 
unspliced viral mRNA. Nature 338:254-257. 
213. Marshall, W.L., C. Yim, E. Gustafson, T. Graf, D R. Sage, K. Hanify, L. Williams, 
J. Fingeroth, and R.W. Finberg. 1999. Epstein-Barr virus encodes a novel homolog of the 
bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J Virol 73:5181-
5185. 
214. Martinand, C., C. Montavon, T. Salehzada, M. Silhol, B. Lebleu, and C. Bisbal. 
1999. RNase L inhibitor is induced during human immunodeficiency virus type 1 infection 
and down regulates the 2-5A/RNase L pathway in human T cells. J Virol 73:290-296. 
215. Marvaldi, J., M.J. Sekellick, P.I. Marcus, and J. Lucas-Lenard. 1978. Inhibition of 
mouse L cell protein synthesis by ultraviolet-irradiated vesicular stomatitis virus requires viral 
transcription. Virology 84:127-133. 
216. Maxfield, F.R. 1982. Weak bases and ionophores rapidly and reversibly raise the pH 
of endocytic vesicles in cultured mouse fibroblasts. J Cell Biol 95:676-681. 
217. McCaffrey, A.P., H. Nakai, K. Pandey, Z. Huang, F.H. Salazar, H. Xu, S.F. 
Wieland, P.L. Marion, and M.A. Kay. 2003. Inhibition of hepatitis B virus in mice by RNA 
interference. Nat Biotechnol 21:639-644. 
218. McCloskey, T.W., M. Ott, E. Tribble, S.A. Khan, S. Teichberg, M.O. Paul, S. 
Pahwa, E. Verdin, and N. Chirmule. 1997. Dual role of HIV Tat in regulation of apoptosis in 
T cells. J Immunol 158:1014-1019. 
219. McHutchison, J.G., S C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. 
Rustgi, Z.0. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht. 1998. Interferon a!fa-2b 
alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis 
Interventional Therapy Group. N Engl J Med 339:1485-1492. 
220. McManus, M.T. and P.A. Sharp. 2002. Gene silencing in mammals by small 
interfering RNAs. Nat Rev Genet 3:737-747. 
141 
221. Melville, M.W., S.L. Tan, M. Wambach, J. Song, R.I. Morimoto, and M.G. Katze. 
1999. The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-
activated co-chaperone that modulates heat shock protein 70 activity. J Biol Chem 
274:3797-3803. 
222. Merrick, W.C. 1992. Mechanism and regulation of eukaryotic protein synthesis. 
Microbiol Rev 56:291-315. 
223. Meurs, E., K. Chong, J. Galabru, N.S. Thomas, I.M. Kerr, B.R. Williams, and A.G. 
Hovanessian. 1990. Molecular cloning and characterization of the human double-stranded 
RNA-activated protein kinase induced by interferon. Cell 62:379-390. 
224. Meyers, G., N. Tautz, R. Stark, J. Brownlie, E.J. Dubovi, M.S. Collett, and H.J. 
Thiel. 1992. Rearrangement of viral sequences in cytopathogenic pestiviruses. Virology 
191:368-386. 
225. Mignotte, B. and J.L. Vayssiere. 1998. Mitochondria and apoptosis. Eur J Biochem 
252 :1 -15. 
226. Molla, A., A.V. Paul, and E. Wimmer. 1991. Cell-free, de novo synthesis of 
poliovirus. Science 254:1647-1651. 
227. Moormann, R.J. and M.M. Hulst. 1988. Hog cholera virus: identification and 
characterization of the viral RNA and the virus-specific RNA synthesized in infected swine 
kidney cells. Virus Res 11:281-291. 
228. Morehouse, L.G. 1999. Rabies, In W. L. Mengeling (ed.) Diseases of Swine, Iowa 
State University Press/ Ames, Iowa. 247-254. 
229. Mosser, A.G., L.A. Caliguiri, and I. Tamm. 1972. Incorporation of lipid precursors 
into cytoplasmic membranes of poliovirus-infected HeLa cells. Virology 47:39-47. 
230. Mourelatos, Z., J. Dostie, S. Paushkin, A. Sharma, B. Charroux, L. Abel, J. 
Rappsilber, M. Mann, and G. Dreyfuss. 2002. miRNPs: a novel class of ribonucleoproteins 
containing numerous microRNAs. Genes Dev 16:720-728. 
231. NAGANO, Y. and Y. KOJIMA. 1958. [Inhibition of vaccinia infection by a liquid factor 
in tissues infected by homologous virus.]. C R Seances Soc Biol Fil 152:1627-1629. 
142 
232. Napthine, S., J. Liphardt, A. Bloys, S. Routledge, and I. Brierley. 1999. The role 
of RNA pseudoknot stem 1 length in the promotion of efficient -1 ribosomal frameshifting. J 
Mol Biol 288:305-320. 
233. Nemeroff, M.E., S.M. Barabino, Y. Li, W. Keller, and R.M. Krug. 1998. Influenza 
virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end 
formation of cellular pre-mRNAs. Mol Cell 1:991-1000. 
234. Neubauer, G., A. King, J. Rappsilber, C. Calvio, M. Watson, P. Ajuh, J. Sleeman, 
A. Lamond, and M. Mann. 1998. Mass spectrometry and EST-database searching allows 
characterization of the multi-protein spliceosome complex. Nat Genet 20:46-50. 
235. Nilsen, T.W. and C. Baglioni. 1979. Mechanism for discrimination between viral and 
host mRNA in interferon-treated cells. Proc Natl Acad Sci U S A 76:2600-2604. 
236. O'Connell, M.A., S. Krause, M. Higuchi, J.J. Hsuan, N.F. Totty, A. Jenny, and W. 
Keller. 1995. Cloning of cDNAs encoding mammalian double-stranded RNA-specific 
adenosine deaminase. Mol Cell Biol 15:1389-1397. 
237. Ohnimus, H., M. Heinkelein, and C. Jassoy. 1997. Apoptotic cell death upon 
contact of CD4+ T lymphocytes with HIV glycoprotein-expressing cells is mediated by 
caspases but bypasses CD95 (Fas/Apo-1) and TNF receptor 1. J Immunol 159:5246-5252. 
238. Olsen, C. and F. Scott. 1993. Evaluation of antibody-dependent enhancement of 
feline infectious peritonitis virus infectivity using in situ hybridization. Microb Pathog 14:275-
285. 
239. Orendi, J.M., K. Boer, A.M. van Loon, J.C. Borleffs, A.C. van Oppen, and C.A. 
Boucher. 1998. [Vertical HIV-l-transmission. I. Risk and prevention in pregnancy], Ned 
Tijdschr Geneeskd 142:2720-2724. 
240. Ostareck-Lederer, A., D.H. Ostareck, and M.W. Hentze. 1998. Cytoplasmic 
regulatory functions of the KH-domain proteins hnRNPs K and E1/E2. Trends Biochem Sci 
23:409-411. 
241. Paddison, P.J., A .A. Caudy, E. Bernstein, G.J. Hannon, and O.S. Conklin. 2002. 
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. 
Genes Dev 16:948-958. 
242. Palese, P. and R.W. Compans. 1976. Inhibition of influenza virus replication in 
143 
tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism 
of action. J Gen Virol 33:159-163. 
243. Palese, P., K. Tobita, M. Ueda, and R.W. Compans. 1974. Characterization of 
temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397-
410. 
244. Palmenberg, A.C. 1982. In vitro synthesis and assembly of picornaviral capsid 
intermediate structures. J Virol 44:900-906. 
245. Parsley, T.B., J.S. Towner, LB. Blyn, E. Ehrenfeld, and B.L. Semler. 1997. Poly 
(rC) binding protein 2 forms a ternary complex with the ô'-termina! sequences of poliovirus 
RNA and the viral 3CD proteinase. RNA 3:1124-1134. 
246. Pastan, I.H. and M.C. Willingham. 1981. Journey to the center of the cell: role of 
the receptosome. Science 214:504-509. 
247. Patel, R.C., D.J. Vestal, Z. Xu, S. Bandyopadhyay, W. Guo, S.M. Erme, B.R. 
Williams, and G.C. Sen. 1999. DRBP76, a double-stranded RNA-binding nuclear protein, is 
phosphorylated by the interferon-induced protein kinase, PKR. J Biol Chem 274:20432-
20437. 
248. Patterson, J.B. and C.E. Samuel. 1995. Expression and regulation by interferon of 
a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two 
forms of the deaminase. Mol Cell Biol 15:5376-5388. 
249. Patterson, J.B., D.C. Thomis, S.L. Hans, and C.E. Samuel. 1995. Mechanism of 
interferon action: double-stranded RNA-specific adenosine deaminase from human cells is 
inducible by alpha and gamma interferons. Virology 210:508-511. 
250. Paul, P.S. and G.W. Stevenson. 1999. Rotavirus and Reovirus, In W. L. Mengeling 
(ed.) Diseases of Swine, Iowa State University Press/Ames, Iowa. 255-276. 
251. Pavlovic, J., O. Haller, and P. Staeheli. 1992. Human and mouse Mx proteins 
inhibit different steps of the influenza virus multiplication cycle. J Virol 66:2564-2569. 
252. Pavlovic, J., T. Zurcher, O. Haller, and P. Staeheli. 1990. Resistance to influenza 
virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 
64:3370-3375. 
144 
253. Pawlotsky, J.M., G. Germanidis, P.O. Frainais, M. Bouvier, A. Soulier, M. 
Pellerin, and D. Dhumeaux. 1999. Evolution of the hepatitis C virus second envelope 
protein hypervariable region in chronically infected patients receiving alpha interferon 
therapy. J Virol 73:6490-6499. 
254. Peiris, J.S., S. Gordon, J.C. Unkeless, and U.S. Porterfield. 1981. Monoclonal 
anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. 
Nature 289:189-191. 
255. Pelletier, J., G. Kaplan, V.R. Racaniello, and N. Sonenberg. 1988. Cap-
independent translation of poliovirus mRNA is conferred by sequence elements within the 5' 
noncoding region. Mol Cell Biol 8:1103-1112. 
256. Pensaert, M.B. 1999. Hemagglutinating Encephalomyelitis Virus, In W. L. Mengeling 
(ed.) Diseases of Swine, Iowa State University Press/ Ames, Iowa. 151-158. 
257. Pensaert, M.B. 1999. Porcine Epidemic Diarrhea, In W. L. Mengeling (ed.) Diseases 
of Swine, Iowa State University Press/ Ames, Iowa. 179-186. 
258. Persaud, S.J. and P.M. Jones. 1994. Antisense oligonucleotide inhibition of gene 
expression: application to endocrine systems. J Mol Endocrinol 12:127-130. 
259. Pestova, T.V. and C.U. Hellen. 1999. Ribosome recruitment and scanning: what's 
new? Trends Biochem Sci 24:85-87. 
260. Pestova, T.V. and C.U. Hellen. 1999. Internal initiation of translation of bovine viral 
diarrhea virus RNA. Virology 258:249-256. 
261. Pestova, T.V., C.U. Hellen, and I.N. Shatsky. 1996. Canonical eukaryotic initiation 
factors determine initiation of translation by internal ribosomal entry. Mol Cell Biol 16:6859-
6869. 
262. Pestova, T.V., I.N. Shatsky, S.P. Fletcher, R.J. Jackson, and C.U. Hellen. 1998. A 
prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon 
during internal translation initiation of hepatitis C and classical swine fever virus RNAs. 
Genes Dev 12:67-83. 
263. Pestova, T V., I.N. Shatsky, and C.U. Hellen. 1996. Functional dissection of 
eukaryotic initiation factor 4F: the 4A subunit and the central domain of the 4G subunit are 
sufficient to mediate internal entry of 43S preinitiation complexes. Mol Cell Biol 16:6870-
145 
6878. 
264. Philipson, L, P. Andersson, U. Olshevsky, R. Weinberg, D. Baltimore, and R. 
Gesteland. 1978. Translation of MuLV and MSV RNAs in nuclease-treated reticulocyte 
extracts: enhancement of the gag-pol polypeptide with yeast suppressor tRNA. Cell 13:189-
199. 
265. Piccone, M.E., M. Zellner, T.F. Kumosinski, P.W. Mason, and M.J. Grubman. 
1995. Identification of the active-site residues of the L proteinase of foot-and-mouth disease 
virus. J Virol 69:4950-4956. 
266. Plotch, S.J., M. Bouloy, I. Ulmanen, and R.M. Krug. 1981. A unique 
cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to 
generate the primers that initiate viral RNA transcription. Cell 23:847-858. 
267. Pollack, R. and R. Goldman. 1973. Synthesis of infective poliovirus in BSC-1 
monkey cells enucleated with cytochalasin B. Science 179:915-916. 
268. Poison, A.G. and B.L. Bass. 1994. Preferential selection of adenosines for 
modification by double-stranded RNA adenosine deaminase. EMBO J 13:5701-5711. 
269. Poison, A.G., H.L. Ley 3rd, B.L. Bass, and J.L. Casey. 1998. Hepatitis delta virus 
RNA editing is highly specific for the amber/W site and is suppressed by hepatitis delta 
antigen. Mol Cell Biol 18:1919-1926. 
270. Proudfoot, N. 2000. Connecting transcription to messenger RNA processing. 
Trends Biochem Sci 25:290-293. 
271. Racaniello, V.R. and D. Baltimore. 1981. Molecular cloning of poliovirus cDNA and 
determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci 
usa 78:4887-4891. 
272. Ramaiah, K.V., M.V. Davies, J.J. Chen, and R.J. Kaufman. 1994. Expression of 
mutant eukaryotic initiation factor 2 alpha subunit (elF-2 alpha) reduces inhibition of guanine 
nucleotide exchange activity of elF-2B mediated by elF-2 alpha phosphorylation. Mol Cell 
Biol 14:4546-4553. 
273. Ramana, C.V., N. Grammatikakis, M. Chernov, H. Nguyen, K.C. Goh, B.R. 
Williams, and G.R. Stark. 2000. Regulation of c-myc expression by IFN-gamma through 
Statl-dependent and -independent pathways. EMBO J 19:263-272. 
146 
274. Rasola, A., D. Gramaglia, C. Boccaccio, and P.M. Comoglio. 2001. Apoptosis 
enhancement by the HIV-1 Nef protein. J Immunol 166:81-88. 
275. Rijnbrand, R., T. van der Straaten, P A. van Rijn, W.J. Spaan, and P.J. 
Bredenbeek. 1997. Internal entry of ribosomes is directed by the 5' noncoding region of 
classical swine fever virus and is dependent on the presence of an RNA pseudoknot 
upstream of the initiation codon. J Virol 71:451-457. 
276. Roberts, P.J. and G.J. Belsham. 1995. Identification of critical amino acids within 
the foot-and-mouth disease virus leader protein, a cysteine protease. Virology 213:140-146. 
277. Robertson, H.D. and M.B. Mathews. 1996. The regulation of the protein kinase 
PKR by RNA. Biochimie 78:909-914. 
278. Rolsma, M.D., H.B. Gelberg, and M.S. Kuhlenschmidt. 1994. Assay for evaluation 
of rotavirus-cell interactions: identification of an enterocyte ganglioside fraction that 
mediates group A porcine rotavirus recognition. J Virol 68:258-268. 
279. Rombaut, B., R. Vrijsen, and A. Boeye. 1990. New evidence for the precursor role 
of 14 S subunits in poliovirus morphogenesis. Virology 177:411-414. 
280. Roth, M.G., D. Gundersen, N. Patil, and E. Rodriguez-Bouian. 1987. The large 
external domain is sufficient for the correct sorting of secreted or chimeric influenza virus 
hemagglutinins in polarized monkey kidney cells. J Cell Biol 104:769-782. 
281. Saif, L.J. and R.D. Wesley. 1999. Transmissible Gastroenteritis and Porcine 
Respiratory Coronavirus, In W. L. Mengeling (ed.) Diseases of Swine, Iowa State University 
Press/ Ames, Iowa. 295-326. 
282. Samuel, C.E. 1979. Mechanism of interferon action: phosphorylation of protein 
synthesis initiation factor elF-2 in interferon-treated human cells by a ribosome-associated 
kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc 
Natl Acad Sci U S A 76:600-604. 
283. Samuel, C.E. 1989. Polycistronic animal virus m RNAs. Prog Nucleic Acid Res Mol 
Biol 37:127-153. 
284. Samuel, C.E. 1991. Antiviral actions of interferon. Interferon-regulated cellular 
proteins and their surprisingly selective antiviral activities. Virology 183:1-11. 
147 
285. Samuel, C.E. 1993. The elF-2 alpha protein kinases, regulators of translation in 
eukaryotes from yeasts to humans. J Biol Chem 268:7603-7606. 
286. Sanz-Ezquerro, J.J., S. de la Luna, J. Ortin, and A. Nieto. 1995. Individual 
expression of influenza virus PA protein induces degradation of coexpressed proteins. J 
Virol 69:2420-2426. 
287. Sarnow, P. 1989. Role of 3'-end sequences in infectivity of poliovirus transcripts 
made in vitro. J Virol 63:467-470. 
288. Schlesinger, J.J. and M.W. Brandriss. 1981. Antibody-mediated infection of 
macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol 8:103-
117. 
289. Schneider-Schaulies, S., J. Schneider-Schaulies, A. Schuster, M. Bayer, J. 
Pavlovic, and V. ter Meulen. 1994. Cell type-specific MxA-mediated inhibition of measles 
virus transcription in human brain cells. J Virol 68:6910-6917. 
290. Schulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg, and M.E. Peter. 1998. 
Apoptosis signaling by death receptors. Eur J Biochem 254:439-459. 
291. Schweizer, M. and E. Peterhans. 1999. Oxidative stress in cells infected with 
bovine viral diarrhoea virus: a crucial step in the induction of apoptosis. J Gen Virol 80 ( Pt 
5):1147-1155. 
292. Shapiro, G.I., T. Gurney Jr, and R.M. Krug. 1987. Influenza virus gene expression: 
control mechanisms at early and late times of infection and nuclear-cytoplasmic transport of 
virus-specific RNAs. J Virol 61:764-773. 
293. Shatkin, A.J. and J.L. Manley. 2000. The ends of the affair: capping and 
polyadenylation. Nat Struct Biol 7:838-842. 
294. Shen, Y. and T.E. Shenk. 1995. Viruses and apoptosis. Curr Opin Genet Dev 
5:105-111. 
295. Silvera, D., A.V. Gamarnik, and R. Andino. 1999. The N-terminal K homology 
domain of the poly(rC)-binding protein is a major determinant for binding to the poliovirus 5'-
untranslated region and acts as an inhibitor of viral translation. J Biol Chem 274:38163-
38170. 
148 
296. Silverman, R.H. 1997. 2-5A-dependent RNase L: a regulated endoribonuclease in 
interferon system. In Ribonuclease: Structure and function, pp.515-551. Edited by 
G.D'Alessio, J.F. Riordan. New York; Academic Press. (Abstract) 
297. Simoes, E.A. and P. Sarnow. 1991. An RNA hairpin at the extreme 5' end of the 
poliovirus RNA genome modulates viral translation in human cells. J Virol 65:913-921. 
298. Skehel, J.J., P.M. Bayley, E.B. Brown, S.R. Martin, M.D. Waterfield, J.M. White, 
I.A. Wilson, and D C. Wiley . 1982. Changes in the conformation of influenza virus 
hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U 
S A 79:968-972. 
299. Spingola, M. and M. Ares Jr. 2000. A yeast intronic splicing enhancer and NamBp 
are required for Mer1 p-activated splicing. Mol Cell 6:329-338. 
300. Staeheli, P., R. Grob, E. Meier, J.G. Sutcliffe, and O. Haller. 1988. Influenza virus-
susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 
8:4518-4523. 
301. Staeheli, P., O. Haller, W. Boll, J. Lindenmann, and C. Weissmann. 1986. Mx 
protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers 
selective resistance to influenza virus. Cell 44:147-158. 
302. Staeheli, P., F. Pitossi, and J. Pavlovic. 1993. Mx proteins: GTPases with antiviral 
activity. Trends Cell Biol 3:268-272. 
303. Stark, R., G. Meyers, T. Rumenapf, and H.J. Thiel. 1993. Processing of pestivirus 
polyprotein: cleavage site between autoprotease and nucleocapsid protein of classical swine 
fever virus. J Virol 67:7088-7095. 
304. Stephano, A. 2002. Blue Eye disease: Clinical signs and lesions, In AMorilla et al. 
(ed) Trends in Emerging Viral Infections of Swine, Iowa State Press/Ames, Iowa, pp.47-
51. 
305. Stephens, E.B. and R.W. Compans. 1988. Assembly of animal viruses at cellular 
membranes. Annu Rev Microbiol 42:489-516. 
306. Stranden, A.M., P. Staeheli, and J. Pavlovic. 1993. Function of the mouse Mx1 
protein is inhibited by overexpression of the PB2 protein of influenza virus. Virology' 
197:642-651. 
149 
307. Subramaniam, P.S. and H.M. Johnson. 1997. A role for the cyclin-dependent 
kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. J 
Interferon Cytokine Res 17:11-15. 
308. Suzuki, Y., Y. Hirabayashi, T. Suzuki, and M. Matsumoto. 1985. Occurrence of O-
glycosidically peptide-linked oligosaccharides of poly-N-acetyllactosamine type 
(erythroglycan II) in the l-antigenically active Sendai virus receptor sialoglycoprotein GP-2. J 
Biochem (Tokyo) 98:1653-1659. 
309. Svitkin, Y.V., A. Gradi, H. Imataka, S. Morino, and N. Sonenberg. 1999. 
Eukaryotic initiation factor 4GII (elF4GII), but not elF4GI, cleavage correlates with inhibition 
of host cell protein synthesis after human rhinovirus infection. J Virol 73:3467-3472. 
310. Tabara, H., A. Grishok, and C.C. Mello. 1998. RNAi in C. elegans: soaking in the 
genome sequence. Science 282:430-431. 
311. Takizawa, T., R. Fukuda, T. Miyawaki, K. Ohashi, and Y. Nakanishi. 1995. 
Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection 
involving spontaneously produced beta-interferon. Virology 209:288-296. 
312. Takizawa, T., K. Ohashi, and Y. Nakanishi. 1996. Possible involvement of double-
stranded RNA-activated protein kinase in cell death by influenza virus infection. J Virol 
70:8128-8132. 
313. Tan, S.L. and M.G. Katze. 1999. The emerging role of the interferon-induced PKR 
protein kinase as an apoptotic effector: a new face of death? J Interferon Cytokine Res 19 
:543-554. 
314. Tang, H., G.M. Gaietta, W.H. Fischer, M.H. Ellisman, and F. Wong-Staal. 1997. A 
cellular cofactor for the constitutive transport element of type D retrovirus. Science 
276:1412-1415. 
315. Tautz, N., G. Meyers, and H.J. Thiel. 1993. Processing of poly-ubiquitin in the 
polyprotein of an RNA virus. Virology 197:74-85. 
316. Taylor, D R., S T. Shi, P R. Romano, G.N. Barber, and M.M. Lai. 1999. Inhibition 
of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110. 
317. Teodoro, J.G. and P.E. Branton. 1997. Regulation of apoptosis by viral gene 
products. J Virol 71:1739-1746. 
150 
318. Terpstra, C. and G. Wensvoort. 1988. Natural infections of pigs with bovine viral 
diarrhoea virus associated with signs resembling swine fever. Res Vet Sci 45:137-142. 
319. Thomas, H.C., M.E. Torok, and G.R. Foster. 1999. Hepatitis C virus dynamics in 
vivo and the antiviral efficacy of interferon alfa therapy. Hepatology 29:1333-1334. 
320. Thomis, D.C. and C.E. Samuel. 1993. Mechanism of interferon action: evidence for 
intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-
dependent protein kinase PKR. J Virol 67:7695-7700. 
321. Thomis, D.C. and C.E. Samuel. 1995. Mechanism of interferon action: 
characterization of the intermolecular autophosphorylation of PKR, the interferon-inducible, 
RNA-dependent protein kinase. J Virol 69:5195-5198. 
322. Tolskaya, E.A., L.I. Romanova, M.S. Kolesnikova, T.A. Ivannikova, E.A. 
Smirnova, N.T. Raikhlin, and V.I. Agol. 1995. Apoptosis-inducing and apoptosis-
preventing functions of poliovirus. J Virol 69:1181 -1189. 
323. Trono, 0., J. Pelletier, N. Sonenberg, and 0. Baltimore. 1988. Translation in 
mammalian cells of a gene linked to the poliovirus 5' noncoding region. Science 241:445-
448. 
324. Tycko, B. and F.R. Maxfield. 1982. Rapid acidification of endocytic vesicles 
containing alpha 2-macroglobulin. Cell 28:643-651. 
325. Tyler, K.L., M.K. Squier, S.E. Rodgers, B E. Schneider, S.M. Oberhaus, T.A. 
Grdina, J.J. Cohen, and T.S. Dermody. 1995. Differences in the capacity of reovirus 
strains to induce apoptosis are determined by the viral attachment protein sigma 1. J Virol 
69:6972-6979. 
326. Ulmanen, I., B. Broni, and R.M. Krug. 1983. Influenza virus temperature-sensitive 
cap (m7GpppNm)-dependent endonuclease. J Virol 45:27-35. 
327. Van kuppeveld, F.J., W.J. Melchers, K. Kirkegaard, and J R. Doedens. 1997. 
Structure-function analysis of coxsackie B3 virus protein 2B. Virology 227:111-118. 
328. Van Oirschot, J.T. 1992. Hog Cholera, In Mengeling (ed.) Swine diseases . Iowa 
State University Press/ Ames, Iowa. 274-286. 
151 
329. Vannier, P. and E. Albina. 1999. Bovine Viral Diarrhea and Border Disease, In 
Mengeling (ed.) Swine diseases . Iowa State University Press/Ames, Iowa. 113-119. 
330. Vorburger, S.A., A. Pataer, K. Yoshida, G.N. Barber, W. Xia, P. Chiao, L.M. Ellis, 
M.C. Hung, S.G. Swisher, and K.K. Hunt. 2002. Role for the double-stranded RNA 
activated protein kinase PKR in E2F-1-induced apoptosis. Oncogene 21:6278-6288. 
331. Wang, Z., N. Day, P. Trifillis, and M. Kiledjian. 1999. An mRNA stability complex 
functions with poly(A)-binding protein to stabilize mRNA in vitro. Mol Cell Biol 19:4552-
4560. 
332. Waskiewicz, A.J., J.C. Johnson, B. Penn, M. Mahalingam, S R. Kimball, and J.A. 
Cooper. 1999. Phosphorylation of the cap-binding protein eukaryotic translation initiation 
factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 19:1871-1880. 
333. Week, P.K. and R.R. Wagner. 1979. Transcription of vesicular stomatitis virus is 
required to shut off cellular RNA synthesis. J Virol 30:410-413. 
334. Weissenhorn, W., A. Carfi, K.H. Lee, J.J. Skehel, and D.C. Wiley. 1998. Crystal 
structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein 
ectodomain. Mol Cell 2:605-616. 
335. Weissenhorn, W., A. Dessen, L.J. Calder, S.C. Harrison, J.J. Skehel, and D.C. 
Wiley. 1999. Structural basis for membrane fusion by enveloped viruses . Mol Membr Biol 
16:3-9. 
336. White, J. and A. Helenius. 1980. pH-dependent fusion between the Semliki Forest 
virus membrane and liposomes. Proc Natl Acad Sci U S A 77:3273-3277. 
337. White, J., K. Matlin, and A. Helenius. 1981. Cell fusion by Semliki Forest, 
influenza, and vesicular stomatitis viruses. J Cell Biol 89:674-679. 
338. Whittaker, G.R. and A. Helenius. 1998. Nuclear import and export of viruses and 
virus genomes. Virology 246:1-23. 
339. Wien, M.W., M. Chow, and J.M. Hogle. 1996. Poliovirus: new insights from an old 
paradigm. Structure 4:763-767. 
340. Wu, S., C.M. Romfo, T.W. Nilsen, and M.R. Green. 1999. Functional recognition of 
152 
the 3' splice site AG by the splicing factor U2AF35. Nature 402:832-835. 
341. Xiao, H., C. Neuveut, M. Benkirane, and K.T. Jeang. 1998. Interaction of the 
second coding exon of Tat with human EF-1 delta delineates a mechanism for HIV-1-
mediated shut-off of host mRNA translation. Biochem Biophys Res Commun 244:384-389. 
342. Xing, Z., A. Zganiacz, J. Wang, M. Divangahi, and F. Nawaz. 2000. IL-12-
independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 
for IFN-gamma release in the lung but not for the differentiation of viral-reactive Th1-type 
lymphocytes. J Immunol 164:2575-2584. 
343. Yang, Y.L., L.F. Reis, J. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B.R. 
Williams, M. Aguet, and C. Weissmann. 1995. Deficient signaling in mice devoid of 
double-stranded RNA-dependent protein kinase. EMBO J 14:6095-6106. 
344. Yekta, S., I.H. Shih, and O.P. Bartel 2004. MicroRNA-directed cleavage of HOXB8 
mRNA. Science 304:594-596. 
345. Yewdell, J.W. and J R. Bennink. 1989. Brefeldin A specifically inhibits presentation 
of protein antigens to cytotoxic T lymphocytes. Science 244:1072-1075. 
346. Yogo, Y. and E. Wimmer. 1972. Polyadenylic acid at the 3'-terminus of poliovirus 
RNA. Proc Natl Acad Sci U S A 69:1877-1882. 
347. Yoon, K.J., L.L. Wu, J.J. Zimmerman, H.T. Hill, and K B. Piatt. 1996. Antibody-
dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus 
(PRRSV) infection in pigs. Viral Immunol 9:51-63. 
348. Young, A.T. 2001. Virus entry and uncoating, In D.M. Knipe et. al (ed) Fields 
Virology 4th edition. Lppincott Williams & Wilkins, Philadelphia, PA. 1:87-105. 
349. Yuan, H., B.K. Yoza, and O.S. Lyles. 1998. Inhibition of host RNA polymerase II-
dependent transcription by vesicular stomatitis virus results from inactivation of TFIID. 
Virology 251:383-392. 
350. Zamore, P.O. 2001. RNA interference: listening to the sound of silence. Nat Struct 
Biol 8:746-750. 
351. Zebedee, S.L. and R.A. Lamb. 1988. Influenza A virus M2 protein: monoclonal 
153 
antibody restriction of virus growth and detection of M2 in virions. J Virol 62:2762-2772. 
352. Zhang, G., S. Aldridge, M.C. Clarke, and J.W. McCauley. 1996. Cell death 
induced by cytopathic bovine viral diarrhoea virus is mediated by apoptosis. J Gen Virol 77 
( Pt 8):1677-1681. 
353. Zhang, L., W. Yu, T. He, J. Yu, R E. Caffrey, E.A. Dalmasso, S. Fu, T. Pham, J. 
Mei, J.J. Ho, W. Zhang, P. Lopez, and D.D. Ho. 2002. Contribution of human alpha-
defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298:995-1000. 
354. Zhao, H., B P. De, T. Das, and A.K. Banerjee. 1996. Inhibition of human 
parainfluenza virus-3 replication by interferon and human MxA. Virology 220:330-338. 
355. Zhao, J., L. Hyman, and C. Moore. 1999. Formation of mRNA 3' ends in 
eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA 
synthesis. Microbiol Mol Biol Rev 63:405-445. 
356. Zhou, A., J. Paranjape, T.L. Brown, H. Nie, S. Naik, B. Dong, A. Chang, B. 
Trapp, R. Fairchild, C. Colmenares, and R.H. Silverman. 1997. Interferon action and 
apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J 
16:6355-6363. 
357. Zhu, H., J.P. Cong, G. Mamtora, T. Gingeras, and T. Shenk. 1998. Cellular gene 
expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. 
Proc Natl Acad Sci U S A 95:14470-14475. 
358. Zinszner, H., M. Kuroda, X. Wang, N. Batchvarova, R.T. Lightfoot, H. Remotti, 
J.L. Stevens, and D. Ron. 1998. CHOP is implicated in programmed cell death in response 
to impaired function of the endoplasmic reticulum. Genes Dev 12:982-995. 
359. Zorio, D A. and T. Blumenthal. 1999. Both subunits of U2AF recognize the 3' splice 
site in Caenorhabditis elegans. Nature 402:835-838. 
360. Zupancic, Z., B. Jukic, M. Lojkic, Z. Cac, L. Jemersic, and V. Staresina. 2002. 
Prevalence of antibodies to classical swine fever, Aujeszky's disease, porcine reproductive 
and respiratory syndrome, and bovine viral diarrhoea viruses in wild boars in Croatia. J Vet 
Med B Infect Dis Vet Public Health 49:253-256. 
154 
ACKNOWLEDGMENT 
This work would not be possible without input and support from many people at Iowa State 
University and elsewhere. The list of people is tremendously long but some of them must be 
mentioned. I would like to say a big thank you to the faculty and staff at VDL for their 
tremendous support over all these years of my employment in the diagnostic laboratory. 
Special thanks to the people in virology for their understanding of the importance of the 
research work that I was doing. Excellent technical assistance was provided by Raquell 
HanseH and Anna Young during my last three years in graduate school. Special 
acknowledgment should go to my POS committee members: Drs. Zimmerman, Ackermann, 
Evans and Phillips for their scientific input, help and understanding during this project. 
I would like to say thank you to my major professor Dr. Kyoung-Jin Yoon for his 
patience and support during the research work and preparation of manuscripts. He taught 
me what it means to be a faculty member in academia and helped me grow professionally at 
the same time. 
Many of my officemates deserve special thanks for all the good things that they did 
during the period of time of our interaction. 
This scientific work would not be possible and this acknowledgment would not be 
complete without deep thanks to my wife Sherry for her exclusively dedicated support, help 
and patience all these years of my professional training. And to my children Nicholas and 
Sophia who behaved and listened to their mother while I was away from home doing my 
research and work. 
Thanks to all who have made some contribution in one way or another to this project. 
